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Recent evidences indicate that most of the cytotoxicity attributed to nitric 
oxide (NO*) is rather due to peroxynitrite, produced from the diffusion-controlled 
reaction between NO* and the superoxide anion. Peroxynitrite interacts with lipids, 
DNA, and proteins via direct oxidative reactions or via indirect radical-mediated 
mechanisms. Peroxynitrite can inflict both oxidative and nitrosative damages on 
DNA bases, generating abasic sites, resulting in the single strand breaks. The 
formation of DNA single-strand breaks represents a critical aspect of peroxynitrite-
mediated cytotoxicity, since they represent the obligatory trigger for the activation 
of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), a pathway ultimately 
related to the induction of cell death and tissue inflammation. 
In vivo, peroxynitrite generation represents a crucial pathogenic 
mechanism in conditions such as stroke, myocardial infarction, chronic heart 
failure, diabetes, circulatory shock, chronic inflammatory diseases, cancer and 
neurodegenerative disorders. Diabetes mellitus is one of the most chronic 
diseases with an estimated worldwide prevalence of 170 million in 2002, which 
is expected to double by 2030. Indians are genetically more susceptible to 
diabetes and the WHO has predicted that the number of diabetics in India 
would go up to 40 million by the year 2010 and 74 million by 2025. The 
WHO has also issued a warning that India is going to be the diabetic capital of 
the world. If the predictions turned real then the Asian continent appears to be 
the hub of the disease in times to come. Compared to urban population (13%), 
people living in rural areas are reporting low incidence of diabetes (3%). Type 
2 diabetes, accounting for nearly 90% of total diabetic patients, is characterized 
by insulin resistance and more often it is associated with obesity and 
dyslipidemia. While Type 1 diabetes, occurring predominantly in children and 
young adults and accounting for 5-10% of diagnosed cases, is characterized by 
insulin deficiency as a result of destruction of insulin-producing p-ce!ls of 
pancreas. Although the actual trigger of the P-cell destruction is still unknown, 
various external (chemicals, viruses) or internal (free radicals, cytokines) 
factors have been proposed to initiate a deleterious chain of events leading to 
immune cell infiltration, release of immune mediators such as free radicals and 
cytokines, and eventually resulting in the destruction of P-cells. 
I I 
Type I diabetes (or insulin-dependent diabetes mellitus) is characterized by 
autoimmune destruction of the pancreatic islet insulin producing P-cell resulting in 
prolonged hyperglycemia via reduced uptake of glucose and relative increase in 
glucagon secretion and gluconeogenesis. Type I diabetes is a conventional example 
of T-cell mediated disease which selectively targets pancreatic P-cell. It presents a 
complex interaction between genetic and environment factors, most of which is yet 
to be identified. Although there is extensive information on the pathogenesis of 
autoimmune diabetes in the NOD mice and the BB rat, there is relatively little 
direct information on the pathogenesis of type 1 diabetes in humans. In fact, many 
of our ideas about the pathogenesis of human type I diabetes are the result of 
extrapolation from rodents. Numerous autoantibodies have been reported in type-1 
diabetes. The most significant of them are autoantibodies to glutamic acid 
decarboxylase-65 (GAD-65), protein tyrosine phophatase (IA-2A) and insulin 
(lAA). 
The possibility that diabetes is also associated with increased nitrosative 
stress is supported by recent detection of increased nitrite and nitrate levels in 
diabetes type I patients. Peroxynitrite has been reported to attack various 
biomolecules, such as DNA, protein and lipids. One of these pathways involves 
DNA strand breakage and consequent activation of the nuclear enzyme FRAP. 
The PRAP-1 activation has recently emerged as a crucial process in the 
development of diabetic cardiovascular dysfunction both in diabetic animals 
and humans and may also contribute to the development of other diabetic 
complication. According to this concept, high-glucose-induced elevated 
superoxide generation from mitochondria induces DNA strand breaks and 
PRAP activation, which in turn induces the poly (ADP-ribosylation). Inhibition 
of insulin secretion, induction of DNA damaging radicals and the islets cell 
lysis and apoptosis have all been observed in rat and human islets exposed to 
NO', reactive nitrogen species or peroxynitrite in vitro. The development of the 
hypothesis that primary DNA damage in the P-cell leads to activation of PRAP 
with subsequent depletion of intercellular NAD leading to inhibition of 
proinsulin synthesis, P-cell necrosis and diabetes. 
HI 
In the present study plasmid, pUC 18 was isolated from E. coli and 
modified with peroxynitrite generated by quenched flow process. The generation 
of peroxynitrite was assessed by yellow color and absorbance at 302 nm using 
molar extinction coefficient of 1670 M''cm" . The modified plasmid was analysed 
by UV & fluorescence spectroscopy, circular dichroism, HPLC and melting 
temperature studies. The modified plasmid sample showed a marked 
hyperchromicity at 260 nm as compared to the native form. The data reflect the 
presence of single strand breaks, destabilization of hydrogen bonds and 
modification of nitrogenous bases. The decrease in fluorescence intensity in 
peroxynitrite modified plasmid shows the destruction of structural integrity and 
generation of single strand breaks as compared to native plasmid.Melting 
temperature studies revealed the susceptibility of modified plasmid to temperature 
transition. A net decrease of 12 °C in the Tm value of peroxynitrite modified 
plasmid indicates strand scission, generation of single-stranded regions and 
disruption of hydrogen bonding. Decrease in ellipticity of the positive peaks in the 
CD spectra of the peroxynitrite modified plasmid again reflects generation of 
strand breaks and unstacking of bases as a result of helix destabilization of the 
modified DNA. On the basis of chromatographic and spectral evidence, the major 
compound formed when peroxynitrite reacts with DNA is 8-nitroguanine, a 
specific marker for peroxynitrite induced DNA damage in inflamed tissues. The 
concentration of 8-nitroguanine was found to be 3.8 i^ M. The HPLC of native 
plasmid did not show any peak resembling 8-nitroguanine hence confirming that 
the presence of 8-nitroguanine in the modified plasmid is the result of nitration 
caused by peroxynitrite. The single strand breaks induced in the plasmid upon 
peroxynitrite modification were further ascertained by agarose gel electrophoresis 
of nuclease SI treated samples. 
Peroxynitrite modified plasmid was found to be highly immunogenic, 
inducing high titre antibodies in rabbits. Antigenic specificity of the induced 
antibodies was ascertained by competition ELISA. The immunogen showed a high 
degree of specificity towards the induced antibodies. Affinity purified immune IgG 
showed higher specificity as compared to serum. The induced antibodies though 
highly specific for peroxynitrite modified plasmid, exhibited polyspecificity. 
IV 
recognizing of various nucleic acid conformers and nitrogenous bases in 
competitive inhibition assay. 
Diabetes type I patients were screened for the presence of antibodies 
reactive with native and peroxynitrite modified plasmid. The study comprised of 
54 active sera from diabetic patients of different age groups. Direct binding ELISA 
results showed preferential binding of diabetes autoantibodies to peroxynitrite 
modified plasmid in comparison to native plasmid. Sera from age group of 31-60 
years showed higher recognition of peroxynitrite modified plasmid than native 
plasmid as compared to other age groups (4-15 and 16-30 years ). It shows that 
with the aging, the diabetes autoantibodies exhibited high degree of binding with 
peroxynitrite modified plasmid. The higher binding of autoantibodies to modified 
plasmid in comparison to the native form is suggestive of the generation of 
immunogenic epitopes on the DNA as a result of peroxynitrite modification 
leading to antibody induction in diabetic patients. The inhibition ELISA reiterated 
the direct binding results. Gel retardation assay further substantiated the binding of 
native and modified plasmid with autoantibodies in diabetes patients . The 
retarded mobility of peroxynitrite modified plasmid complexed with IgG of 
diabetes patients confirmed the appreciably high recognition of autoantibodies in 
diabetes type 1 by the peroxynitrite modified plasmid as compared to the native 
plasmid. Similarly, the binding specificity of diabetes type-2 anti-DNA antibodies 
with native and peroxynitrite was analyzed by direct binding and competitive 
inhibition assay. Direct binding ELSIA results showed almost similar binding with 
both the native and peroxynitrite modified plasmid. Furthermore, the results of the 
direct binding in solid phase assay were confirmed by the competitive inhibition 
studies, where also the native and peroxynitrite modified showed low and almost 
similar inhibition of diabetes type II autoantibody. 
Nitrosative damage in human genomic DNA in diabetic patients was 
detected immunochemically using anti-peroxynitrite modified plasmid antibody as 
a probe. DNA samples from different age groups of type I diabetic patients caused 
appreciable inhibition in the binding of induced antibodies. This demonstrates the 
presence of nitrosative lesions on DNA molecules isolated from diabetic patients. 
Data obtained from our studies on serum antibodies and lymphocytes DNA isolates 
could be correlated. DNA isolates from patients whose antibodies showed higher 
recognition of peroxynitrite modified plasmid exhibited higher binding to the 
experimentally induced anti-peroxynitrite modified plasmid antibodies. In addition 
the DNA isolates from different diabetic sera inhibited antibody binding to greater 
extent in those sera of the patients that showed higher inhibition with peroxynitrite 
modified plasmid. However, the DNA from the type II diabetes patients did not 
show any appreciable inhibition of the antibody binding. 
In conclusion, peroxynitrite causes extensive damage to plasmid and 
renders it highly immunogenic. Polyclonal antibodies generated against the 
modified antigen showed preferential recognition of peroxynitrite modified 
epitopes on DNA and free bases. The induced antibodies were demonstrate as a 
good probe to detect nitrosative damage in the DNA of diabetic patients. Higher 
recognition of peroxynitrite modified plasmid by diabetes type 1 autoantibodies is 
a clear indication of peroxynitrite induced DNA damage in these patients. It could, 
therefore, be one of the factors for the autoimmune response leading to the 
induction of circulating anti-DNA autoantibodies in diabetes mellitus, type I. 
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Recent evidenced indicate that most of the cytotoxicity attributed to nitric 
oxide (NO*) is rather due to peroxynitrite, produced from the diffusion-controlled 
reaction between NO' and the superoxide anion. Peroxynitrite interacts with lipids, 
DNA, and proteins via direct oxidative reactions or via indirect radical-mediated 
mechanisms. Peroxynitrite can inflict both oxidative and nitrosative damages on 
DNA bases, generating abasic sites, resulting in the single strand breaks. The 
formation of DNA single-strand breaks represents a critical aspect of peroxynitrite-
mediated cytotoxicity, since they represent the obligatory trigger for the activation 
of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), a pathway ultimately 
related to the induction of cell death and tissue inflammation. 
In vivo, peroxynitrite generation represents a crucial pathogenic 
mechanism in conditions such as stroke, myocardial infarction, chronic heart 
failure, diabetes, circulatory shock, chronic inflammatory diseases, cancer and 
neurodegenerative disorders. Diabetes mellitus is one of the most .chronic 
diseases with an estimated worldwide prevalence of 170 million in 2002, which 
is expected to double by 2030. Indians are genetically more susceptible to 
diabetes and the WHO has predicted that the number of diabetics in Indit 
wo«4d-ge-«p-to 40 million by the year 2010 and 74 million by 2025.—Ihe 
WHO-hfw~aJsn is<;iieH a warning that India is going to he.the diabetic capital ol 
the world. If ther predictions turned real then the Asian continent appears to be 
the hub of the disease in times to come. Compared to^urban population (13%), 
people living in rural areas are reporting^lovJ incidence of diabetes (3%>rrype 
2 diabetes, accounting for nearly 90% of total diabetic patients, is characterized 
by insulin resistance and more often it is associated with obesity and 
dyslipidemia> "yhile Type 1 diabetes, occurring predominantly in children and 
young adults and accounting for 5-10% of diagnosed cases, is characterized by 
insulin deficiency as a result of destruction of insulin-producing P-cells of 
pancreas. Although the actual trigger of the p-cell destruction is still unknown, 
various external (chemicals, viruses) or internal (free radicals, cytokines) 
factors have been proposed to initiate a deleterious chain of events leading to 
immune cell infiltration, release of immune mediators such as free radicals and 
cytokines, and eventually resulting in the destruction of P-cells. 
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Type I diabetes (or insulin-dependent diabetes mellitus) is characterized by 
autoimmune destruction of the pancreatic islet insulin producing P-cell resulting in 
prolonged hyperglycemia via reduced uptake of glucose and relative increase in 
glucagon secretion and gluconeogenesis. Type I diabetes is a conventional example 
of T-cell mediated disease which selectively targets pancreatic P-cell. It presents a 
complex interaction between genetic and environment factors, most of which is yet 
to be identified. Although there is extensive information on the pathogenesis of 
autoimmune diabetes in the NOD mice and the BB rat, there is relatively little 
direct information on the pathogenesis of type I diabetes in humans. In fact, many 
of our ideas about the pathogenesis of human type I diabetes are the result of 
extrapolation from rodents. Numerous autoantibodies have been reported in type-1 
diabetes. The most significant of them are autoantibodies to glutamic acid 
decarboxylase-65 (GAD-65), protein tyrosine phophatase (IA-2A) and insulin 
(lAA). 
The possibility that diabetes is also associated with increased nitrosative 
stress is supported by f^ ecent detection of increased nitrite and nitrate levels in 
diabetes type I patients. Peroxynitrite has been reported to attack various 
biomolecules, such as DNA, protein and lipids. One of these pathways involves 
DNA strand breakage and consequent activation of the nuclear enzyme FRAP. 
•^fee^PRAP-l activation has recently emerged as a crucial process in the 
development of diabetic cardiovascular dysfunction both in diabetic animals 
and humans and may also contribute to the development of other diabetic 
complicatiorT According to this concept, highVglucose-induced elevated 
superoxide generation from mitochondria induces DNA strand breaks and 
PRAP activation, which in turn induces the poly (ADP-ribosylation). Inhibition 
of insulin secretion, induction of DNA-damaging radicals.and tftfislet<( cell 
lysis and apoptosis have all been observed in rat and human islets exposed to 
NO', reactive nitrogen species,or peroxynitrite in vitro. The dcvclupineiiL of the 
hypothesis that primary DNA damage in the P-cell leads to activation of PRAP 
with subsequent depletion of intercellular NAD leading to inhibition of 
proinsulin synthesis, P-cell necrosis and diabetes. 
in 
In the present study plasmid, pUC 18 was isolated from E. coH and 
modified with peroxynitrite generated by quenched flow process. The generation 
of peroxynitrite was assessed by yellow color and absorbance at 302 nm using 
molar extinction coefficient of 1670 M"'cm"'. The modified plasmid was analysed 
by UV & fluorescence spectroscopy, circular dichroism, HPLC and melting 
temperature studies. The modified plasmid sample showed a marked 
hyperchromicity at 260 nm as compared to the native form. The data reflect the 
presence of single strand breaks, destabilization of hydrogen bonds and 
modification of nitrogenous bases. The decrease in fluorescence intensity in 
peroxynitrite modified plasmid shows the destruction of structural integrity and 
generation of single strand breaks as compared to native plasmid.Melting 
temperature studies revealed the susceptibility of modified plasmid to temperature 
transition. A net decrease of 12 °C in the Tm value of peroxynitrite modified 
plasmid indicates strand scission, generation of single-stranded regions and 
disruption of hydrogen bonding. Decrease in ellipticity of the positive peaks in the 
CD spectra of the peroxynitrite modified plasmid again reflects generation of 
strand breaks and unstacking of bases as a result of helix destabilization of the 
modified DNA. On the basis of chromatographic and spectral evidence, the major 
compound formed when peroxynitrite reacts with DNA is 8-nitroguanine, a 
specific marker for peroxynitrite induced DNA damage in inflamed tissues. The 
concentration of 8-nitroguanine was found to be 3.8 ^M. The HPLC of native 
plasmid did not show any peak resembling 8-nitroguanine hence confirming that 
the presence of 8-nitroguanine in the modified plasmid is the result of nitration 
caused by peroxynitrite. The single strand breaks induced in the plasmid upon 
peroxynitrite modification were further ascertained by agarose gel electrophoresis 
of nuclease SI treated samples. 
Peroxynitrite modified plasmid was found to be highly immunogenic, 
inducing high titre antibodies in rabbits. Antigenic specificity of the induced 
antibodies was ascertained by competition ELISA. The immunogen showed a high 
degree of specificity towards the induced antibodies. Affinity purified immune IgG 
showed higher specificity as compared to serum. The induced antibodies though 
highly specific for peroxynitrite modified plasmid, exhibited polyspecificity, 
IV 
recognizing o)r various nucleic acid conformers and nitrpgenous bases in 
competitive inhibition assay. 
Diabetes type I patients were screened for the presence of antibodies 
reactive with native and peroxynitrite modified plasmid. The study co^jg^sed of 
54 active sera from diabetic patients of different age groups/Direct binding ELISA 
results showed preferential binding of diabetes autoantibodies to peroxynitrite 
modified plasmid in comparison to native plasmid. Sera from age group-m 31-60 
years showed higher recognition' of peroxynitrite modified plasmid than native 
plasmid as compared to other age groups (4-15 and 16-30 years ). ft-3hews that 
,4. 
with the agingj-tbe-diabetes autoantibodies exhibited liigh degree of binding with 
peroxynitrite modified -pl-asm-id. The higher binding of autoantibodies to modified 
plasmid in comparison to the native form io-auggcctivr nf^the generation of 
immunogenic epitopes on the DNA as a rcoult of peroxynitrite mudificaiiUTl' 
leading to antibody induction in diabetic patients. The inhibition ELISA reiterated < 
the direct binding results. Gel retardation assay further subofantiatGd-the binding of 
• 'j^ 
native and modified plasmid with autoantibodies in diabete^ patients . The 
retarded mobility of peroxynitrite modified plasmid complexed with IgG of 
diabetes patients confirmed the appreciably high recognition of autoantibodies in 
diabetes type 1 by the peroxynitrite modified plasmid as compared to the native 
plasmid. Similarly, the binding specificity of diabetes type-2 anti-DNA antibodies 
with native and peroxynitrite was analyzed by direct binding and competitive 
inhibition assay. Direct binding ELSIA results showed aJi<ost similar binding, with 
both the native and peroxynitrite modified plasmid. Furthermore, the results of the 
direct binding in solid phase assay were confirmed by the cornpetitive inhibition 
studies, where also the native and peroxynitrite modified^ showed low and almost 
similar inhibition of diabetes type II autoantibody. 
Nitrosative damage in human genomic DNA ?h diabetic patients was 
eretected immunochemically using anti-peroxynitrite modified plasmid antibody as \ 
a probe. DNA samples from different age groups of type I diabetic patients caused 
appreciable inhibition in the binding of induced antibodies. This demonstrates the 
presence of nitrosative lesions on DNA molecules isolated from diabetic patients. 
Data obtained from our studies on serum antibodies and lymphocytes DNA isolates 
could be correlated. DNA isolates from patients whose antibodies showed higher 
recognition of peroxynitrite modified plasmid exhibited higher binding to the 
experimentally induced anti-peroxynitrite modified plasmid antibodies. In addition 
the DNA isolates from different diabetic sera inhibited antibody binding to greater 
extent in those sera of the patients that showed higher inhibition with peroxynitrite 
modified plasmid. However, the DNA from the type II diabetes patients did not 
show any appreciable inhibition of the antibody binding. 
In conclusion, peroxynitrite causes extensive damage to plasmid and 
renders it highly immunogenic. Polyclonal antibodies generated against the 
modified antigen showed preferential recognition of peroxynitrite modified 
epitopes on DNA and free bases. The induced antibodies were demonstrate as a 
good probe to detect nitrosative damage in the DNA of diabetic patients. Higher 
recognition of peroxynitrite modified plasmid by diabetes type 1 autoantibodies is 
a clear indication of peroxynitrite induced DNA damage in these patients. It could, 
therefore, be one of the factors for the autoimmune response leading to the 
induction of circulating anti-DNA autoantibodies in diabetes mellitus, type I. 
VI 
LIST OF FIGURES 
Page No. 
Fig. 1 Cellular diffusion of superoxide and peroxynitrite. 6 
Fig. 2 Mechanism of cardiovascular dysfunction in diabetes, role of 33 
superoxide and peroxynitrite. 
Fig. 3 Relationship between peroxynitrite, DNA damage, FRAP and 35 
diabetes. 
Fig. 4 Assembly of peroxynitrite generation. 43 
Fig. 5 Ultraviolet absorption spectra of isolated plasmid. 54 
Fig. 6 Absorption spectrum of peroxynitrite. 55 
Fig. 7 Agarose gel electrophoresis of native and peroxynitrite modified 56 
plasmid. 
Fig. 8 Ultraviolet absorption spectra of native and peroxynitrite 57 
modified plasmid. 
Fig. 9 Fluorescence emission spectra of native and peroxynitrite 59 
modified plasmid . 
Fig. 10 Circular dichroic profile of native and peroxynitrite modified 60 
plasmid. 
Fig. 11 Thermal denaturation profile of native calf thymus DNA and 62 
peroxynitrite modified plasmid. 
Fig. 12 Nuclease SI digestibility of native and peroxynitrite modified 63 
plasmid. 
Fig. 13 HFLC chromatogram of standard 8-nitroguanine at two different 66 
concentrations (l[im and 2|im). 
Fig. 14 HFLC chromatogram of standard 8-nitroguanine at two different 67 
concentration (3 jam and 4|am). 
Fig. 15 HFLC chromatogram of standard 8-nitroguanine at 5^m 68 
concentration. 
Fig .16 HFLC chromatogram of acid hydrolysate of native plasmid. 69 
Fig. 17 HFLC chromatogram of acid hydrolysate of peroxynitrite 70 
modified plasmid. 
Fig. 18 Effect of free radical scavengers, antioxidants, NO-trapping agent 71 
and metal ion chelator on the modification of plasmid by 
peroxynitrite. 
Fig. 19 Level of induced antibodies against peroxynitrite modified 73 
plasmid. 
VII 
Fig. 20 Inhibition ELISA of preimmune and immune sera against 74 
peroxynitrit^iodified plasmid. 
Fig. 21 Level of induced antibodies against native plasmid. 75 
Fig. 22 Inhibition ELISA of preimmune and immune sera against native 76 
p l^ id . 
Fig. 23 Elution profile of anti-peroxynitritaj^odified plasmid IgG on 77 
Protein-A-agarose column. 
Fig. 24 Direct binding ELISA of preimmune and immune IgG with 78 
peroxynitrit^Sodified plasmid. 
Fig. 25 Inhibition of anti- peroxynitrite plasmid IgG binding to 80 
peroxynitriti^modified plasmid by native and peroxynitrite£]^ 
modified plasmid. 
Fig. 26 (a) Band shift assay of anti peroxynitrit^^iodified plasmid IgG 81 
binding to peroxynitrit^iodified plasmid. 
(b) Band shift assay of anti peroxynitritai^iodified plasmid IgG 
binding to native plasmid. 
Fig. 27 Inhibition of anti-peroxynitritd9nodified plasmid IgG binding by 83 
calf thymus DNA, ROS modified calf thymus DNA, ROSSJ 
modified plasmid and peroxynitrit@iodified calf thymus DNA. 
Fig. 28 Inhibition of anti-peroxynitritO^odified plasmid IgG binding by 84 
placental DNA, ROSSiodified placental DNA and peroxynitrit^^^ 
modified placental DNA. 
Fig. 29 Inhibition of ai^trp^roxynitrite modified plasmid IgG binding by 85 
lymphocyte DNA, ROS(5^odified lymphocyte DNA and 
peroxynitritlShodified lymphocyte DNA. 
Fig. 30 Inhibition of anti-peroxynitriteSnodified plasmid IgG binding by 86 
200 bp DNA, ROS£»^odified 200 bp DNA and peroxynitrite© 
modified 200 bp DNA. 
Fig. 31 Inhibition of anti-peroxynitritg9nodified plasmid IgG binding by 87 
guanme, ROSS^odified guanine and peroxynitritotSjWodified 
guanine. 
Fig. 32 Inhibition of anti-peroxynitrit^^odified plasmid IgG binding by 88 
cytosine, ROg^modified cytosine and peroxynitrit^^^odified 
cytosine. 
Fig. 33 Inhibition of anti-peroxynitrit^i^odified plasmid IgG binding by 89 
thymine, ROSmodified thymine and peroxynitrite^^odified 
thymine. 
VllI 
Fig. 34 Inhibition of anti-peroxynitritGfiodified plasmid IgG binding by 90 
adenine, ROS!3iodified adenine and peroxynitritd3nodified 
adenine. ^ / 
Fig. 35 Direct binding ELISA of.diaDetes patients (age group: 4-15 year) 93 
anti-DNA autoantibodies to native plasmid and peroxynitrite^^ 
modified plasmid. . 
Fig. 36 Direct binding ELISA of.d^^betes patients (age group: 16-30 year) ^ 94 
anti-DNA autoantibodies to native plasmid and peroxynitrite 
modified plasmid. / 
Fig. 37 Direct binding ELISA o^diabetes patients (age group: 31 -60 year) 95 
anti-DNA autoantibodies to native plasmid and peroxynitrite^^ 
modified plasmid. 
Fig. 38 Serum autoantibodies detection against native and peroxynitrite ^ ^ 9 6 
modified plasmid in type I diabetic patients sera (3, 5 and 9) in 4-
15 year age group. 
Fig. 39 Serum autoantibodies detection against native and peroxynitrite ^ 97 
modified plasmid in type I diabetic patients sera (12, 13 and 16) in 
4-15 year age group. 
Fig. 40 Serum autoantibodies detection against native and peroxynitrite^j^98 
modified plasmid in type 1 diabetic patients sera (17,18 and 19) in 
4-15 year age group. 
Fig. 41 Serum autoantibodies detection against native and peroxynitrit^^" 99 
modified plasmid in type I diabetic patients sera (2land 22) in 4-
15 year age group. 
Fig. 42 Serum autoantibodies detection against native and peroxynitrite<c:J>103 
modified plasmid in type I diabetic patients sera (3, 4 and 5) in 16-
30 year age group. 
Fig. 43 Serum autoantibodies detection against native and peroxynitrite(£) 104 
modified plasmid in type I diabetic patients sera (6, 7 and 8) in 16-
30 year age group. 
Fig. 44 Serum autoantibodies detection against native and peroxynitrite(=i^l05 
modified plasmid in type 1 diabetic patients sera (9,10 and 15) in 
16-30 year age group. 
Fig. 45 Serum autoantibodies detection against native and peroxynitritCc;^ 106 
modified plasmid in type 1 diabetic patients sera (3,4 and 5) in 31-
60 year age group. 
Fig. 46 Serum autoantibodies detection against native and peroxynitrite(iE:>^107 
modified plasmid in type I diabetic patients sera (9,10 and 11) in 
31 -60 year age group. 
IX 
Fig. 47 Serum autoantibodies detection against native and peroxynitrite£-^108 
modified plasmid in type I diabetic patients sera (14, 18, 19 and 
20) in 31 -60 year age group. 
Fig. 48 Elution profile of diabetes IgG on Protein-A-agarose column. 110 
Fig. 49 Inhibition of IgG, samples 3,5 and 9 isolated from type 1 diabetic 111 
patients by native and peroxynitrit( i^:£»bdified plasmid in 4-15 year 
age group. 
Fig. 50 Inhibition of IgG, samples 12,13 and 16 isolated from type I 112 
diabetic patients by native and peroxynitritQ(S3*odified plasmid in 
4-15 year age group. 
Fig. 51 Inhibition of IgG, samples 17,18 and 19 isolated from type I 113 
diabetic patients by native and peroxynitritolS^odified plasmid in 
4-15 year age group. 
Fig. 52 Inhibition of IgG, samples 21 and 22 isolated from type I diabetic 114 
patients by native and peroxynitrit^modified plasmid in 4-15 year 
age group. 
Fig. 53 Inhibition of IgG, samples 3, 4 and 5 isolated from type I diabetic 117 
patients by native and peroxynitrite^odified plasmid in 16-30 
year age group. 
Fig. 54 Inhibition of IgG, samples 6, 7 and 8 isolated from type I diabetic 118 
patients by native and peroxynitrit^^'odified plasmid in 16-30 
year age group. 
Fig. 55 Inhibition of IgG, samples 9, 10 and 15 isolated from type I 119 
diabetic patients by native and peroxynitrit£3^odified plasmid in 
16-30 year age group. 
Fig. 56 Inhibition of IgG, samples 3, 4 and 5 isolated from type I diabetic 121 
patients by native and peroxynitritat^odified plasmid in 31-60 
year age group. 
Fig. 57 Inhibition of IgG, samples 9, 10 and 11 isolated from type I 122 
diabetic patients by native and peroxynitriteCSSodified plasmid in 
31-60 year age group. 
Fig. 58 Inhibition of IgG, samples and 14,18,19 and 20 isolated from type 123 
I diabetic patients by native and peroxynitrit^$^odified plasmid in 
31-60 year age group. 
Fig. 59 (a) Band shift assay of diabetic patient IgG biding to native 125 
plasmid 
(b) Band shift assay of diabetic patient IgG biding to peroxynitrite<3::y 
modified plasmid. 
Fig. 60 Inhibition of anti-peroxynitrite modified plasmid antibody binding 127 
to peroxynitrite modified plasmid by DNA isolated from 
lymphocytes of diabetic type I patients in age group of 4-15 year 
(3,5,9 and 12). 
Fig. 61 Inhibition of anti-peroxynitrite modified plasmid antibody binding 128 
to peroxynitrite modified plasmid by DNA isolated from 
lymphocytes of diabetic type I patients in age group of 4-15 year 
(13,16,17 and 18). 
Fig. 62 Inhibition of anti-peroxynitrite modified plasmid antibody binding 129 
to peroxynitrite modified plasmid by DNA isolated from 
lymphocytes of diabetic type I patients in age group of 4-15 year 
(19,21 and 22). 
Fig. 63 Inhibition of anti-peroxynitrite modified plasmid antibody binding 130 
to peroxynitrite modified plasmid by DNA isolated from 
lymphocytes of diabetic type I patients in age group of 16-30 year 
(3,4, 5 and 6). 
Fig. 64 Inhibition of anti-peroxynitrite modified plasmid antibody binding 131 
to peroxynitrite modified plasmid by DNA isolated from 
lymphocytes of diabetic type I patients in age group of 16-30 year 
(7,8,9,10 and 15). 
Fig. 65 Inhibition of anti-peroxynitrite modified plasmid antibody binding 132 
to peroxynitrite modified plasmid by DNA isolated from 
lymphocytes of diabetic type I patients in age group of 31-60 year 
(3,4,5,9 and 10). 
Fig. 66 Inhibition of anti-peroxynitrite modified plasmid antibody binding 133 
to peroxynitrite modified plasmid by DNA isolated from 
lymphocytes of diabetic type I patients in age group of 31 -60 year 
(11,14,18,19 and 20). 
Fig. 67 Comparison of serum nitrite content in normal human sera and 135 
diabetic type I patients of each age group. 
Fig. 68 Direct binding ELISA of diabetes type 2 patients anti-DNA 136 
autoantibodies to native plasmid and peroxynitrite modified 
plasmid. 
XI 
LIST OF TABLES 
P^ge No. 
Table :1 Selected cytotoxic processes initiated by peroxynitrite. 9 
Table:2 UV absorption and thermal denaturation characteristics of 64 
native and peroxynitrite modified plasmid. 
Table:3 8-nitroguanine content of peroxynitrite modified plasmid. 64 
Table:4 Cross-reaction of anti-peroxynitrite modified plasmid IgG. 91 
Table:5 Competitive inhibition data of serum antibodies in diabetic 100 
patients, age group of 4-15 year. 
Table:6 Competitive inhibition data of serum antibodies in diabetic 101 
patients, age group of 16-30 year. 
Table:? Competitive inhibition data of serum antibodies in diabetic 109 
patients, age group of 31 -60 year. 
Table:8 Competitive inhibition data of IgG isolated from diabetic 115 
patients, in 4 to 15 years age group. 
Table:9 Competitive inhibition data of IgG isolated from diabetic 120 
patients, in 16 to 30 years age group 
Table: 10 Competitive inhibition data of IgG isolated from diabetic 124 
patients, in 31 to 60 years age group. 
Table: 11 Detection of nitrosative lesions in DNA of diabetic patients. 134 
Binding of anti-peroxynitrite plasmid IgG to DNA isolated 
from lymphocytes of diabetic type I patients. 
Table: 12 Competitive inhibition data of serum antibodies from 138 
diabetic type 2 patients. 
Table: 13 Competitive inhibition data of IgG isolated from diabetic 139 
type 2 patients. 
Table:14 Detection of nitrosative lesions in DNA of diabetic patients. 140 
Binding of anti- peroxynitrite plasmid IgG to DNA isolated 
from lymphocytes of diabetic type 2 patients. 
XII 
ABBREVIATIONS 
A260 
A2g0 
APS 
bp 
BSA 
CTDNA 
DNA 
DMSO 
DTPA 
EDTA 
ELISA 
gm 
hr 
H2O2 
HPLC 
IgG 
L 
HL 
M 
HM 
mBSA 
NO 
NO' 
NO3 
nM 
NHS 
nDNA 
O2-
ONOO" 
PAGE 
Absorbance at 26Qnm 
Absorbance at 280 nm 
Ammonium persulph^ 
Base pair 
Bovine serum albumin 
Calf thymus 
Deoxyribonucleic acid 
Dimethyl sulfoxide 
Diethylenetriamine pentacetic acid 
Ethylene diamine tetraacetic acid 
Enzyme linked immunosorbent assay 
Gram 
Hour 
Hydrogen peroxide 
High performance liquid chromatography 
Immunoglobulin G 
Liter 
Microlitre 
Molar 
Micromolar 
Methylated bovine serum albumin 
Nitric oxide 
Nitric oxide radical 
Nitrate 
Nanometer 
Normal human sera 
Native DNA 
Superoxide anion radical 
Peroxynitrite 
Polyacrylamide gel electrophoresis 
XIII 
PBS 
ROS 
RNS 
rpm 
SSC 
SDS 
SOD 
Tris 
TBS-T 
Tm 
TEMED 
UV 
^min 
Phosphate buffer saline 
Reactive oxygen species 
Reactive nitrogen species 
Revolution per minute 
Saline sodium citrate 
Sodium dodecyl sulphate 
Superoxide dismutase 
Tris (hydroxymethyl) amino methane 
Tris buffer saline with 0.05% Tween- 20 
Melting temperature 
N,N,N,N-tetraethylmethylene diamine 
Ultraviolet 
Wavelength maxima 
Wavelength minima 

In 1953, British physicist turned biologist, Francis Crick and American 
biochemist James Watson determined the structure of DNA. The helical structure 
as described by Watson and Crick, called B-DNA, is only one of the several 
possible conformations. Other DNA conformations, though having the same 
nucleotides and molecular bonds, exhibit different three dimensional helical 
structure. At least six different DNA conformations have been identified V 
/designated as A, B, C, D, E and Z), but only the A, Z and B conformations are 
found in nature (Adams et ai, 1981; Rich et al, 1984; Pechenaya, 1993). B- DNA 
is the most common form of DNA found in living organisms. Z-DNA is ajso 
called because phosphate groups in the backbone are zig-zagged (Rich et al., 
1984). Besides\/the double helical structure, DNA can adopt many more different 
conformations or structures (Rich et ai, 1984). Tripld-strkuded nucleic acids and 
quadrup^- Stranded nucleic acid have also been found in DNA (Felsenfeld et al., 
1957; Rich , 1958) The different conformations adopted by DNA reflect i>s 
enormous versatility that is inherent in the molecule. The conformational stability 
of DNA duplex is considered as a function of component energy terms, 
hydrophobic, base stacking, hydrogen bonding, Vanper Waals and electrostatic 
parameters (Sundaralingam and Ponnuswamy, 2004). 
Essential Features of Plasmid 
Plasmids are self-replicating DNA which are stably inherited in an 
extrachromosomal state. These are widely distributed throughout fbi^prokaryotes, 
vary in size from less than 1x10^ Daltons to greater than 200x10^ Daltonsiand are 
generally dispensaole. Plasmids encode only few proteins required for their own 
replication and in many cases encode only one of them. Plasmids exist in^ 
supercoiled, open circular, and linear form. All plasmids do not exist as circular 
molecules; linear plasmids have been found in a variety of bacteria e.g 
Streptomyces species and Borelia burgdorferri. They are transmitted from bacteria 
to bacteria by conjugation or by transformatipny* / . 
Different^derivatives^ cf[ pBR322 l0ve been constructed for the purpose of 
cloning-^  pUC18 is a small, higlTcopy number E. coli plasmid, 2.686 base pairs in 
length. pUClS arKf'pUC19 plaS i^iids are identical except that they contain multiple 
cloning sites (MCSTaTfanged in opposite orientations. 
Antigenicity of Plasmid 
Immunization with naked plasmid DI^A encoding foreign antigens induces 
cell-mediated and humoral, Thl-^sed, immune responses, which provide 
protective immunity against different pathogens in a variety of animal species. 
These responses include protective neutralizing antibodies and antigen-specific 
cytotoxic T-lymphocytes. Antigen presenting cells such as dendritic cells (DC) 
play a key role in initiating primary imniune response after DNA vaccination 
(Babiuk et al., 2000; Nayak et a\., 2006).,Molecular basis of adjuvant effect of 
plasmid DNA was shown to be because of the presence of unmethylated CpG 
motifs in certain base context (Sato et a\., 1996; Kreig, 2000; Schneeberger et al., 
2004; Smolarczyk and Szala, 2004; Coban et al., 2005). 
The immunogenicity of plasmid DNA requires.short immunostimulatory 
DNA sequence (ISS) that contain^ CpG dinucleotide m a particular base content 
(Krieg et a/., 1995; Sato et al,. 1996; Grifantini et al, 1998) . The ISSs include the 
following CpG containing hexameraS'- GACGTC- 3', 5'- AGCGTC- 3' and 5'-
AACGTT-3' (Yamamoto et al., 1992; Yamamoto et al., 1994). The CpG motifs 
of bacterial-derived plasmids augment antigen-specific immune responses and 
steer those responses towards the T helper 1 type , leading to the induction of IgG 
2a and interferon y expression and to the suppression of immunoglobulin E (IgE) 
synthesis (Roman et al., 1997). The immunostimulatory function of their CpG 
motifs probably resulJjBrf from the secretion of various cytokines, such as 
interleukin 12 (IL-12), IFN-y, tumor necrosis factor (TNF)-a and IL-6, from 
macrophages or natural killer (NK) cells in the local environment (Klinman et al., 
1996; Roman e/a/., 1997). 
Immunologic plasmid DNA can be divided into two distinct units: a 
transcription unit that directs antigen synthesis and an adjuvant unit in plasmid 
backbone that elicits the production of type-I IFN and IL-12 in transfected skin 
keratinocytes and antigen presenting cells (APCs) (Tighe et al., 1998). 
Keratinocytes and APCs transfected with ISS-containing plasmid DNA produces 
IFN-a and IL-12, which then induce Thi immune response against plasmid DNA-
encoded protein. Manipulations of plasmid DNA transcription unit^to yield higher 
levels of antigen expression do not necessarily produce stronger immune response. 
Both the localization and the precise multiple repeats of immunostimulatory 
sequences (ISS) within the plasmid backbone are important for DNA vaccination 
{Sato etal., 1996). 
DNA immunization technology is a very promising approach to the 
formulation of multivalent vaccine (Grifantini et ai, 1998). Purified plasmid 
DNA containing an antigen coding sequences and the necessary regulatory 
elements to express them is introduced into the tissue. The effectiveness of DNA 
vaccines against virusues, parasites and cancer cells has been demonstrated in 
numerous animal models . DNA vaccine research is providing new insights into 
some of the basic immunological mechanism of vaccination such as antigen 
presentation, the role of effector cells and immunoregulatory factors (Mor and 
Eliza, 2001). Multiepitope DNA vaccines can be engineered to enhance^TL 
immunogenicity by increasing processing efficiency (Livingston et al, 2001). 
Epstein Barr Virus (EBV) based plasmid vectors may greatly contribute to 
nonviral gene therapy against a variety of disorders, including malignant, 
congenital chronic and infectious diseases. These vectors contain EBNA 1 gene 
and Ori P element that enable!^ high transfer efficiency, strong transgene 
expression, and long term maintenance of expression (Mazda, 2002). DNA 
vaccines can activate immunity against tumor antigens expressed as MHC class I 
associated peptides . However priming of CDS'^ CTL against weak tumor antigen 
may require adjuvant molecules (Rice et al, 2002). 
Despite an abundance of preclinical data, relatively little is known 
regarding the efficiency of DNA vaccination in humans. Conry et al. (2002) have 
conducted, dose escalation clinical trail of a dual expression plasmid encoding 
carcinoembryonic antigen (CEA) and hepatitis B surface antigen (HBSAg) in 
patients with metastatic colorectal carcinoma. This pivot trial has provided 
encouraging human immune response data in support of this vaccine technology. 
Reactive Nitrogen Species 
More recently, the role of reactive nitrogen species, such as nitric oxide and 
its by-products such as peroxynitrite (ONOO"), nitrate (NOs") and nitrite (NO2') 
have been shown to directly affect cellular signaling, vasodilation and immune 
response (Drew and Leeuwenburg, 2002). 
Nitric oxide 
Nitric oxide is a small molecule that contains one unpaired electron on the 
antibonding 2ii*y orbital and is, therefore, a radical. NO* is generated in biological 
tissues by specific nitric oxide synthases (NOSs), which metabolise arginine to 
citrulline with the formation of NO* via a five electron oxidative reaction 
(Ghafourifar and Cadenas ,2005). Nitric oxide (NO*) is an abundant reactive 
radical that acts as an important oxidative biological signalling molecule in a large 
variety of diverse physiological processes, including neurotransmission, blood 
pressure regulation, defence mechanisms, smooth muscle relaxation and immune 
regulation (Bergendi, et al, 1999). Due to its extraordinary Drooerties, NO* was 
acclaimed as the "molecule of the year" in 1992. 
Nitrate (NO3) and Nitrite (NO2) 
NO* reacts with O2 to form higher oxides of nitrogen, in a relatively slow 
reaction in places where there is high concentration of O2. The essential fate of 
NO" is oxidation to (NOj") and (NO2'), end products of NO* metabolism 
that are rapidly distributed throughout the body and excreted in the urine. 
Overall, this oxidative metabolism of NO* involves the formation of a number of 
intermediates in which the oxidation state of nitrogen ranges from +1 to +5 (N2O 
nitrous oxide, N2O3 dinitrogen trioxide, NO2 nitrogen dioxide, N2O4 dinitrogen 
tetroxide, N2O5 dinitrogen pentoxide) and several of these intermediates are 
presumed to be actively involved in the various biological actions of NO* (van der 
Vliete/a/., 1999). 
Peroxynitrite (ONOO) 
Overproduction of reactive nitrogen species is called nitrosative stress 
(Klatt & Lamas, 2000; Ridnour et al, 2004). This may occur when the generation 
of reactive nitrogen species in a system exceeds the system's ability to neutralise 
and eliminate them. Nitrosative stress may lead to nitrosylation reactions that can 
alter the structure of proteins and so inhibit their normal function. The reaction of 
NO with superoxide(02') to form the much more powerful oxidant peroxynitrite 
(OONO ) isrf key element in resolving the contrasting role of NO in physiology 
and pathology. Peroxynitrite is an important chemical species relative to the 
cytotoxic effect of NO'. This compound, formed with NO' and superoxide anion 
(Carreras et ai, 1994) is a strong oxidant that damages cell membranes and 
proteins (Beckman et al., 1990; Koppenol et al, 1992; Matheis et ai, 1992; Yu 
et al., 1994). Neither superoxide nor NO' is particularly toxic in vivo because there 
are efficient means to minimize their accumulation (Beckman, 1990; Beckman, 
1996). Superoxide is rapidly removed by high concentrations of scavenging 
enzymes called superoxide dismutases (SOD) with distinct isoenzymes located in 
the mitochondria, cytoplasm, and extracellular compartments, |^0" is rapidly 
removed by its rapid diffusion through tissues into red blood cells, where it is 
rapidly converted to nitrate by reaction with oxyhemoglobin (Fig.l). This limitlhe 
biological half-life of NO* in vivo to less than a second. However when both 
superoxide and NO' are synthesized within a few cell diameters of each other, they 
will combine spontaneously to form peroxynitrite by diffusion limited reaction 
(Huhmer et al.,1997) . Peroxynitrite is able to traverse cell membrane in part 
through anion channels (Denicola el al., 1998; Macfadyen el al., 1999) 
Physiological Relevance of Peroxynitrite 
Peroxynitrite has been proposed to be produced in several cell types, such as 
endothelial cells (Palmer et al., 1988) macrophages (Ischiropoulos, et al., 1992) 
neuronal cells, (Lafon-Cazal el al., 1993), neutrophils (Carreras et al.,\994) and 
smooth muscle cells (Schulz el al. 1991,). At physiological pH, peroxynitrite and 
its protonated form are present at a ratio of 4 to 1 and therefore isomerise at 37 °C 
with a rate constant of 1.1 s '^ (Kissner el al., 1997; Padmaja, et a/., 1998) The 
unstable protonated form (ONOOH) is most probably more cytotoxic than the 
stable, anionic form. But the peroxynitrite anion reacts with carbon dioxide 
(physiological concentration of the latter compound is about 1 mM in blood 
plasma) with a rate constant of 3 x 104 M"'s^' at 25°C (Lymar and Hurst, 1995) 
ife^  .,. _ - i " ^ C-$ > ^*j,iM.^^ 
^^ftd^roduce^ l-carboxylato-2-nitrosodioxidane(ONOOC02 ) vUiicli is pi'opti^ riW 
to be mainly responsible for the toxicity of peroxynitrite. In the absence of other 
reactants, 0N00C02~ undergoes homolysis to nitrogen dioxide and 
trioxocarbonate radicals with a yield of 4 - 30 % (Coddington, el al, 1995,- Bonini 
et al, 1999; Meli, el al, 2002) and isomerises to nitrate and carbon dioxide. 
Fig. 1 Cellular diffusion of superoxide and peroxynitrite 
Source: Pacher etai. 2007 
The cytotoxic reactions of peroxyilitrite.„j»-gr triggering of DNA strand 
breakage, inhibition of lipid peroxidation, direct inhibition of mitochondrial 
respiratory chain enzymes and other oxidative protein modifications sh#w-how 
dangerous-peroxynitrite in viva can-be-the mentioned cytotoxic pathways of-
perQxyaitdte_.show how important it is to find a substance to prevent these 
reactions*. 
Cytotoxicity of Peroxynitrite 
Peroxynitrite is more cytotoxic than NO* or superoxide in a variety of 
experimental systems. In fact, recent studies suggest t'nat, peroxynitrite, and not 
NO', may be the ultimate cytotoxic species in many conditions. In cells exposed to 
authentic peroxynitrite or to compounds that simultaneously generate NO* and 
superoxide, marked changes in the level of cellular energetics and DNA integrity 
occur (Szabo', 1996). 
In addition to being a terminal mediator of cell injuryy< also enhances and 
triggers a variety of pro-inflammatory processes. For example, peroxynitrite 
enhances the expression of ICAM-1 and P-selectin in human endothelial cells 
(Zingarelli et al. 1998), and it mediates th^ cytokine-induced IL- 8 expression in 
human leukocytes (Zouki et al, 2001). In human neutrophils, peroxynitrite triggers 
the down-regulation of L-selectin expression, and up-regulaUon of CDl lb/CD 18 
expression (Zouki et al, 2001). These effects are likely to be mediated, at least in 
part, by the ability of peroxynitrite to trigger and enhance nuclear factor kappa B 
(NF-kB) mediated pro-inflammatory signal transduction pathways (Matata and 
Galinanes,2001). The^e-alterations can culminate in a global dysregulation of 
ccHtitar signal transduction pathways. 
In pathophysiologically relevant situations^ e.g. in macrophages that 
produce NO and superoxide, and thus peroxynitrite from endogenous sources, 
DNA strand breakage also occurs.The time course of the strand breakage parallels 
the time course of NO and peroxynitrite production (Zingarelli et al. 1996). 
Moreover, in immunostimulated macrophages, (5-hydromethyl)uracil; 2,6-
diamino-4-hydroxy-5-formamidopyrimidine and 8-oxoguanine formation have 
been reported, indicating both oxidative and deaminative DNA injury (Rojas-
8 
Walker et al, 1995). In motor neurons, both taxonomy and peroxynitrite exposure 
leads to a time-dependent accumulation of DNA single strand breaks (Liu and 
Martin, 2 0 0 1 ) . ^ 
^DNA single strand breakage, initiated by endogenous or exogenous 
peroxynitrite, is a potent trigger of PARP activation (Vira'g and Szabo', 2002), a 
major contributor to cell necrosis under conditions of severe oxidative stress. 
While exposure to high concentrations of peroxynitrite leads to rapid cell 
death, associated with rapid energetic derangements, lower concentrations of 
peroxynitrite, after several hours, can lead to apoptotic cell death which is 
dependent on cytochrome c release from the mitochondria and activation of 
caspases 3, 2, 8 and 9 (Vira'g et al, 1998). 
In variouo ticcuec and organs, •pefOxynttritealJeitya'TarfetygfatiefatiOfis. 
^Table 1 overviews some of the peroxynitrite-mediated deleterious molecular, 
subcellular and cellular pathophysiological alterations. Peroxynitrite has been 
implicated in the pathogenesis of a wide variety of diseases and toxicologically 
relevant conditions. 
Toxicity of Peroxynitrite 
Recent works demonstrate the formation of peroxynitrite, and its potential 
pathogenetic relevance in cells or animals exposed to various environmental 
toxins. For example, certain in vitro studies have concluded that peroxynitrite 
formation contributes to the in vitro cytotoxicity induced by peroxyacetyl nitrate, 
an ubiquitous air pollutant (Liu et al, 1999; Lin et al, 2000). Similarly, benzene-
induced cytotoxicity may involve peroxynitrite (Tuo et al, 1998). It has been 
suggested that the increased production of peroxynitrite during chronic 
inflammation combined with benzene exposure may increase the carcinogenicity 
of benzene by a mechanism that includes the formation of metabolites from the 
chemical reaction between benzene and peroxynitrite. 
Peroxynitrite formation has been implicated in various forms of pulmonary 
injury induced by respirable mineral dusts or asbestos fibers (Choe el al, 1998; 
Tanaka et al, 1998; Zhu et al, 1998; Morio et al, 2001), diesel exthaust particles 
(Bai e/a/., 2001) ozone and bleomycin (Yamazaki e/a/., 1998). With respect to 
TABLE 1 
Selected Cytotoxic Processes Intitated By Peroxynitrite 
Action Mechanism 
At the molecular level 
Cytosolic enzyme inhibition 
Membrane pump inhibition 
Antioxidant enzyme inhibition 
Signal transduction pathway 
disturbance 
DNA injury 
Surfactant protein damage 
Metailoproteinase activation 
Antioxidant enzyme depletion 
Inhibition of BH4-dependent enzyme 
Inhibition of NAD-dependent 
enzyme 
Lipid peroxidation 
On the subcellular level 
Mitochondrial dysfunction 
NADdepletion 
Upregulation of adhesion receptors 
DNA fragmentation 
Calcium dysregulation 
On the cellular level 
Necrosis 
Apoptosis 
Oxidation, nitration 
Oxidation, nitration 
Oxidation, nitration 
Oxidation, nitration 
Oxidation, nitration, deamination, adduct 
formation 
Nitration 
S-glutoxidation of pro-metallo-proteinase 
Glutathione, cysteine oxidation 
BH4 oxidation 
NAD oxidation 
Peroxidation,lipid peroxidation chain reaction 
Inhibition of cytochromes,NADH-COQI,etc 
PARP activation, direct NAD oxidation 
NF-KB activation 
DNA injury, caspase activation 
Dysfuctional calcium pumps and cell 
energetics 
Mitochondrial injury, energetic collapse, 
oxidation, nitration, antioxidant depletion. 
calcium dysregulation 
Mitochondrial injury, DNA injury, caspase 
activation, signal transduction disturbance, 
calcium dysregulation 
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asbestos, studies in Chinese hamster cells have demonstrated a link between 
peroxynitrite formation and mutagenacity (Park and Aust, 1998). 
Peroxynitrite and Apoptosis 
When peroxynitrite-induced cellular damage reaches a level that cannot be 
handled by the repair mechanisms, cells undergo one of the basic cell death 
pathways, apoptosis or necrosis. Apoptosis is the "default ^ e a t h pathway 
characterized anrongrrttrerparametefssj^by a compact morphology, maintenance of 
plasma membrane integrity , mitochondrial depolarization , secondary oxidant 
production , activation of caspases (cysteinyl aspartate specific proteases) and 
oligonucleosomal DNA fragmentation (Green and Kroemer, 1998). 
Peroxynitrite can trigger apoptotic deatlr,and DNA fragmentation has been 
detected in peroxynitrite treated thymocytes (Salgo et al.,1995). Later , activation 
of caspase-3 , a key player in the caspase cascade has also been detected in 
thymocytes and HL-60 cells (Lin et o/., 1998). Prototypical apoptosis models utilize 
apoptosis inducers such as tumor necrosis factor acting upon cell surface death 
receptors . Channeling the death signal from these receptors to apoptotic effector 
machineries is well described (Green and Kroemer, 1998) . However , it is not 
quite clearVhow peroxynitrite triggers the apoptotic machinery .Mitochondria are 
likely sites for peroxynitrite induced apoptosis initiation . Mitochondria are now 
recognized as central organizations of apoptosis (Green and Kroemer, 1998). A 
characteristic sequence of events including opening of mitochondrial permeability 
transition pore, mitochondrial depolarization , secondary superoxide production , 
release of apoptotic mediators from the intermembrane space to the cytoplasnv 
takes place in apoptosing cells (Green and Kroemer, 1998). Furthermore, adenosine 
nucleotide translocator , a member of the permeability pore is also targeted by 
peroxynitrite (Vieira et al., 2001) . The role of mitochondria in peroxynitrite-
induced apoptosis is also supported by findings that bcl-2, a mitochondrial 
antiapoptotic protein inhibits peroxynitrite- induced apoptosis (Virag and Szabo, 
2000). The cellular energetics may become compromised by peroxynitrite also via 
alternative mechanisms (e.g. inactivation of creatine kinase in cardiomyocytes) 
which may also contribute to peroxynitrite cytotoxicity (Mihm et a/.,2001). It has 
been found that low concentrations of peroxynitrite trigger apoptosis, higher 
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concentrations of the oxidant compromise the apoptotic machinery forcing the 
cells to die by necrosis (Mihm et al, 2001).Recently, a new method has emerged 
identifying an active element in oxidative stress-induced necrosis. Accordingto 
jnethoii, degree of the activation of poly (ADP- ribose) polymerase-1 (PARP-1) 
determines the fate of the oxidatively-injured cells (Virag et al., 1998). PARP-1 is 
activated by DNA strand breakage. 
Activated PARP-1 cleaves NAD^ into nicotinamide and ADP- ribose and 
polymerizes the latter on nuclear acceptor proteins. Peroxynitrite-induced over 
activation of PARP consumes NAD^ and consequently ATP culminating in cell 
dysfunction, apoptosis or necrosis. These findings indicate that PARP-1 activation 
diverts the default apoptotic process toward necrosis (Virag and Szabo, 2002). jL 
•Mefeevetweroxynitrite-induced DNA breakage activates PARP leading to 
_NAP^ and ATP depletion and consequently to necrosis. The concerted action of 
'ARP-l and PARG maintains a highly accelerated ADP- ribose turnover in 
'peroxynitrite treated cells. As a result, NAD^ becomes depleted in the cells leading 
to malfunctioning glycolysis, Krebs cycle, mitochondrial electron transport and 
eventually to ATP depletion (Berger et al.,1986). The deterioration of cellular 
energetic status may play a central role in the "cell death switch" of PARP-1. 
Peroxynitrite Induced Necrosis: Role of Poly (ADP-Ribose) 
Polymerase-1 
Whilst low concentrations of peroxynitrite trigger apoptosis, higher 
concentrations of the oxidant compromise the apoptotic machinery forcing the 
cells to die by necrosis (Bonfoco et al, 1995 ;Virag et al, 1998a &b). For a long 
time, necrosis was thought to be a passive process resulting from the inability of 
the cells to cope with high degree of oxidative stress. Recently, a new paradigm 
has emerged identifying an active element in oxidative stress-induced necrosis. 
According to this concept, degree of the activation of poly (ADP-ribose) 
polymerase-] (PARP-1) determines the fate of the ox>datively-injured cells (Virag 
and Szabo, 2002). PARP-1 is activated by DNA strand break. Activated PARP-1 
catalyzes the cleavage of NAD^ into nicotinamide and ADP-ribose and uses the 
to synthesize branched nucleic acid like polymers poly (ADP-ribose) 
covalently attached to nuclear acceptor proteins. The branched polymer, the size of 
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which varies from a few to 200 ADP-ribose units, may facilitate recruitment of 
DNA repair enzymes to the sites of DNA injury (Virag and Szabo, 2002). 
In vivo, the most abundantly poly-ADP-ribosylated protein is PARP-1 itself 
and ^au^;;jioly (ADP-ribosylation) represents a major regulatory mechanism for 
P]^\p=i-fesulting in the down regulation of the enzyme acitivity. The polymer is 
degraded by poly (ADP-ribose) glycohydrolase (PARG) and ADP-ribosyl protein 
lyase with the latter enzyme removing the protein proximal ADP-ribose residue 
(Virag and Szabo, 2002). The concerted action of PARP-1 and PARG maintains a 
highly accelerated ADP-ribose turn over in peroxynitrite treated cells. As a result, 
NAD becomes depleted in the cells leading to malfunctioning glycolysis, Krebs 
cycle, mitochondrial electron transport and eventually to ATP depletion (Berger et 
al, 1986). Moreover, shortage of ATP is exaggerated by attempts of the cells to 
resynthesize NAD from ATP and nicotinamide. The net result of this pathway is a 
dramatic drop in cellular ATP (Berger et al., 1983). As the apoptotic machinery is 
known to depend on ATP (Nicotera et al., 1998; Volbracht et al, 1999; Nicotera et 
al.,2000), apoptosis is incapacitated and necrosis takes predominance. Inhibition of 
PARP-1 by 3-aminobenzamide or the absence of PARP-1 in PARP-1 deficient 
thymocytes resulted in dramatic protection against the loss of plasma membrane 
integrity (necrosis). ; ^ h e same time, output of apoptotic parameters (DNA 
fragmentation and caspase activation) increased in cells treated with PARP 
inhibitors or in PARP-1 deficient cells (Virag et al., 1998b). These findings 
indicate that PARP-1 activation diverts the default apoptotic process toward 
necrosis. 
The deterioration of cellular energetic status may play a central role in the 
'cell death switch role' of PARP-1. This hypothesis is supported by findings that 
cellular ATP levels determine the mode of cell death (apoptosis versus necrosis) 
(Bonfoco e/a/., 1995; Leist e/«/., 1997; Nicotera e/a/., 1998,2000). 
Biological Targets of Peroxynitrite 
A major asp^t of peroxynitrite-dependent cytotoxicity Kiliea rm its ability 
to trigger lipid peroxidation in membranes (Radi et al, 1991), liposomes and 
lipoproteins by abstracting a hydrogen atom from polyunsaturated fatty acids 
13 
(PUFA). Resulting products include lipid hydroperoxyradicals, conjugated dienes, 
and aldehydes (Denicola and Radi, 2005).Such radicals in turn attack neighboring 
PUFAs, generating additional radicals which propagate free radical reactions and 
the degeneration of membrane lipids (Radi et al, 1991; Hogg and Kalyanaraman, 
1999), causing membrane permeability and fluidity changes with significant 
biological consequences (Richter, 1987). Peroxynitrite may play a critical role in 
inflammatory diseases of the nervous system by initiating peroxidation of myelin 
lipids, leading to demyelination (Shi et al, 1999; Smith et a/., 1999; Vander et 
a/., 1999). It also acts as a potent oxidizing agent towards low-density lipoprotein 
(LDL) (Leeuwenburgh et al, 1997; Trostchansky et al, 2003). Peroxynitrite 
modified LDL binds with high affinity to scavenger receptors leading to the 
accumulation of oxidized cholesteryl esters and foam cell formation, which 
represent a key early event in atherogenesis (Graham et al, 1993; Guy et al, 2001; 
Hogg et al, 1993). Finally, the interactions of peroxynitrite with membrane lipids 
may lead to the formation of various nitrated lipids, with potential biological 
properties as mediators of signal transduction both under physiological and 
pathological conditions (Baker et al, 2004) and of several intermediate products, 
including isoprostanes and 4-hydroxynonenal that can further trigger secondary 
oxidative insults (Denicola and Radi, 2005). 
Protein 
The direct reaction of peroxynitrite with transition metal centers is among 
the fastest known for peroxynitrite (Alvarez and Radi , 2003). Peroxynitrite 
modifies proteins containing a heme prosthetic group, such as hemoglobin 
(Boccini and Herold, 2004), myoglobin (Herold et al, 2003), cytochrome c 
(Thomson et al, 1995), oxidizing ferrous heme into the corresponding ferric 
forms. Similarly, peroxynitrite can inactivate inducible NOS by oxidative 
modification of its heme group (Huhmer et al, 1997), a reaction which might serve 
as a feedback negative regulation of peroxynitrite generation under inflammatory 
conditions. Peroxynitrite reacts particularly rapidly with iron-sulfur clusters, 
inactivating enzymes involved in critical metabolic processes, including 
mitochondrial aconitase (Castro et a/., 1994) and phoshogluconate dehydratase 
(Kettle et al, 1997), as well as with Zn '^^ sulfur motifs, an effect resulting in the 
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activation of eNOS (Zou et al ., 2004) and alcohol dehydrogenase (Crow et 
a/., 1995). 
Peroxynitrite may alter protein structure and function by reacting with 
various amino acids in the peptide chain. The most prevalent reaction is that with 
cysteine, making thiol oxidation a major modification introduced by peroxynitrite 
(Radi et al., 1991). The direct second-order reaction of peroxynitrite with thiols 
(particularly with the anion form, RS") results in the formation of an intermediate 
sulfenic acid (RSOH), which then reacts with another thiol, forming a disulfide 
(RSSR) (Alvarez and Radi , 2003). Thiols may also be oxidized by the radicals 
formed from peroxynitrite, generating thiyl radicals (RS). Thiyl radicals may react 
with oxygen and promote oxidative stress by propagating free radical reactions 
(Ducrocq et al., 1999). Protein tyrosine nitration is a covalent protein modification 
resulting from the addition of a nitro (-N02) group adjacent to the hydroxyl group 
on the aromatic ring of tyrosine residues (Grandati et al., 1997). 
Nucleic acids 
Peroxynitrite can damage DNA by introducing oxidative modifications in 
both nucleobases and sugar phosphate backbone (Burney et al., 1999; Niles et al., 
2006). Among the four nucleobases, guanine is the most reactive with peroxynitrite 
due to its low reduction potential (Yu et al., 2005). The major product of guanine 
oxidation is 8-oxoguanine , which further reacts with peroxynitrite, yielding 
cyanuric acid and oxoazolone (Niles et al., 2006). Ultimatlety, guanine oxidation 
by peroxynitrite results in guanine fragmentation, a critical step towards 
mutagenesis and carcinogenesis (Burney et al., 1999; Niles et al., 2006). 
Peroxynitrite can nitrate guanine , yielding 8-nitro-guanine, which leads to the 
formation of ajbasic site that can be cleaved by endonuclease in vivo to give DNA 
single strand breaks (Burney et al., 1999; Yu et al., 2005; Niles et al., 2006). 
Peroxynitrite may also attack the sugar phosphate backbone by abstracting a 
hydrogen atom from the deoxyribose moiety, resulting in the opening of the sugar 
ring and the generation of DNA strand break (Burney et al., 1999; Niles et al., 
2006). The formation of DNA single-strand breaks represents a critical aspect of 
peroxynitrite -mediated cytotoxicity, since they represent the obligatory trigger for 
the activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) (Szabo 
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et a/.,2005), a pathway ultimately related to the induction of cell death and tissue 
inflammation. 
Nitration Products 
It was found that purine bases, such as guanine and adenine, yielded a 
strong yellow color (a characteristic of nitro and nitroso compounds), where as 
pyri^iJitie bases, such as thymine, cytosine, 5-methycytosine and uracil, did not. 
The first nitration product to be identifed was 8-nitroguanine, (8-NO2G) (Yermilov 
et a/., 1995). This modifed base, when formed in the context of oligonucleotides 
(Tretyakova et al, 2000) or double stranded DNA (Yermilov et al, 1995), 
depurinates with a half-life in the order of hours under simulated physiologic 
conditions. Thus, 8-NO2G formation in vivo may be an important source of 
apurinic sites arising from peroxynitrite production. The major yellow compound 
was isolated and accounted for about 80% of all products of this reaction. It had 
maximum UV/visible absorbance at 375,400 and 402 nm under acidic, neutral and 
basic conditions, respectively, indicating that it remains yellow across a wide range 
of pH values. 
5-nitro-4-guanidinohydantoin, (NI) has also been identified as a novel 
peroxynitrite-induced guanine nitration product (Niles et al, 2001). Unlike 8-
NO2G, this compound has a stable glycosidic bond, and persists either as the free 
nucleoside or nucleotide in DNA. NI represents the only peroxynitrite-induced 
guanine nitration product characterized to date in which the pyrimidine ring has 
been disrupted. 
There is a single report of a peroxynitrite addition product, 4,5-dihydro-5-
hydroxy-4-(nitroso-oxy)guanine (Douki et al, 1996). Apparently, this compound 
does not spontaneously depurinate, and appears to be stable despite the favorable 
elimination of nitrous acid to extend the ^-conjugation in the pyrimidine ring. 
Furthermore, several C-8 substituted 5-hydroxypurines are known to be 
hydrolytically unstable, readily undergoing hydration at the C-6 position to yield 
hydantoin products ( Goyal et o/., 1982; Kahn et al, 1997; Luo et al, 2000; Niles 
et al, 200^»i"he extent to which the C-8 substitution impacts the rate of this 
reaction has not been fully explored, but the above issues need to be reconciled 
before acceptance of this proposed structure. 
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Oxidation Products 
Two main oxidation products are formed during the peroxynitrite-induced 
oxidation of guanine, namely, 8-oxo-7,8 dihydro-2'-deoxyguanosine (Kennedy et 
ai, 1997) and 2,5di-amino-4H-imidazol-4one (Douki and Cadet, 1996). 2, 5 di-
amino-4H- imidazol-4 one which had previously been identified as a product of 
Type I guanine photo oxidation, undergoes hydrolysis to 2,2,4-triamino-5-(2H) 
oxazolone at physiologic pH ( Cadet et al.,1994). Thus, in tissues under oxidative 
stress in which 2,5,di-amino-4H-imidazol-4one is initially formed, 2,2,4-triamino-
5-(2H) oxazolone is the product that is expected to accumulate . 
The proposed formation of 8-oxo-7,8dihydro-2'-deoxyguanosine from the 
reaction of guanine with peroxynitrite was initially controversial, with some 
investigators using fairly high ratios of peroxynitrite to guanine claiming no 
formation of 8-oxo-7,8dihydro-2'-deoxyguanosine (Yermilov et a/., 1995; Douki 
and cadet, 1996) and others using lower ratios reporting its formation (Kennedy et 
al., 1997). This apparent discrepancy was finally resolved when it was 
demonstrated that peroxynitrite reacted preferentially with 8-oxo-7,8dihydro-2'-
deoxyguanosine over guanine (Uppu et a/., 1996). When relatively high 
concentrations of peroxynitrite are used, the resulting 8-oxo-7,8dihydro-2'-
deoxyguanosine formed is rapidly consumed in subsequent reactions with excess 
peroxynitrite. Thus, a compound previously identified as 4-hydroxy-7,8-dihydro-8-
oxoG was isolated from the reaction of guanine with peroxynitrite (Ravanat and 
Cadet, 1995; Douki and Cadet, 1996). However, further work has since established 
that, first, this product is in fact spiroiminodihydantoin, (Luo et al., 2000; Niles et 
al., 2001; Adam et al., 2002) and second, that it most likely arises from further 
oxidation of 8-oxo-7,8dihydro-2" -deoxyguanosine. 
DNA Single Strand Breakage Induced by Peroxynitrite 
^jL-0^ 
Potassium peroxynitrite (OONOK) cause DNA cleavage involution of 
end -labeled DNA restriction fragment (King et al , 1 9 9 2 ) . 0 T ^ past years,-ieveral 
groups have demonstrated the induction of single strand breakage in DNA upon 
exposure to peroxynitrite or to NO' and superoxide concurrently in various system^. 
For instance, peroxynitrite can induce DNA strand break^ />7 vitro in plasmid DNA 
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such as pBR322, PM2, and pUC 19, converting the supercoiled form to relaxed or 
linear forms which can be separated by agarose gel electrophoresis.( Groves and 
Maria, 1995; Salgo et al, 1995; Epe et a/.. 1996; Roussyn et al, 1996; Rubio et 
al, 1996; Tamir et al, 1996 ;Yermilov et al, 1996; Yoshie and Ohshima, 1997a). 
A significant induction of single strand breakage was observed in pBR322 plasmid 
treated with as low as 1 |iM peroxynitrite, whereas much higher concentration of 
peroxynitrite (>lmM) ( Rubio et al, 1996) or the presence of catalyst such as 
manganese porphyrin (Groves and Maria, 1995) were needed to inducek^double 
strand breakage. Several studies have shown that NO' itself does not cause strand 
breakage in vitro in plasmid DNA (Yoshie and Ohshima, 1997b; Tamir et al, 
1996), whereals exposure of plasmid DNA to preformed peroxynitrite (Inoue and 
Kawanishi, 1995) ,SINM^(Inoue and Kawanishi, 1995 ; Yoshie and Ohshima, 
1997b) or NO' plus superoxide generated from quinone redox (Yoshie and 
Ohshima, 1997 a ; Yoshie and Ohshima, 1997 b) can induce strand breakage. 
The mechanism for DNA strand breakage by peroxynitrite has not been 
studied extensively so far. DNA cleavage caused by peroxynitrite or SIN-1 was 
observed at almost every nucleotide with a small dominance at guanine residues 
(Inoue and Kawanishi, 1995). Peroxynitrite induced significantly more single 
strand breaks at acidic pH than at neutral or alkaline pH, suggesting that hydroxyl 
radical-like intermediate(s) peroxynitrous acid are responsible for the damage 
(Yermilov et al, 1996 ). Salgo et al.(1995) reported that mannitol failed to protect 
DNA from damage by peroxynitrite while benzoate and dimethyl sulfoxide 
amplified breakage, indicating that the free hydroxyl radical is not involved in the 
damage.^hese authors postulated that dimethyl sulfoxide and benzoate react with 
peroxynitrite to form NO2, which is responsible for the increased DNA damage 
observed with these compounds, rather than allowing peroxynitrite to decompose 
to nitrate, an inert product (Salgo et al, 1995) On the other hand, various 
compounds can inhibit peroxynitrite-mediated strand breakage, including 
selenCJrnethionine, selenocystine (Epe et a/., 1996; Roussyn et al, 
1996)jdisferrioxamine (Epe et a/., 1996; Yoshie and Ohshima, 1997 a ), 
antioxidants such as ascorbate and urate (Yoshie and Ohshima, 1997a), carbon 
dioxide/bicarbonate a^nd car ^ bxy-PTlO (Yoshie and Ohshima, 1997 a). 
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In theory, all of these potent peroxynitrite scavengers are expected to 
reduce the extent of DNA single strand breakage in cells exposed to peroxynitrite. 
However^such an effect has so fary only^ reported m relatl^an-to-few such as the 
vitamin E analog . DNA single strand breakage, however, has also been reported in 
intact cell-^exposed to peroxynitrite indicating that extracellular peroxynitrite has 
the ability to enter the cells and reach the nucleus (Salgo et al, 1995; Szabo' et al, 
1996 ; Kennedy et al, 1997 ). More importantly, indirect evidence supports the 
views that endogenously produced peroxynitrite can also induce DNA strand 
breakage./ For instance, in immunostimulated macrophages, the generation of 
DNA single strand breaks parallels the production of peroxynitrite (Zingarelli et 
al.. 1996). 
Biological Implications of Peroxynitrite-Mediated Guanine and 8-
Oxo-Guanine Oxidation in DNA 
Several studies have shown that peroxynitrite mediated guanine and 8-oxo-
guanine oxidation product are also produced in single and double stranded 
oligodeoxynucleotides and calf thymus DNA treated with peroxynitrite. Both 
guanine-derived nitration products, 8-nitroguanine (Tretyakova et al.,2000; 
Yermilov et al.,1995) and 5-nitro-4-guanidinohydantoin (Gu et al., 2002) have 
been reported, albeit the later at lower levels in double stranded DNA relative to 
the single stranded form. The oxidation product 8-oxoguanine has also been 
detected in peroxynitrite- treated plasmid DNA (Kennedy et a/., 1997), and its 
further oxidation products have been identified in oligodeoxynucleotides 
(Tretyakova et al.,\999; Henderson et al., 2002). Taken together, these 
observations demonstrate that the same products formed at the nucleoside level are 
produced in DNA, and hence may be important in understanding peroxynitrite 
induce mutagenicity. 
•4ndced, ^^trong correlation exists between the preferential reactivity of 
peroxynitrite with guanine and 8-oxoguanine and its ability to induce DNA 
mutations, predominantly at guanine residues. The mutation types and frequencies 
in initial studies consisted of G:C-*T:A (75%), G:C-^C:G (12%) and G:C->A:T 
(14%) and were determined using shuttle vectors treated with high peroxynitrite 
fluxes (Juedes et a/., 1996 ). Most of the studies demonstratmg'a dramatic shift in 
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the products obtained at high and low peroxynitrite fluxes, prompjira further 
investigations comparing mutational profiles at high (bolus addition), intermediate 
(infusion) and low (SIN-l generated) peroxynitrite fluxes. While mutation 
frequencies were significantly reduced for both infusion and SIN-l reactions 
relative to bolus addition, G:C—>T:A transversions were still the predominant 
mutations observed (Kim et al, 2005 ). These results suggest that the DNA-
damage products formed at low and high peroxynitrite fluxes may differ, but there 
is significant overlap in their propensity to induce similar mutations originating at 
damaged guanine residues. 
This conclusion is supported by studies examining the mutational 
properties of the individual oxidation products introduced site-specifically into 
oligonucleotides or viral genomes for in vitro and in vivo study, respectively. 8-
oxoguanine is known to induce G:C^T:A mutations (Wood et al., 1990; Shibutani 
et al., 1991; Cheng et al., 1992; Lowe anGuengerich., 1996; Duarte et al., 1999). 
Of the other guanine-derived products, 2,5-diamino-4H-imidazol-4-one gives rise 
mainly to G:C^C:G mutations (Neeley et al., 2004) in agreement with a previous 
preliminary prediction made, based on molecular orbital calculations (Kino et al., 
1998). However, its hydrolysis product 2,2,4-triamino-5-(2H)-oxazolone causes 
G:C^T:A mutations (Duarte et al.,2000; Henderson et al., 2002). 5-nitro-4-
guanidinohydantoin gives rise to G:C-^T:A (22%), G:C^A:T (19%), and 
G:C^'C:G (9%) mutations (Neeley et al., 2004). 8-nitroguanine depurinates to 
leave an abasic site, and in systems that conform to the A -^rule^  is expected to lead 
to G:C^T:A mutation (Leob and Preston, 1986; Shibutani et a/., 1997). Recently, 
this product has also been shown to be a miscoding lesion, directly inducing 
G:C^^T:A mutations predominantly, and G:C^^C:G and G:C^A:T mutations 
and deletions to a lesser extent (Suzuki et al., 2005). Therefore, 8-nitroguan[e 
induces mutations directly and indirectly, but the principal mechanism cannot 
easily be diulii'iguisliLU by examining mutational spectra, as both pathways lead to 
the same predominant mutation. Of the 8-oxoguanine products, oxaluric acid and 
urea are expected to be the major stable products in bolus addition studies. 
Oxaluric acid and urea have been shown to induce G:C—>T:A mutafions at high 
frequency (Duarte et a/.,2001; Henderson et al., 2002). Similarly, carboxylic acid 
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causes predominantly G:C-*T:A mutations (Gasparutto et al, 1999; Henderson et 
al, 2002) 
On the other hand, the major products of low peroxynitrite fluxes, 
guanidinohydantoin and spiroiminodihydantoin will induce both G:C—+C:G and 
G:C^T:A transversions (Komyushyna et al.,2002; Henderson et al., 2003) with 
the former as the predominant mutation (98% for guanidinohydantoin and 65% for 
spiroiminodihydantoin, respectively) (Henderson eto/.,2003).Unfortunately, 
dihydroguanidinohydantoin and N-nitro-dihydroguanidinohydantoin are too 
unstable for determination of mutational spectra, while the more recently 
elucrdkted 4-hydroxy-2,5-dioxo-imidazolidine-4-carboxylic acid has not been 
studied. Overall, the strong concordance between the types of mutationjjnduced 
by the individual products with those observed in aggregate studies lend further 
support to the conclusion that oxidation.flf-guanine-and-B-oxo-guanine can explain 
the majority of peroxynitrite-induced mutatioris.' 
Peroxynitrite, Inflammation and Immune l^esponse 
Potential biological targets of peroxynitrite include membrane as well as 
cytosolic and nuclear receptors. Putative targets for peroxynitrite include the 
epidermal growth factor (EGF) receptor, the Pi-and P2-adrenoceptors (ADRBl and 
ADRB2), platelet/endothelial cell adhesion molecule 1 (PECAMl), insulin 
receptor substrate 1 (IRSl) and PPARy (Pacher et al., 2007). The peroxynitrite-
mediated oxidation and/or nitration of these receptors has been linked to 
disturbances in downstream signalling. For example, the peroxynitrite-induced 
modifications of PPARy inhibit the PPARy-ligand-dependent translocation from 
the cytosol into the nucleus, which may affect cellular inflammatory responses 
(Shibuya et al., 2002). Receptor ligands are also targeted for modification. The 
reaction of peroxynitrite with fibroblast growth factor 1 (FGFl) induces extensive 
cysteine oxidation, tyrosine nitration and irreversible inactivation of protein 
activity (Bagnasco et al., 2003). The inactivation of FGFl was proposed to impede 
the ability of this signalling pathway to serve as an inhibitory feedback mechanism 
restoring cellular homeostasis during the resolution of inflammation and repair 
(Bagnasco et al., 2003). Peroxynitrite can also upregulate signalling processed p r 
example, interactions with protein kinase C-s (PKCe) promote its translocation to 
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the nuclei and further signalling (Balafanova et a/.,2002 ),and it has been ibstC 
shown that nitration of nerve growth factor (NGF) converts this growth factor into 
a pro-apoptotic mediator in neurons (Pehar et ai, 2006)!7Peroxynitrite may 
profoundly influence inflammatory responses at multiple levels. During 
inflammation, which provides a setting that favours the biological formation of 
peroxynitrite, reactions of peroxynitrite with inflammatory mediators such as 
interleukins (ILs) and with inducible NOS (iNOS) may provide the means for 
regulating the inflammatory response. Although peroxynitrite mediates the 
cytokine-induced expression of ILS in human leukocytes (Zouki et al.,2001) the 
direct reaction of peroxynitrite with ILS leads to the inactivation of ILS as well as 
other pro-inflammatory modulators such as macrophage inflammatory protein-la 
(MlPla; also known as CCL3) and eotaxin ( Freels et ai, 2002). In contrast to ILS, 
peroxynitrite was found to enhance the anti-inflammatory function of ILIO (Freels 
et al., 2002) and decrease the activity of iNOS (Lanone et ai, 2002), which could 
be viewed as a negative-feedback mechanism for NO' and peroxynitrite formation 
during inflammation. Additional pro-inflammatory actions for peroxynitrite have 
been attributed to the expression of intracellular adhesion molecule 1 (ICAMl) and 
P-selectin in human endothelial cells (Zingarelli et ai, 1998). In human 
neutrophils, peroxynitrite triggers the downregulation of L-selectin expression and 
the upregulation of CDl lb/CD IS expression (Zouki et ai, 2001). These effects are 
likely to be mediated, at least in part, by the ability of peroxynitrite to trigger and 
enhance nuclear factor-KB (NFKB)-mediated pro-inflammatory signal-transduction 
pathways (Matata and Galinanes,2001) by modifying proteins that are associated 
with the activation of this transcription factor (Matata and Galinanes,2001; Zouki 
et ai, 2001; Levrand et a/.,2005; Bar-shai and Reznick,2006). Additional pro-
inflammatory actions of peroxynitrite may involve its capacity to serve 
as a cyclooxygenase (COX) substrate (Landino et ai, 1996), although larger 
concentrations of the oxidant may inactivate the enzyme (Trostchansky et ai, 
2007). The interplay between peroxynitrite and inflammatory mediators is 
further complicated by the fact that nitrated lipids seem to have an anti-
inflammatory role. Thus, peroxynitrite can be in general considered a pro-
inflammatory compound, although in the late phases of inflammation, inactivation 
of COX as well as nitration of lipids may facilitate the finalization of the process. 
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Peroxynitrite is also able to affect other signal-transduction pathways, 
including PKC, mitogen-activated protein (MAP) kinase and Src tyrosine kinases. 
Another pathway involves the phosphoinositide 3-kinase (PI3K)-dependent 
activation of the 5'-AMP-activated kinase (AMPK) by peroxynitrite (Xie et al, 
2005). In human skin primary fibroblasts, peroxynitrite has been shown to activate 
the PI3K/AKT pathway (Klotz et al, 2000), which, however, may be stimulus-
specific or cell-specific, as in other experimental systems the inhibition of the same 
pathway by peroxynitrite has been demonstrated (Shacka et al, 2006). In 
microvascular endothelial cells, peroxynitrite has been shown to activate signal 
transducer and activator of transcription 3 (STAT3), which is linked to the 
enhanced upregulation of vascular endothelial growth factor (VEGF) expression by 
peroxynitrite (Piatt et al, 2005). The earliest known upstream signalling that may 
induce the activation of MEK/ERK (mitogenactivated protein kinase 
kinase/extracellular signal regulated kinase) and PI3K/AKT pathways is the ability 
of peroxynitrite to induce a direct S'-glutathiolation of p21Jras cysteine-118, which 
increases p2|ras activity and appears to mediate much of the downstream 
signalling (Clavreul et al, 2006). Peroxynitrite can also contribute to the enhanced 
production of pro-inflammatory mediators, which involves the reduction of histone 
deacetylase 2 (HDAC2) activity through HDAC2 nitration (Ito et al, 2004). 
Overall, elevated local levels of peroxynitrite during inflammatory 
conditions may lead to a deregulation of cellular signal-transduction pathways 
(Levonen et al, 2001) , upregulation of localized inflammatory stress responses 
and possibly promotion of cellular and tissue injury. The upregulation of adhesion 
receptors by peroxynitrite may also result in an increased expression of endothelial 
adhesion molecules and such cells might represent a preferential site for the 
adhesion and migration of neutrophils when simultaneously high concentrations of 
NO and neutrophil-derived superoxide are present ( Sohn et al, 2003). Under 
inflammatory conditions, formation of peroxynitrite may also influence 
cardiovascular responses derived from the sustained impairment of Pi- and (32-
adrenoceptor function (Lewis et al, 2005) that can be further aggravated by 
vascular hyporesponsiveness due to a combmahon of direct vascular injury and by 
the peroxynitrite-induced oxidative modification and inactivation of circulating 
catecholamines (Kerry and Rice, 1998; Macarthur et al, 2000). 
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Scavengers and Neutralizers of Peroxynitrite 
Various molecules can react directly with peroxynitrite, with peroxynitrite-
derived radicals or with both. Some of the physiological modulators of 
peroxynitrite reactivity (for example, uric acid, which reacts slowly with 
peroxynitrite, but readily scavenges peroxynitrite derived radicals) have been used 
in various studies and have demonstrated beneficial effects in animal models of 
inflammation and reperfusion injury (Kooy et al, 1994; Lanone et al, 2002; 
Whiteman et al, 2002; Scott et al, 2002; Szabo C 2003; Robinson et al, 2004; 
Scott et al, 2005). 
SimpJe thiol-based antioxidants, such as mercaptoalkyJguanidines, N-
acetylcysteine and dihydrolipoic acid, have been shown to reduce peroxynitrite-
mediated toxicity and reduce 3-nitrotyrosine immunoreactivity in various 
pathophysiological conditions (Szabo C et al, 1997; Zingarelli et al, 1997; Ploner 
et al, 2001; Szabo C 2003; Lancel et a/.,2004; Moochhala et al, 2005) However, 
the interpretation of these findings is complicated by the fact that many of these 
thiols exert additional actions as inhibitors of the activity and/or the expression of 
iNOS (and therefore, act at levels upstream of peroxynitrite formation). 
Klotz and Sies (2003) -have also comprehensively summarized the 
characteristics of ebselen (as well as other selenocompounds) as peroxynitrite 
scavengers (Klotz and Sies, 2003). Ebselen exerts protective effects in several 
models of inflammation and reperfusion injury 1 (Sugiura et al, 1999; Daiber et 
a/.,2000; Noiri et al, 2001) and some of these actions are likely to be associated 
with the ability of the compound to neutralize peroxynitrite. Ebselen has also been 
shown to improve endothelial function in diabetic blood vessels and kidneys 
(Gealekman et al, 2005), consistent with the pathological role of peroxynitrite in 
the disease. 
Tempol is a stable nitroxide radical that has been successfully used to 
protect cells and animals from nitro-oxidative stress conditions. Although some of 
these protective actions of tempol may relate to its antioxidant function, which is 
linked to the elimination of reactive oxygen species, recent data has shown that it 
effectively protects against the toxic effects of peroxynitrite. Indeed, tempol 
catalytically diverts peroxynitrite/carbon dioxide reactivity from nitration to 
nitrosation reactions, both in vitro and in vivo (Fernandes et al, 2005). 
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Desferrioxamine has been typically used in vivo as an iron chelator and 
therefore an inhibitor of iron dependent generation of hydroxyl radicals. However, 
desferrioxamine has been also shown to inhibit peroxynitrite-dependent oxidation 
and nitration by reacting with the CO3 and NO2* radicals (Bartesaghi et a/.,2004). 
There is evidence that in some pathological models, desferrioxamine protection 
may be at least partially attributed to the inhibition of peroxynitrite reactions. 
(Ourye/a/.,1993) 
Recent results demonstrate that tyrosine-containing peptides can also act as 
scavengers of peroxynitrite derived radicals at the cellular level and may neutralize 
the cytotoxic effects of both exogenous and endogenous peroxynitrite, inhibiting 
its pro-apoptotic effect on neurons ( Ye et ai, 2007). 
Numerous molecules that are present in natural or dietary products, such as 
carotenoids, polyphenol oligomers and epicatechin, have shown to effectively 
protect cells from peroxynitrite (Arteel et o/.,1999; Arteel and Sies 1999; 
Panasenko et al, 2000; Schroeder et al., 2003). Again, caution must be exercised 
in interpreting the pharmacological responses obtained with these agents, as they 
tend to react slowly with peroxynitrite itself and so react with other reactive 
species instead, including peroxynitrite derived radicals. 
Diabetes mellitus (DM) 
Diabetes mellitus (DM) is a metabolic disease characterized by absolute 
insulin deficiency, or relative insulin deficiency when insulin secretion is 
inadequate to overcome co-existent resistance to insulin action on carbohydrate, 
protein or fat metabolism. Absolute deficiency of insulin can occur in a number of 
different ways: by an autoimmune destruction of insulin producing cells in the 
pancreas (Type lA); by destruction without clear evidence of autoimmunity (Type 
IB); by genetic defects that prevent regulated insulin secretion (mitochondrial gene 
defects, genetic defects in the KATP channels and their regulatory sub-units); 
surgical removal; vascular infarcts; crush injuries, etc. Some of these genetic 
defects are milder and may not manifest as limited insulin secretion until there is 
concomitant resistance to insulin action induced by obesity, pregnancy (gestational 
diabetes) or other factors. In general, the term Type 1 DM (TIDM) is used to 
denote childhood diabetes usually associated with autoimmunity and absolute 
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insulin deficiency, even though the deficiency need not be absolute at the clinical 
outset of the disease. Likewise, the term Type 2 DM (T2DM) is used to denote 
childhood diabetes associated with obesity and insulin resistance. The term 
MODY, so-called maturity onset diabetes of youth, is a "milder" form of diabetes 
caused by specific gene defects that impair insulin secretion. In the western 
hemisphere DM is one of the most common chronic diseases in childhood. 
Whereas the incidence of TIDM in developing countries is significantly less than 
that in the western hemisphere, epidemiological studies indicate that there is 
gradual but steady increase in the incidence of both TIDM and T2DM in both 
developed and developing countries. 
Juvenile, insulin-dependent diabetes mellitus (type 1 diabetes, TIDM) is a 
consequence of selective autoimmune destruction of the insulin-producing beta 
cells in the pancreatic islets of Langerhans. The resulting insulin deficiency leads 
to a chronic metabolic derangement associated with significant secondary 
morbidity. According to the traditional opinion consistent within most autoimmune 
diseases, both a genetically predisposed individual and a suitable environmental 
trigger are needed for the destructive process in the case of TID against beta cells, 
to begin. Today, the group of human leukocyte antigen (HLA) genes is considered 
to account for the major genetic risk and virus infections to represent prime 
environmental triggers. 
Natural History of Type 1 Diabetes 
The acute manifestations of TIDM include symptoms such as polyphagia, 
polydipsia, polyuria and ketoacidosis; indications that collectively result as a 
consequence in the loss of glucose homeostasis. However, thanks in large part to 
the ability of TIDM associated autoantibodies to identify, prior to the symptomatic 
onset of disease, those in whom the disorder will eventually develop, it is now 
understood that there is a prodrome lasting from months to decades during which 
autoimmune destruction of the insulin producing p-cells within pancreatic islets 
occurs (Atkinson and Eisenbarth ,2001). The trigger or possibly, triggers of the 
autoimmune events underlying TIDM events remain elusiv^l^owever many agree 
that an individual's genetic predisposition to this disease modified by 
environmental factors likely form a key facet for development (Knip., 2003). 
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Indeed, the genetic predisposition for TIDM, like most autoimmune disorders, in 
large part resides within genes controlling the immune response, principal amongst 
these being the major histocompatiblity complex (MHC). However, susceptibility 
and resistance for TIDM does not reside in the MHC alone as more than two 
dozen additional loci outside of the MHC complex have been identified to 
influence risk for this disease (Melanitou et al.,2003). Among the many potential 
candidate genes residing in such loci are BCL2, CD28, CTLA-4, CXCL12, 
interleukin-2 receptor and INS genes (Atkinson, 2005). 
The potential influence of environmental factors in TIDM development has 
been suggested through multiple observations, the primary ones being the 500-fold 
variance in disease incidence based on geographic locale, seasonal variance in 
disease onset and somewhat dramatic increases in the frequency of this disease, 
particularly over the last half-century. While environmental factors influencing 
TIDM development have remained elusive (i.e., none have specifically been 
isolated), epidemiological studies have associated infant diet, viruses and perhaps 
increased hygiene as contributing events to this disease (Knip M., 2003). In terms 
of how they might contribute to disease, without specific identification, such 
models remain hypothetical, but it is currently speculated that once the pathway to 
TIDM has been initiated, either through as yet unknown triggers or natural 
physiological processes, various aberrant immune responses begin to play a role. It 
is important to note that many theories for environmental contributions to TIDM 
development (e.g., viral molecular mimicry, P-cell trophic viruses, cow milk 
consumption, childhood vaccines, etc.), while popular in terms of their notion, 
have not proven themselves reproducible across a variety of study populations over 
time (Atkinson, 2005). 
Despite genetics and enviroiQment fmrnm for TIDM 
pathogenesis, models for TIDM development have been proposed that include 
these factors in combination with other findings (e.g., immunoregulatory defects, 
rate of metabolic loss, formation of anti-islet antibodies, etc.) which have been 
subject to better and more detailed description. Under one such natural history 
model, defects in antigen presentation as well as antigen presenting cell maturation 
imparts an unnatural arrest in clearance of immune cells from the islets (Litherland 
et o/.,1999). The additional inability to regulate this response to self-antigens, a 
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facet largely controlled by genetic susceptibility, would ultimately lead to a 
destructive islet cell inflammation (i.e., insulitis), with death of the insulin 
secreting P-cells (Brusko et al.,2005). As the total P-cell mass declines, a critical 
point is reached where glucose homeostasis is lost and eventually exogenous 
insulin is an absolute requirement for survival. 
Aside from model systems, thoughts continue that T-lymphocytes play the 
predominant role either directly (cytotoxicity) or indirectly (cytokine mediated P-
cell apoptosis) in the destruction of islets (Roep, 2003). Adoptive transfer 
experiments in animal models have shown that T-lymphocytes transfer disease and 
serum does not. At the same time, recent studies have suggested key roles for B-
lymphocytes in this process as one mouse model for TIDM, the NOD mouse, 
when rendered deficient in these cells (either through genetic manipulation or 
through antibody treatment) fail to develop overt disease (Serreze et al, 1996). 
Hence, at one level, it is clear that B-lymphocytes are also involved in as much as 
they do produce autoantibodies ((Brusko et al, 2005)) and in reality, it has been 
hypothesized that antigens presented by B lymphocytes may represent a critical 
feature to the development of TIDM. 
Autoantibodies in Type 1 Diabetes 
Since the discovery of autoantibodies to islet cells (IC A) in 1974 (Bottazzo 
et al, 1974), subsequent work demonstrated the presence of these autoantibodies 
not only at diagnosis or in patients with TIDM but also in subjects prior to the 
symptomatic onset of disease (Riley et al. 1990). ICA are polyclonal 
autoantibodies that react with all cells of the islet (i.e., a, p, 5, and pancreatic 
polypeptide cells). The next major discovery in terms of humoral autoimmunity in 
TIDM was that of autoantibodies to insulin (lAA) (Palmer et al, 1983). For a 
period of time after that initial description, lAA were deemed controversial and 
thought perhaps to represent another form of ICA. However, the way that ICA are 
detected, by indirect immunofluorescence utilizing human pancreas as the 
substrate, the pancreas is not fixed, allowing insulin to wash out. Therefore, the 
ICA reaction does not include reactivity to insulin. This, as well as technical 
challenges faced in performing the traditional ICA assay, led to a search for the 
autoantigens that comprise this anti-islet cell reaction. As previously mentioned, 
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such searches have yielded approximately two dozen candidates, however 
autoantibodies against two enzymes are now thought to provide a significant 
portion of the humoral anti-islet cell immunity (and in some instances, ICA 
reactivity), that being autoantibodies against glutamic acid decarboxylase (GAD) 
(Baekkeskov et al., 1990) and a protein tyrosine phophatase termed either ICA512 
(Rabin et al, 1994) or IA-2 (Lan et a/., 1996). Interestingly, these two autoantigens 
are expressed in multiple tissues and it is important to note that for TIDM 
associated autoantibodies, the only antigen unique to P-cells identified thus far is 
insulin. As far as why these autoantibodies have garnered such research interest, 
while many other autoantibodies have been described in TIDM, GAD A, IA-2 A 
and lAA have proved to be the major ones in terms of sensitivity and specificity 
(Verge e/a/., 1998). 
Parallel studies have shown the presence of these autoantibodies in the sera 
of individuals prior to the onset of TIDM (Bingley et a/., 1997; Achenbach et 
a/., 2004). At the onset of disease using GADA, IA-2 A and lAA in combination 
offers >85% sensitivity and 98% specificity (Bingley et al, 2001). The sensitivity 
at onset of TIDM for ICA is 70-90%, GADA 70-80%, lA- 2A 50-70% and lAA 
30-50% respectively, with the variances in the ranges reflecting the population 
differences between studies. In terms of prediction, multiple large intervention 
trials, while failing to prevent TIDM, have validated the predictive value of these 
autoantibodies for TIDM (Gale et al, 2004). The data also supported the notion 
that the presence of multiple autoantibodies was more predictive than the presence 
of a single type of autoantibody. 
As far as diagnosis of TIDM versus other forms of diabetes, the autoantibodies 
and metabolic markers are of great value. There remains a subset of patients that 
are autoantibody negative at onset. This subset may at times present a diagnostic 
challenge (Botero and Wolfsdrof, 2005) and it is of importance for treatment to 
know if TIDM (absolute requirement for insulin) or type 2 diabetes with a relative 
insulin resistance is present. 
Apoptosis and Autoimmunity in Type 1 Diabetes Mellitus 
Type 1 diabetes remains a common disease, although it accounts for only a 
relative small proportion of the overall diabetes population. Its onset occurs early 
29 
in life due to rapid loss of pancreatic P-cells by cell-mediated autoimmunity; 
pathological infiltration of islets with lymphocytes occurs prior to clinical 
manifestations. Both helper (004"") and cytotoxic (CD8^) T cells are actively 
involved, and are under the influence of MHC loci as well as non-MHC 
determinants. Indeed, the link between hyperactive immune response and Type 1 
diabetes is so striking that T cell depleted NOD (non-obese diabetic) mice fail to 
develop diabetes. In contrast, adoptive transfer of T cells from a diseased donor to 
a disease-free recipient concomitantly transfers the disease. 
Infection-associated molecular mimicry has been a popular hypothesis for 
the development of autoimmunity in Type 1 diabetes. However, there is evidence 
that early developmental remodeling and/or homeostasis of P-cell mass involves p-
cell apoptosis (Trudeau et al, 2000), which might trigger autoimmunity. In NOD 
mice, CD8* cells are primed in the pancreatic lymph nodes, remain undetectable 
for up to 3-4 weeks after birth and progressively increase to maximal levels by 8 
weeks of age. T cell priming is achieved by antigen-presenting cells that transport 
P-cell antigens specifically to pancreatic lymph nodes (Hoglund et al, 1999). 
Although the relationship between P -cell apoptosis and auto-immunity remains to 
be fully established, there is emerging evidence that T cell-induced apoptosis is a 
dominant effect or mechanism in Type 1 diabetes. In this regard, pancreatic P-cells 
derived from newly diagnosed patients with Type 1 diabetes were found to have 
increased cell surface expression of Fas(CD95) as compared to P -cells from 
healthy subjects that did not constitutively express detectable Fas(CD95). The 
apoptotic signal is then delivered via the Fas(CD95)L (Fas-ligand) expressed on 
infiltrating T lymphocytes (Stassi et al, 1997). Furthermore, expression of 
dominant-negative Fas(CD95) or neutralizing antibodies to Fas(CD95)L 
significantly blocks apoptosis, maintains adequate P -cell function, blocks adoptive 
transfer of diabetes by primed T cells, and retards the course of diabetes 
development (Allison et al, 2005). In contrast, transgenic expression of 
Fas(CD95) in P -cells accelerates the course of the disease (Pelrovsky et al, 2002). 
A similar mechanism has been demonstrated for cytokine-induced p-cell death 
(Riachy et al, 2006), thus highlighting the role of the extrinsic apoptotic pathway. 
Other studies provide evidence to implicate mitochondria as well in P -cell loss 
leading to Type 1 diabetes (Chang et al, 2004). 
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Similar to Type 2 diabetes, inhibition of Akt is implicated in Type 1 
diabetes and activation of Akt (i.e., by insulin-like growth factor) delays the onset 
of the diabetes (Chen et al, 2004). Recent findings have also implicated the 
transcription factor NF-KB in cell apoptosis more so in Type 1 than Type 2 
diabetes (Cnop et al, 2005). However, there still is a fair amount of controversy on 
whether NF-KB is upregulated or downregulated in p -cell apoptosis in diabetes. 
Pathogenesis of Diabetic Endothelial Dysfunction: Role of 
Nitrosative Stress and Peroxynitrite 
There are muhiple lines of evidence showing that reactive oxygen species 
such as superoxide anions, hydroxyl radicals and hydrogen peroxide, as well as the 
reactive nitrogen species, peroxynitrite, contribute to the injury of P-cells, which 
underlies the pathogenesis of type 1 diabetes. 
One of these pathways involves DNA strand breakage and consequent 
activation of the nuclear enzyme poly(ADP-ribose) polymerase (Virag and Szabo 
2002; Pacher et ai,2005). PARP-1 activation emerges as a key process in the 
development of diabetic cardiovascular dysfunction both in diabetic animals and in 
humans (Garcia Soriano et al .,2001; Pacher et al.,2002; Szabo et al .,2002) and 
might also contribute to the development of other diabetic complications such as 
nephropathy, neuropathy and retinopathy (Pacher and Szabo, 2005). Recent work 
on endothelial cells in conditions of elevated extracellular glucose has identified a 
novel mechanism by which PARP activation regulates the development of various 
pathways related to diabetic complications. In this scheme, elevated superoxide 
generation from the mitochondria (directly, or indirectly via the generation of 
peroxynitrite) induces DNA strand breaks and activates PARP which, in turn, 
induces the poly (ADP-ribosyl)ation of glyceraldehyde- 3-phosphate 
dehydrogenase. The resulting metabolic alterations activate NF-kB, aldose 
reductase and the polyol pathways (Du et al .,2003; Jagtap and Szabo, 2005). 
Accumulating evidence supports the hypothesis that diabetes is associated with 
increased nitrosative stress and peroxynitrite formation in numerous tissues, both 
in experimental animals and in humans (Pacher et al., 2005). 
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Diabetic Cardiomyopathy: Role of Nitrosative Stress and 
Peroxynitrite 
Diabetic cardiomyopathy is characterized by complex changes in the 
biochemical, mechanical, structural and electrical properties of the heart, which 
can underlie the development of early diastolic or late systolic dysfunction (or 
both), and the increased incidence of cardiac arrhythmias in diabetic patients. 
Diabetes is now considered a potent independent risk factor for mortality in 
patients hospitalized with heart failure, particularly in females (Sobel and 
Schneider, 2005). 
The experimental and clinical evidence suggest that nitrosative stress and 
peroxynitrite play an important role in the pathogenesis of diabetic 
cardiomyopathy. It appears that pharmacological neutralization of peroxynitrite 
improves vascular and/or cardiac function, not only in experimental models of 
diabetes but also in other pathophysiological conditions of the heart that are 
associated with increased peroxynitrite formation. These include acute myocardial 
infarction, chronic ischemic heart failure, doxorubicin-induced cardiomyopathy 
and diabetic cardiomyopathy (Mihm et al, 2001; Pacher et al, 2002; Pacher et al., 
2003 ). The mechanism by which neutralization of peroxynitrite protects against 
cardiovascular dysfunction involves protection against vascular and myocardial 
tyrosine nitration, PARP activation and lipid peroxidation, as all of these have 
previously been linked to diabetic cardiomyopathy as well as to peroxynitrite-
induced cardiac injury. Additional mechanisms of peroxynitrite-mediated diabetic 
cardiac dysfunction include inhibition of myofibrillar creatine kinase (Mihm et al., 
2001) and succinyl-CoA:3-oxoacid CoA-transferase (Turko et al., 2001) and 
activation of metalloproteinases. The mechanism is shown in figure 2. 
Peroxynitrite Induced DNA Damage in Diabetes 
There is accumulating evidence that nitric oxide, superoxide, 
peroxynitrite and later effectors such as poly (ADP-ribose) polymerase (PARP) 
are major effectors of P-cell death. Nitric oxide (NO") plays a fundamental role 
as a cellular signaling molecule in a variety of cells with a wide ranging 
spectrum of physiological processes within the body. However, excess NO' 
produced by cytokine-inducible NOS may act as an effector molecule 
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responsible for the cytotoxic effects of activated macrophages on the (3 cells 
(Kaneto et al, 1995; Mauricio and Mandrup-Poulsen , 1998; Spinas 1999; 
Pacher et al, 2007). In addition to macrophages, other sources of production of 
NO are the P cells themselves or endothelial lining cells possessing endothelial 
nitric oxide synthase (eNOS) activated when exposed to IL-lp, TNF-a, INF-y 
or other cytokines (Mandrup-Poulsen, 1998). While NO* has the ability to 
directly damage the islet cells, it also contributes to many other indirect 
deleterious effects on the P-cell such as binding iron-containing enzymes, 
reacting with protein prosthetic groups and combining with oxygen to produce 
reactive oxygen species. 
Peroxynitrite triggers nitration and nitrosylation which induce DNA damage 
and PARP activation. Nitrosative stress from nitration and nitrosylation leads to 
P cell destruction and diabetic complications such as cardiomyopathy, 
nephropathy, neuropathy and retinopathy (Kiss and Szabo , 2005; Pacher et al, 
2005). The P cell contains low levels of protective antioxidants and enzymes 
that metabolize free radicals; therefore, they are especially susceptible to 
oxidative and cytotoxic injury. Poly(ADP-ribose) polymerase (PARP) is a 
nuclear enzyme which senses DNA strand breaks and transfers ADP ribose 
units from nicotinamide adenine dinucleotide (NAD^) onto nuclear acceptor 
proteins to facilitate DNA repair. While PARP activation is a normal 
physiological process, oxidative damage from reactive oxygen species causes 
DNA strand breakage and triggers the overactivation of PARP. Excessive 
activation of PARP leads to the depletion of its substrate, NAD" ,^ and the cells 
energy source of ATP, both of which lead to cell dysfunction and death. In 
addition to depletion of necessary substrates for DNA repair, PARP also plays a 
role in iNOS activation, NF-KB-mediated transcription and activation of the 
MHC class 11. While these are necessary biological functions, when 
overactivated they may be deleterious to cells such as the pancreatic islets. In 
diabetes, hyperglycemia produces oxidative stress which induces DNA damage 
and strand breaks leading to PARP overactivation. While PARP initially has a 
protective effect on islet cells, excessive PARP activation causes depletion of 
NAD and ATP leads to apoptosis and necrosis of the pancreatic P cells (Kiss 
and Szabo , 2005;Pacher et al, 2005; Pacher et al, 2007). PARP activation 
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plays a central role in the path physiological changes during the development 
of Type I diabetes and also during the development of various forms of diabetic 
complication. PARP is a DNA damage sensor and signaling molecules and bind 
to both single and double stranded DNA breaks, becomes activated forms 
homodimers and initiates an energy-consuming cycle by transferring ADP-
ribose units from NAD"^  onto nuclear acceptor proteins such as histones, 
transcriptional factors. Diabetes is associated with chronic hyperglycemia, 
which triggers the production of advanced glycated end products, altered 
cellular redox state, activation of the polyol pathway, increased formation of 
diacylglycerol and the activation of protein kinase C (Pacher et al.,2005 & 
2007). Many of these pathways act together to stimulate the production 
oxidants and free radicals such as nitric oxide, superoxide and peroxynitrite 
stimulating oxidative and ntirosative stress. Oxidation and nitration lead to the 
development of diabetic complications, with dysfunction of the macro- and 
microvasculature accounting for disabilities and high morbidity and mortality 
rates of patients with diabetes. In type 1 diabetes PARP-mediated islet cell 
damage may be preventable at the level of autoimmune attack, at the level of 
oxidant and free radical generation, as well as at the level of enzymatic 
activation of PARP itself (Fig. 3). The development of the hypothesis that 
primary DNA damage in the p-cell leads to activation of PARP with subsequent 
depletion of intracellular NAD leading to inhibition of proinsulin synthesis, 
P-cell necrosis and diabetes has led to the testing of various pharmacological 
inhibitors of PARP in all animal models of diabetes. 
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Objectives of the Present Study 
Recent evidence*^ indicate? that most of the cytotoxicity attributed to NO' is 
rather due to peroxynitrite, produced from the diffusion-controlled reaction between 
NO and another free radical, the superoxide anion. Peroxynitrite interacts with lipids, 
DNA, and proteins via direct oxidative reactions or via indirect, radical-mediated 
mechanisms. These reactions trigger cellular responses ranging from subtle 
modulations, cell signaling to overwhelming oxidative injury, committing cells to 
necrosis or apoptosis. Peroxynitrite can damage DNA by introducing oxidative 
modifications in both nucleobases and sugar-phosphate backbone. It can also nitrate 
guanine, yielding 8-nitro-guanine, which leads to the formation of a basic sites that 
can be cleaved by endonucleases in vivo to give DNA single-strand breaks. The 
formation of DNA single-strand breaks represents a critical aspect of peroxynitrite-
mediated cytotoxicity, since they represent the obligatory trigger for the activation of 
the nuclear enzyme poly(ADP-ribose) polymerase (PARP), a pathway ultimately 
related to the induction of cell death and tissue inflammation. In vivo, peroxynitrite 
generation represents a crucial pathogenic mechanism in conditions such as stroke, 
myocardial infarction, chronic heart failure, diabetes, circulatory shock, chronic 
inflammatory diseases, cancer, and neurodegenerative disorders. 
In the present work, pUC 18 plasmid will be isolated from TBI strain of 
E. coU by using Qiagen plasmid Mega kit and modified with peroxynitrite. The 
modifications on DNA would be studied by ultraviolet and fluorescence 
spectroscopy, circular dichroism, thermal denaturation studies, nuclease SI 
digestibility and HPLC. Polyclonal antibodies against native and peroxynitrite 
modified plasmid will be generated in experimental animals. The specificity of 
induced antibodies will be evaluated by competition ELISA, gel retardation assay. 
These antibodies will be used as an immunochemical probe to detect nitrosative 
damage to DNA (by ELISA), isolated from diabetic patients. In order to assess the 
possible role of peroxynitrite modified DNA in the etiology of type I diabetes 
mellitus, serum antibodies of diabetes type I, sera from various age group will be 
assessed for their binding to native and peroxynitrite modified plasmid. It is also 
planned to evaluate the binding of serum antibodies in type II diabetes pafients 
with native and peroxynitrite modified plasmid. 
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MATERIALS 
Chemicals 
Diethylenetriamine pentaacetic acid (DTPA), nuclease SI, anti-human 
and anti-rabbit IgG alkaline phosphatase conjugates, methylated bovine serum 
albumin (MBSA), bovine serum albumin, p-nitrophenyl phosphate, ethidium 
bromide, Coomassie Brilliant Blue G-250, sodium dodecyl sulphate, Tween-20, 
Protein A-agarose (2.5ml pre-packed column), Freund's complete & incomplete 
adjuvants, agarose. Proteinase K, mannitol, uric acid , superoxide dismutase, 
carboxy-PTIO, sodium azide and dialysis tubing were purchased from Sigma 
Chemical Company, U.S.A. Plasmid isolation kit was from Qiagen, U.S.A. 
FicoU 400 and xylene cyanole FF were purchased from Pharmacia Fine 
Chemicals, Sweden. Luria broth was from Hi-Media Laboratories. Flat bottom 
ELISA plates (96 wells) were purchased from NUNC, Denmark. Acrylamide, 
bisacrylamide, ammonium persulphate and N,N,N',N'-tetramethylethylenediamine 
(TEMED) were from Bio-Rad Laboratories, U.S.A. Agar-Agar, EDTA (disodium 
salt), silver nitrate, dimethyl sulphoxide, (DMSO) formamide, chloroform, 
methanol, glacial acetic acid, iso-propanol, sodium chloride, sodium carbonate, 
sodium nitrite, sodium hydroxide, sodium bicarbonate, magnesium chloride, 
manganese dioxide, and potassium chloride were from Qualigens, India. 
Diphenylamine and ethanol were chemically pure. All other reagents/chemicals 
were of the highest analytical grade available. 
Equipment 
Shimadzu UV-1700 Spectrophotometer equipped with thermo-programmer 
and controller unit, Spectrofluorometer (Shimadzu, RF-5301), Spectropolarimeter 
(Jasco-J720), ELISA microplate reader (Labsystem Multiskan EX, FINLAND), 
ELICO pH meter (Ll-120), UV-transilluminator (Vilber Lourmat, France), 
Agarose and polyacrylamid gel electrophoresis assemblies (Genei, India), Avanti 
30 table top high speed refrigerated centrifuge (Beckman, USA). HPLC Duo flow 
(Bio-Rad Laboratories, U.S.A) and CI8 column (Supelco discovery, U.S.A) were 
the major equipments used in this study. 
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Collection of sera 
Fasting blood samples of diabetic patients were obtained from J.N Medical 
College Hospital, A.M.U, Aligarh. None of the diabetic patients had other 
autoimmune diseases. Specifically there were no cases of lupus or other connective 
tissue disorders. Normal human sera were obtained from healthy subjects. Samples 
were collected in a glass test tube and left to clot for 30 min at 37°C .Serum was 
separated by centrifugation at 3000 rpm for 10 min. Serum samples were heated at 
56°C for 30 min to inactivate complement proteins and stored in aliquots at -20°C 
with 0.1 % sodium azide as preservative. 
METHODS 
Purification of Calf Thymus DNA 
Commercially available calf thymus DNA was purified free of proteins and 
single stranded regions (Ali et ai, 1985). DNA (2 mg/ml) was dissolved in O.lx 
SSC buffer (15 mM sodium citrate and 150 mM sodium chloride, pH 7.3) and 
extracted with an equal volume of chloroform-isoamyl alcohol (24:1) in a 
stoppered container and shaken for 1 hr. The aqueous layer containing DNA was 
separated from organic layer and re-extracted with chloroform-isoamyl alcohol 
mixture. DNA was precipitated with two volumes of chilled absolute ethanol and 
collected on a glass rod. After drying in air, the DNA was dissolved in acetate 
buffer (30 mM sodium acetate containing 30 mM zinc chloride, pH 5.0) and 
treated with nuclease SI (150 units/mg DNA ) at 37°C for 30 min to remove single 
stranded regions. The reaction was stopped by adding one-tenth volume of 200 
mM EDTA, pH 8.0. Nuclease SI treated DNA was extracted twice with 
chloroform-isoamyl alcohol and finally precipitated with two volumes of chilled 
ethanol. The precipitate was dissolved in the required buffer. 
Determination of DNA Concentration 
DNA concentration was estimated colorimetric ally by the method of 
Burton (1956) using diphenylamine reagent. This assay depends upon a color 
reaction of deoxyribose. Exposure of DNA to strong acids removes the purine 
bases, leaving a polymer known as apurinic acid. With the release of purine, the 
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exposed reactive aldehyde group of deoxyribose reacts with diphenylamine 
producing blue color, which serves as the basis for estimating DNA concentration. 
(a) Crystallization of diphenylamine 
Diphenylamine (2 g) was dissolved in 200 ml boiling hexane. After adding 
0.5 g of activated charcoal the hot mixture was filtered through Whatman filter 
paper (No. 1) and the filtrate was kept overnight at 4°C. The preparation was 
finally dried at room temperature before use. 
(b) Preparation of diphenylamine reagent 
To 750 mg of recrystallized diphenylamine was added 50 ml of glacial 
acetic acid followed by 0.75 ml concentrated sulphuric acid. The reagent was 
prepared fresh before use. 
(c) Procedure 
Varying amounts of DNA in 1.0 ml of assay volume was mixed with 1.0 ml 
of IN perchloric acid and incubated at 70°C for 15 min. One hundred microlitre of 
5.43 mM acetaldehyde was added followed by 2.0 ml of freshly prepared 
diphenylamine reagent. The contents were mixed and incubated at room 
temperature for 16-20 hr for colour development. Absorbance was read at 600 nm 
and DNA concentration in unknown samples was determined from the standard 
plot of purified calf thymus DNA. 
Determination of Protein Concentration 
Protein was estimated by the methods of Lowry et at. (1951) and 
Bradford (1976). 
Protein estimation by Folin's-phenol reagent 
Protein estimation by this method utilizes alkali (to keep the pH high), 
Cu^ "^  ions (to chelate proteins) and tartarate (to keep the Cu^ "^  ions in solution 
at high pH). 
(a) Folin-Ciocalteau reagent 
The Folin-Ciocalteau reagent was diluted 1:4 with distilled water before use. 
40 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as under: 
(i) Two percent sodium carbonate in 100 mM sodium hydroxide. 
(ii) 0.5 percent copper sulphate in 1.0 percent sodium-potassium tartarate. 
The working reagent was prepared fresh by mixing components (i) and (ii) in 
50:1 ratio. 
(c) Procedure 
Varying amounts of protein in 1.0 ml of volume was mixed with 5.0 ml of 
freshly prepared alkaline copper reagent and incubated at room temperature for 10 
min. One ml of working Folin-Ciocalteau reagent was added followed by 30 min 
incubation at room temperature. The absorbance was monitored at 660 nm. Protein 
content of unknown sample was determined from the standard plot of bovine 
serum albumin. 
Protein estimation by dye-binding method 
This assay is based on the change in absorption maxima of an acidic solution of 
Coomassie Brilliant Blue G-250 from 465 nm to 595 nm when protein binds to the 
dye. Both hydrophobic and ionic interactions stabilize the anionic form of the dye, 
causing a visible color change. 
(a) Dye preparation 
One hundred mg Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 
95% ethanol and 100 ml of 85% (v/v) orthophosphoric acid was added. The 
resulting solution was diluted to a final volume of 1 litre and filtered through 
Whatman filter paper (No. 1) to remove undissolved particles. 
(b) Protein assay 
To one ml of solutions containing 10-100 |a,g protein was added 5 ml of dye 
solution and contents were mixed by vortexing. The absorbance was read at 595 
nm after 5 min against a reagent blank. 
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Isolation of Plasmid DNA (pUC18) 
(a) Materials used 
(i) Cell strain and media: TB1 strain of E. coli was used throughout the study. 
Luria Bertani (LB) was used as growth medium. AmpicilHn was added at a 
concentration of 100 |ag/ml to the broth. 
(b) Buffers used 
Resuspension buffer (PI) 
50 mM Tris-Cl, pH 8.0; 10 mM EDTA; 100 ng/ml RNase A 
Lysis buffer (P2) 
200 mM NaOH; 1% SDS (w/v) 
Neutralization buffer (P3) 
3.0 M potassium acetate, pH 5.5 
Equilibration buffer (QBT) 
750 mM NaCl; 50 mM MOPS, pH 7.0 
15% isopropanol (v/v); 0.15% Triton X-100 (v/v) 
Wash buffer (QC) 
1.0 M NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol (v/v) 
Elution buffer (QF) 
1.25 M NaCl; 50 mM Tris-HCl, pH 8.5; 15% isopropanol (v/v) 
TE buffer 
10 mM Tris-HCl, pH 8.0; 1 mM EDTA 
Plasmid DNA isolation 
E. coli cells containing plasmid were grown in 10 ml LB medium (starter 
culture) containing ampicillin at a concentration of 100 |J.g/ml. The above flask 
was subjected to vigorous shaking at 300 rpm for 8 hr at 37°C. The culture was 
transferred to 500 ml selective LB medium and incubated for 12 to 16 hr at 37°C 
with vigorous shaking at 300 rpm. Bacterial cells were harvested by centrifugation 
at 6000 rpm for 15 min at 4°C. The supernatant was completely discarded. The 
bacterial pellet was resuspended in 50 ml of PI buffer (containing RNase A) by 
vortexing. Fifty ml of P2 buffer was added to the suspension and contents were 
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mixed gently end to end 5 to 6 times. After 5 min incubation at room temperature, 
50 ml of chilled P3 buffer was added to the suspension and incubated for 30 min 
tjiHiuffy white material was formed. The precipitated material contained genomic 
DNA, proteins, cell debris and traces of SDS. The contents were centrifuged at 
11,000 rpm for 30 min at 4°C and pellet was discarded. Qiagen tip 2500 (the ready 
to use column) was equilibrated by passing 35 ml QBT buffer. Supernatant was 
applied to the tip and allowed to enter by gravity flow. Tip was washed with 200 
ml QC buffer. Bound plasmid DNA was eluted with 35 ml elution buffer (QF). 
The plasmid DNA was precipitated by adding 24.5 ml of isopropanol at room 
temperature and the precipitate was collected by centrifuging at 11,000 rpm for 30 
min at 4°C. The pellet was washed with 7 ml of 70% ethanol and centrifuged at 
11,000 rpm for 10 min. Supernatant was discarded carefully, transparent pellet 
formed was air dried and dissolved in minimal volume of TE buffer, pH 8.0. 
Generation of Peroxynitrite 
Peroxynitrite was synthesized by rapid quenched flow process (Beckman et 
al, 1994). Solutions of sodium nitrite ( 0.6 M in 50 mM sodium phosphate buffer, 
pH 7.4), hydrogen peroxide (0.6 N in 0.7 N HCl) and sodium hydroxide (1.2 M in 
distilled water) were prepared and chilled at 0°C for few minutes prior to use. The 
schematic representation of laboratory wares that were assembled to synthesize 
peroxynitrite is shown in Fig.4. A flow rate of 10 ml/min was adjusted to get the 
most concentrated solution of peroxynitrite. The product in 1.2 M NaOH was kept 
at -20°C. Concentration of stored peroxynitrite was assessed, every time it was 
used by recording absorbance at 302 nm and using molar extinction coefficient of 
1670 M''cnT' (Hughes and Nicklin , 1968). 
Modification of Plasmid by Peroxynitrite 
The experiment was carried out by incubating plasmid (50 faM) in 10 mM sodium 
phosphate buffer, pH 7.4 containing with 150 mM sodium chloride and 100 \iM of 
DTPA (metal ion chelator) with different concentrations of peroxynitrite (125 ^M, 
250 i^M and 500 |iM) at 37" C for 30 min. The samples were extensively dialysed 
at 37°C against PBS, pH 7.4. 
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Fig. 4 Assembly of peroxynitrite synthesis 
44 
Spectroscopic Analysis 
The ultraviolet absorption profile of plasmid and peroxynitrite modified 
plasmid was recorded in the wavelength range of 200-400 nm on Shimadzu UV-
1700 spectrophotometer. 
Fluorescence emission profile of plasmid and peroxynitrite modified plasmid 
were recorded on Shimadzu RF-5301 spectrofluorometer in presence of ethidium 
bromide which functioned as external fluorophor. 
Circular Dichroism Measurements 
Circular dichroism (CD) profile of plasmid and peroxynitrite modified 
plasmid were recorded on spectropolarimeter (Jasco-J720) in a 1 nm path length 
cell at 25°C. The wavelength range was from 202 nm to 322 nm and all the scans 
were recorded at an interval of 0.2 nm. The base line was adjusted with PBS, pH 
7.4 and the plasmid was used at 0.04 mM concentration. Molar ellipticities [0] 
were calculated in terms of base pair concentration according to the following 
equation:-
[e] = — 
lOcd 
where, [9] is measured ellipticity in mdeg, 'c ' is the molar concentration of 
plasmid DNA per base pair and 'd' is the path length. 
Absorption-Temperature Scan 
Thermal denaturation analysis of calf thymus DNA was performed in order to 
ascertain the degree of modification incurred on the DNA by determining mid 
point melting temperature (Tm). Native and modified DNA samples were 
subjected to heat denaturation on a Shimadzu UV-1700 spectrophotometer coupled 
with a temperature programmer and controller assembly (Hasan and AH, 1990). All 
the samples were melted from 30 °C to 95 °C at a rate of 1.5 °C I min after 10 min 
equilibration at 30 °C. The change in absorbance at 260 nm was recorded with 
increasing temperature. 
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Percent denaturation was calculated as per the following equation: 
A - A Percent denaturation = — ^ x 100 
Where, AT = Absorbance at a temperature T °C. 
A max - Final maximum absorbance on the completion of 
denaturation (95 °C). 
A30 = Initial absorbance at 30 °C. 
Detection of Strand Breaks 
The strand breaks generated as a result of modification of pUC 18 plasmid by 
peroxynitrite were detected by nuclease S1 digestibility assay. 
Gel preparation . 
Agarose (1%) in TAE buffer (40 mM Tris-acetate, pH 8.0 containing 2 mM 
EDTA) was dissolved by heating. The solution was cooled to about 50 °C and then 
poured into gel tray and allowed to solidify at room temperature. 
Agarose gel electrophoresis 
Native and modified plasmid were mixed with 1/10 volume of sample 
buffer (0.125% bromophenol blue, 30% Ficoll-400, 5 mM EDTA in 10 X 
electrophoresis buffer). The samples were loaded Jhe wells of 0.8% agarose gels 
electrophoresed for 2 hr at 30mA. The gels were stained with ethidium bromide 
(0.5 ^g/ml), viewed by illumination under UV light and photographed. 
Nuclease SI digestibility 
Plasmid and peroxynitrite modified plasmid were characterized by nuclease S1 
digestibility (Matsuo and Ross, 1987). One )4.g each of plasmid and peroxynitrite-
modified plasmid in acetate buffer (30 mM sodium acetate, 1 mM zinc sulphate, 
100 mM sodium chloride, pH 4.6) were treated with nuclease SI (23 unit/^g of 
DNA) for 30 min at 37°C. The reaction was stopped by adding one-tenth volume 
of 200 mM EDTA, pH 8.0. The digested and control samples were subjected to 
agarose gel electrophoresis. The gels were stained with ethidium bromide (0.5 
^ig/ml), viewed by illumination under UV light and photographed. 
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Quenching Studies 
Quenching studies were preformed to ascertain the type of radical causing 
damage to the plasmid .The effect of various quenchers like superoxide dismutase 
(SOD at 600 units/ml), nitric oxide-trapping agent (carboxy-PTIO at 20 mM), 
hydroxyl radical scavengers (D-mannitol and DMSO at 20 mM each ), 
antioxidants (ascorbic acid at 20 mM and uric acid at 0.04 mM) and a metal ion 
chelator (desferrioxamine at 10 mM) on plasmid modification were studied by 
incubating plasmid (50 ^g) in 100 mM sodium phosphate buffer, pH 7.4 
containing O.lmM DTPA and 0.2 mM of peroxynitrite at 37°C for 3 hours. 
Percent quenching was calculated from absorbance at A260 nm. 
Quantitation of 8-nitroguanine in Modified Plasmid 
Nitration of guanine residues in plasmid DNA is relatively easy to monitor 
by visible spectroscopy owing to characteristic yellow color. At different pH the 
absorbance of 8-nitroguanine falls in the range of 370-410 nm and the molar 
extinction is 9,144 M" cm"'. The extent of guanine nitration in plasmid was 
calculated by the absorbance measurement at 400 nm. 
Detection of 8-nitroguanine in Modified Plasmid by HPLC 
Separation of 8-nitroguanine was achieved by HPLC (Biologic Duo flow 
system, BioRad, (USA) equipped with UV-Visible multi wavelength detector. Its 
concentration was calculated by recording absorbance at 245 nm. Briefly 50 ^M 
plasmid sample was hydrolyzed in O.IN HCl (1 ml/mg DNA) at 100°C for 30 min 
(in order release the bases ) and dried under vacuum. The bases were dissolved in 
50 i^l of 0.1 M Tris HCl buffer, pH 8.5 and filtered through 0.42 i^M Milex, 
disposable syringe filter before loading on C-18 reversed phase column (Supelco, 
Discovery, 25 cm x 4.6 mm). The eluent buffer was 12.5 mM citric acid, 25 mM 
sodium acetate, 25 fiM ethylenediaminetetraacetate (EDTA), pH 5.2 and a flow 
rate of Iml/min was maintained . 8-nitroguanine was detected by identification of 
peak on the basis of retention time of standard 8-nitroguanine and splicing 
experiments . The absorbance of 4 series (I|iM- 5|iM) of known concentration of 
standard 8-nitroguanine was used as reference to determine the concentration of 8-
nitroguanine in modified plasmid. 
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Immunization Schedule 
Rabbits weighing 1-1.5 Kg were respectively, immunized in duplicates 
with native and peroxynitrite modified plasmid (50 [ig each). DNA samples were 
complexed with equal amount of methylated BSA in 1:1 ratio (w/w), emulsified 
with an equal volume of Freund's complete adjuvant and injected intramuscularly 
at multiple sites of the animal. Subsequent injections were given in Freund's 
incomplete adjuvant at weekly intervals. During the course of immunization, each 
animal received 400 ^g antigen. Seven days post boost test bleeds were used to 
find out the litre of induced antibodies. Marginal ear vein of immunized animals 
was punctured and blood was carefully collected to prevent hemolysis. Serum was 
separated and decomplemented by heating at 56 °C for 30 min. Pre-immune serum 
was collected prior to immunization. The sera were stored in small aliquots at 
-20 °C with 0.1% sodium azide as preservative. 
Isolation of IgG on Protein A-agarose 
Serum IgG was isolated by affinity chromatography on Protein A-agarose 
column. Serum (0.3 ml) diluted with equal volume of PBS, pH 7.4 was applied to 
column (12 mm x 45 mm) equilibrated with the same buffer. The wash through 
was recycled 2-3 times. Unbound IgG was removed by extensive washing with 
PBS, pH 7.4. The bound IgG was eluted with 0.58% acetic acid in 0.85% sodium 
chloride (Goding, 1976) and neutralized with 1 ml of IM Tris-HCl, pH 8.5. Three 
ml fractions were collected and read at 251 and 278 nm. IgG concentration was 
determined considering 1.40 OD280 = 1.0 mg mammalian IgG/ml. 
SDS-Polyacrylamide Gel Electrophoresis 
The homogeneity of purified IgG was ascertained by polyacrylamide gel 
electrophoresis under non-reducing conditions (Laemmli, 1970). 
The following stock solutions were prepared. 
(a) Acrylamide-bisacrylamide (30:0.8) 
A stock solution was prepared by dissolving 30 gm of acrylamide and 0.8 gm 
of bisacrylamide in distilled water to a final volume of 100 ml. The solufion was 
filtered and stored at 4°C in an amber colored bottle. 
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(b) Resolving gel buffer 
A stock solution was prepared by dissolving 36 gm Tris base in 48 ml of 
1.0 N HCl, pH was adjusted to 8.8 and the final volume brought to 100 ml 
with distilled water. 
(c) Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled 
water, pH was adjusted to 8.3 and volume adjusted to one litre. 
Procedure of PAGE 
Glass plates separated by 1.5 mm thick spacer were sealed with 1% agarose 
from sides and bottom. The non-reducing gel was prepared, poured between the 
glass plates and allowed to polymerize at room temperature. 
Protein sample (IgG) was mixed with one-fourth volume of sample buffer 
(10% glycerol and 0.002% bromophenol blue in 10 times concentrated 0.5 M Tris-
HCl, pH 6.8) and loaded into the well for electrophoresis at 70 volts for 4 hr in 
Tris-glycine buffer. The gels were stained with silver nitrate, which involved 
fixing the protein bands for 10 min in a mixture of 40% methanol and 13.5% 
formaldehyde followed by 2x washing with distilled water, at an interval of 5 min. 
Then the gel was immersed in 0.02% sodium thiosulphate solution for 1 min 
followed by two washings with distilled water at an interval of 20 sec. The gel was 
immersed in 0.1% silver nitrate solution for 10 min and finally with distilled water. 
The gel was then immersed in developer (3% sodium carbonate, 2% 
sodium dithiosulphate and 0.05% formaldehyde) to facilitate staining and on 
appearance of visible bands, the reaction was stopped by stopper solution (10% 
acetic acid and 10 %> methanol). 
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Recipe for 7.5% SDS-PAGE 
Solutions 
Acrylamide-bisacrylamide 
Stacking gel buffer 
Resolving gel buffer 
Distilled water 
10%SDS 
1.5% ammonium persulphate 
TEMED 
Stacking gel 
1.25 ml 
2.5 ml 
5.65 ml 
0.1ml 
0.5 ml 
0.75 ^1 
Resolving gel 
7.5 ml 
3.75 ml 
16.95 ml 
0.3 ml 
1.5 ml 
15^1 
Immunological Detection of Antibodies 
Sera were tested for antibodies by enzyme linked immunosorbent assay and 
gel retardation assay. 
(a) Enzyme linked immunosorbent assay 
Following reagents were prepared and used in ELISA. 
Tris buffered saline (TBS): 10 mM Tris, 150 mM NaCl, pH 7.4. 
Tris buffered saline containing Tween 20 (TBS-T): 20 mM Tris, 144 mM NaCl, 
2.68 mM KCl, pH 7.4 containing 500 |il Tween 20 per litre. 
Carbonate-bicarbonate buffer: 15 mM sodium carbonate, 35 mM sodium 
bicarbonate, pH 9.6 containing 2 mM magnesium chloride. 
Substrate: 500 ng p-nitophenyl phosphate per ml of carbonate-bicarbonate buffer, 
pH 9.6. 
Procedure 
ELISA was carried out on flat bottom polystyrene plates as described 
earlier (Ali and Alam, 2002). Briefly, microtitre wells were coated with one 
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hundred microlitres of 2.5 |ig/ml of DNA (in TBS, pH 7.4) and incubated for 2 hr 
at 37°C and overnight at 4°C. Each sample was coated in duplicate and half of the 
plate, devoid of antigen, served as control. The test-plate wells were emptied and 
washed thrice with TBS-T to remove the unbound antigen. Unoccupied sites were 
blocked with 150 ^1 of 1.5 % non-fat dry milk (in TBS, pH 7.4) for 4-5 hr at 4°C 
followed by single wash with TBS-T. In direct binding ELISA, antibodies were 
directly added into antigen-coated wells and incubated for 2 hr at 37°C and 
overnight at 4°C respectively. The wells were emptied and extensively washed 
with TBS-T. Anti-immunoglobulin alkaline phosphatase conjugate was added to 
each well. The conjugate was incubated at 37°C for 2 hr and then the plates were 
washed thrice with TBS-T followed by a single wash with distilled water. Para-
nitrophenyl phosphate was added and the developed color was read at 410 nm on a 
microplate reader. The results were expressed as mean of difference of absorbance 
values in test and control wells (Atesi - AcontroO-
(b) Competition ELISA 
The specific binding characteristics of antibodies were ascertained in 
competitive binding assay. Varying amount of inhibitors (0-20 |ag/ml) were mixed 
with constant amount of antiserum or IgG. The mixture was incubated at room 
temperature for 2 hr and overnight at 4°C. Immune complex thus formed was 
coated in the wells instead of the serum. The remaining steps were the same as in 
direct binding ELISA. 
Percent inhibition was calculated using the formula: 
'^inhibited 
Percent inhibition = 1 — x 100 
'^uninhibited 
(c) Gel Retardation Assay 
Antigen-antibody specificity was further confirmed by the gel retardation 
assay. A constant amount of DNA antigen (I f^ g) was mixed with varying amounts 
of IgG (Dixit and Ali, 2004) and incubated for 2 hr at 37°C and overnight at 4°C. 
At the end of incubation, one-tenth volume of sample buffer was added to antigen-
antibody complex and electrophoresed on 1% agarose gel in TAE buffer (pH 7.9) 
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for 2 hr at 30 mA current. The gels were stained with ethidium bromide (0.5 
|xg/ml) and visuaUzed under UV Hght and photographed. 
Isolation of Human DNA from Lymphocytes 
(i) Isolation of lymphocytes 
Blood was collected in EDTA from diabetic patients and normal healthy 
individuals. Lymphocytes were harvested by lysing red blood cells using red blood 
cell lysing solution (155 mM NH4CI; 10 mM NaOHCOj; 0.1 mM EDTA. pH 7.4). 
(b) Procedure 
The blood samples were cooled to 4 °C and 10 volumes of RBC lysis 
solution was added, swirled for 5-10 min. The sample was centrifuged at 2000 rpm 
at 4 °C for 10 min to harvest the lymphocytes. This process was repeated 3-4 
times, until a clear, white pellet of lymphocytes was obtained. 
(c) Isolation of DNA from lymphocytes 
Human DNA was isolated from lymphocytes as described by Ashok et al 
(1998). The lymphocytes were lysed by lymphocyte lysis buffer (10 mM Tris, 2 
mM EDTA, 400 mM NaCl, containing 1% SDS and 1 mg/ml proteinase K, pH 
7.4). 
(d) Procedure 
The lymphocytes were resuspended in lymphocyte lysis buffer, incubated at 
50°C for 1 hr and overnight at 37°C with constant shaking. Equal volume of 
chloroform- isoamyl alcohol (24:1) was added and the sample extracted for 15 min 
and allowed to stand for 30 min. The aqueous layer was removed carefully and the 
extraction step repeated 2-3 times. To the aqueous layer was added one-tenth 
volume of 3 N sodium acetate, pH 5.2 and 2 volumes of cold absolute ethanol to 
precipitate DNA. The DNA was collected by centrifugation, washed once with 
70% ethanol, allowed to dry and subsequently dissolved in PBS, pH 7.4. 
Absorbance of DNA solution was monitored at 260 nm and 280 nm to ascertain its 
purity and concentration. 
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Estimation of Total Nitrite/Nitrate in Sera of Diabetic patients 
Total nitrite (NO2' +NO3" ) analysis is an indicator of c '^er production.of 
nitric oxide in biological samples. It is estimated by Greiss Assay, which provides 
fbr^enzymatic reduction of NO3' by nitrite reductase using Greiss reagent 
(1% sulphanilamide, 0.1% N (l-naphthyl)-ethylenediamine dihydrocholoride in 
5% H3PO4 spectroquant). In short, serum (250 fil) of diabetic patients of all age 
groups were incubated at room temperature with 250 |il substrate buffer (imidazole 
O.lmol/1, NADPH 210 |imol/l, flavine adenine dinucleotide 3.8 ^mol/l at pH 7.6) 
in the presence of nitrate reductase for 45 min to convert NO3" to NO2' . Excess 
reduced NADPH^, which interferes with the chemical detection ..of NO2I,, was 
oxidized by continuation of the incubation of 5\ig (1ml) of LDH , 0.2 mmol/1 
(120fil) pyruvate and 79 ml of water. Total nitrite was then analysed by reacting 
the sample with Griess reagent. Reacted samples were treated with 500 i^l of TCA 
(20%), centrifuged for 15 min at 8000 g and the absorbance was recorded at 
548 nm. It was compared with that of NaN02 standard (0-100 |amol/l). 
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Isolation of Plasmid 
Plasmid (pUC18) was isolated from the culture lysate of E.coii (TBI strain) 
using .plasmid purification kit. The UV absorption spectrum of isolated plasmid 
DNA gave.characteristic A.max at 260 nm (Fig. 5). The purity was f u d g e d from 
absorbance ratio (A260/A280) of 1.8 and agarose gel eletrophoretic pattern. Different 
forms of isolated plasmid DNA are indicated in Fig.5 inset. 
Generation of Peroxynitrite 
Peroxynitrite is identified by/yellow colored characteristic peak with 
X-max at 302 nm (Fig 6). The concentration of peroxynitrite was conveniently 
assayed by diluting the peroxynitrite stock into 1.2 M sodium hydroxide and 
measuring the absorbance at 302 nm using molar extinction coefficient of 
1670 M"'cm"'. Peroxynitrite gradually decomposes with a half life of 1-2 
weeks, so it can be stored at -20°C. 
Agarose Gel Electrophoresis of Native and Peroxynitrite Modified 
Plasmid 
Electrophoresis of native and peroxynitrite modified plasmid was 
performed on 1% agarose gel (Fig.7). As evident from the figure, fluorescence 
intensity of form 1 (supercoiled) decreases proportionately with increasing 
peroxynitrite concentration indicating generation of single strand breaks as a result 
of modification. We observed a near complete destruction of the DNA helical 
structure beyond 0.5mM concentration of peroxynitrite as shown in lanes 6 and 7. 
Ultraviolet Absorption Spectral Studies of Native Plasmid and 
Peroxynitrite Modified Plasmid 
Pilot experiments were undertaken to work gut the optimum concentration 
of peroxynitrite needed to modify the plasmid. Plasmid (50 |a.M) was incubated 
with varying concentrations of peroxynitrite (125 |aM, 250 |aM and 500 yM). As 
shown in Fig.8, native plasmid gave a characteristic peak at 260 nm. Upon 
modification, the hyperchromic effect at 260 nm was proportional to the 
concentration of peroxynitrite. Compared to the absorbance of native plasmid at 
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Fig. 5 UV absorption profile of isolated plasmid DNA. Inset: Eletrophoretic 
pattern of plasmid DNA (0.5 |^ g) on agarose gel. The electrophoresis 
was carried out for 2 hr at 30 mA current. 
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Fig. 6 Absorption spectrum of peroxynitrite. 
Relaxed Form 
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Fig.7 Agarose gel electrophoresis of native plasmid and peroxynitrite 
modified plasmid. Lane (1) Native plasmid. Lane (2-7) contain plasmid 
modified with varying concentrations of peroxynitrite. The amount of 
Plasmid (0.5^g) was constant throughout. 
Lane 2: Plasmid modified with 0.125 mM peroxynitrite. 
Lane 3: Plasmid modified with 0.250 mM peroxynitrite. 
Lane 4: Plasmid modified with 0.4 mM peroxynitrite. 
Lane 5: Plasmid modified with 0.5 mM peroxynitrite. 
Lane 6: Plasmid modified with 0.75 mM peroxynitrite. 
Lane 7: Plasmid modified with l.OM peroxynitrite. 
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Fig. 8 Ultraviolet absorption spectra of native plasmid (o), peroxynitrite 
(125 |aM) modified plasmid (•), peroxynitrite (250 ^M) modified 
plasmid (•) and peroxynitrite (500 |iM) modified plasmid (A). 
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260 nm, the modified form exhibited 19.9 %, 28 %, and 69 % hyperchromicity 
upon treatment with 125 ^M, 250 \xM and 500 ^M of peroxynitrite respectively 
(Fig.8). Furthermore, the peroxynitrite modified counterparts of plasmid showed a 
new peak centered at 400 nm , which could be due to 8-nitroguanine . 
Fluorescence Spectroscopy of Native Plasmid and Peroxynitrite 
Modified Plasmid 
Neither plasmid nor its modified form has its own fluorescence and 
therefore an extrinsic fluorophore, ethidium bromide, was used to look into the 
structure of plasmid and its peroxynitrite modified forms. Plasmid and its modified 
conformers were incubated with ethidium bromide for 30 min and emission profile 
were recorded using excitation wavelength (325 nm) of ethidium bromide (Fig.9). 
Ethidium bromide gave an emission peak at around 595 nm. Its interaction with 
plasmid caused enhancement in fluorescence intensity at 595 nm peak and 
generation of a new peak at 653 nm. A decrease in the fluorescence intensity was 
seen in case of modified plasmid as compared to its native form signifying 
perturbation in DNA structure as a result of modification. On the basis of agarose 
gel pattern and photometric studies, it was decided to use the plasmid modified 
with 500 [iM peroxynitrite for further studies in the thesis. 
Circular Dichroism of Native Plasmid and Peroxynitrite Modified 
Plasmid / x 
The circular dichroism technique is used for elucidating conformation of a 
macromolecule, vv4H€h measures differential absorption of right and left circularly 
polarized light. The CD spectra of nucleic acids result primarily from the spatial 
asymmetry of the constituent nucleotides. Under our experimental conditions, the 
CD spectrum of plasmid (0.04 mM) was recorded in the wavelength range of 202-
322 nm at room temperature with a maximum or positive peak at 274 nm, a cross 
over at about 262 nm and the two negative peaks centered at 250 and 211 nm 
(Fig. 10). The CD profile of peroxynitrite modified plasmid shows two negative 
peaks at about 241 and 208 nm, a cross over at about 259 nm and a positive 
maxima at 277 nm with a shoulder at around 265 nm. Modified plasmid, when 
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Fig. 9 Fluorescence emission spectra of ethidium bromide (A), native 
plasmid (a), peroxynitrite (125|iM) modified plasmid (•), 
peroxynitrite (250|iM) modified plasmid (A), and peroxynitrite 
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Fig.lO Circular dichroic profile of native plasmid (—) and peroxynitrite (500nM) 
modified pJasmid ( ). 
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compared to the native plasmid shows changes in ellipticities from 1.143 mdeg to 
0.5 mdeg at 277 nm for the positive peak and from -1.05 to -0.526 at 250 nm and -
0.945 to -0.586 mdeg at 211 nm for the negative peaks. So there is a decrease of 
56.3% in the positive ellipticity at 277 nm. 
Temperature Induced Melting of Native Plasmid and Peroxynitrite 
Modified Plasmid 
The structural changes in plasmid by peroxynitrite treatment were further 
characterized by measuring the progress of denaturation of peroxynitrite modified 
preparation at 260 nm as a function of temperature (Fig.l 1). Melting behaviour of 
peroxynitrite modified plasmid sample was monitored over a temperature range of 
30-95°C at a rate of 1.5°C/min and increase in absorbance at 260 rmi was taken as a 
measure of melting denaturation. Under our experimental conditions, the isolated 
plasmid did not show any melting in the temperature range of 30-95°C and we did 
not subject it to melting studies below 30°C. The melting temperature of native 
calf thymus DNA at which 50% of the structural organization is lost was found to 
be 84°C, while in case of peroxynitrite modified plasmid , it was found to be 
72 °C. The result exhibits a net decrease of 12°C in the Tm value for the modified 
plasmid when compared to native calf thymus DNA. T^^thermal denaturation 
characteristic of native calf thymus DNA and perox^jftitirte modified plasmid are 
summarized in Table 2. 
Nuclease SI Digestibility of Native and Peroxynitrite Modified 
Plasmid 
Native and peroxynitrite modified plasmid were digested with nuclease S1 
(23 units/)ig DNA) for 30 min at 37 °C. The controls were native and modified 
plasmid without nuclease SI. Samples were run on \% agarose gel. Figure 12 
shows complete disappearance of the linear form and considerably low intensity of 
supercoiled form. Native DNA and SI treated native DNA showed almost identical 
electrophoretic migration pattern and fluorescence intensity. 
Quantitation of 8-nitroguanine in Peroxynitrite Modified Plasmid 
The amount of nitrated guanine residues in peroxynitrite modified plasmid 
has been calculated. Nitrated guanine (8-nitroguanine) is characterized by yellow 
color with maximal absorbance at 400 nm. Under our experimental conditions, the 
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Fig.l2 Nuclease SI digestibility of native and peroxynitrite modified plasmid. 
Lane 1 contained native plasmid, while lane 2 contained native plasmid 
treated with nuclease SI. Lane 3 contained peroxynitrite modified 
plasmid while Lane 4 contained peroxynitrite modified plasmid treated 
with nuclease SI for 30 min. Electrophoresis was carried out on 1% 
agarose for 2 hr at 30 mA. 
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TABLE 2 
UV Absorption and Thermal Denaturation Characteristics of 
Native and Peroxynitrite Modified Plasmid 
Parameters 
Absorbance ratio 
(A260/ A280) 
Hyperchromicity 
at 95 °C 
Melting Temperature 
(Tm), °C 
Onset of duplex 
melting 
Native DNA 
1.86(1.93) 
(36) 
(84) 
(74) 
Peroxynitrite modifled 
plasmid DNA 
1.12 
19 
72 
38 
Values in parentheses are for the experiments done with native calf thymus DNA 
TABLE 3 
8-nitroguanine Content of Peroxynitrite Modified Plasmid 
Peroxynitrite concentration }iM of nitroguanine 
125 [iM 0.54 
250 i^M 2.5 
500 |iM 5.0 
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colorless solution of plasmid changed to pale yellow upon peroxynitrite treatment; 
a clear evidence of nitration. This yellow color was a result of 8-nitroguanine 
content in peroxynitrite-modified plasmid. 8-nitroguanine content was calculated 
from absorbance data at 400 nm. The 8-nitroguanine content of plasmid modified 
with 125 |iM, 250 (xM, and 500 ^M peroxynitrite was found to be 0.54, 2.5 and 5 
I^ M respectively (Table 3). 
HPLC Analysis of 8-nitroguanine in Native and Peroxynitrite 
Modified Plasmid 
Figures 13 to 15 show representative HPLC chromatograms of standard 
solution of 8-nitroguanine (IfaM, 2|aM, 3nM 4^M and 5|aM) dissolved in the 
eluant buffer 12.5 mM citric acid, 25 mM sodium acetate, 25 (iM EDTA (pH 5.2). 
A well defined peak at retention time ~ 9.5 min is observed for 8-nitroguanine. 
When the acid hydrolysate of plasmid modified with 500 ^M of peroxynitrite was 
analyzed, 8-nitroguanine was detected and identified by a well defined peak at a 
retention time of 9.5 minute (Fig. 17 ) The concentration of 8-nitroguanine was found 
to be 3.8 i^ M when calculated from the calibration curve (Fig. 15 inset) derived from 
standard 8-nitroguanine. No peak of 8-nitroguanine (at a retention time of ~9.5 min) 
was observed in the case of acid hydrolyzed native plasmid (Fig. 16). 
Quenching Studies 
The modification of plasmid was carried out in the presence of different 
quenchers. As evident from figure 18, the nitric oxide trapping agent (carboxy-
PTIO) strongly (80%) inhibited the modification by peroxynitrite, whereas 
antioxidant enzyme (SOD) which is a scavenger of super oxide radical (02') was 
less effective (~ 55% inhibition). Effects of various scavengers of hydroxyl radical 
(DMSO, mannitol), antioxidant (ascorbic acid) and metal ion chelator 
(desferrioxamine) on DNA modification induced by peroxynitrite were studied. 
High concentrations of ascorbic acid (20mM) and desferroxamine (10 mM) 
inhibited the DNA modification by 65% and 43.8% respectively, while uric acid 
(0.04 mM) caused 80% inhibition. Whereas, OH scavenger had no effect on DNA 
modification induced by peroxynitrite. 
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Fig. 13 HPLC chromatogram of standard 8-nitroguanine at two different 
concentrations( l^m and 2[a.m) shown in figure a and b respectively. 
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Fig.15 HPLC chromatogram of standard 8-nitroguanine at a concentration of Sjam. 
Inset: Standard curve of different concentrations of 8-nitroguanine loaded on 
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Fig. 17 HPLC chromatogram of acid hydrolysate of peroxynitrite modified plasmid. 
It showed the presence of 8-nitroguanine by a peak at almost identical 
retention time as that of standard 8-nitroguanine. 
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Fig. 18 Effect of free radical scavengers, antioxidants, NO-trapping agent and 
metal ion chelator on the modification of DNA induced by peroxynitrite. 
The NO-trapping agent (carboxy-PTIO), OH scavengers (SOD, DMSO, 
and marmitol), antioxidant (ascorbic acid, uric acid) and metal ion chelator 
(desferrioxamine) were used at different concentrations. SOD was used at a 
concentration of 600 units/ml. 
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Immunogenicity of Peroxynitrite Modified Plasmid 
The antigenicity of peroxynitrite-modified plasmid was evaluated by 
inducing antibodies in rabbits. Antigenic specificity of the induced antibodies 
was assayed by direct binding and competition ELISA. The binding of these 
antibodies to the immunogen and native plasmid DNA was further checked by 
gel retardation assay. 
Antibodies against Peroxynitrite Modified Plasmid 
Antiserum obtained from immunized animal was subjected to direct 
binding immunoassay on immunogen coated polystyrene microtitre plates. 
Preimmune serum, used as control, showed poor binding with the immunogen. The 
antiserum showed a high titre (>I: 12800) in direct binding ELISA on immunogen 
coated plates (Fig. 19). The specificity of induced anti-peroxynitritQjr-modified 
plasmid antibodies was evaluated by competitive inhibition assay. A maximum of 
63.7% inhibition in antibody binding was observed at 20 ^g/ml of the immunogen 
(Fig.20). The concentration of immunogen required for 50% inhibition was 10 
^g/ml. While peroxynitrite modification of pUC 18 DNA rendered it highly 
immunogenic, the native conformer did not produce any appreciable immune 
response in experimental animals (Fig.21 & 22 respectively). 
Purification and Cliaracterization of Serum IgG 
Immunoglobulin G was isolated from preimmune and immune rabbit serum 
by affinity chromatography on Protein A-agarose column (Fig.23). The purity of 
IgG was ascertained by SDS-poIyacrylamide gel electrophoresis in. absence of a 
reducing agent.y^Appearance of a single band in SDS-polyacrylamide gel under non 
reducing condition (Fig.23 inset) establishes the purity of our IgG. 
IgG isolated from preimmune and anti-peroxynitrite plasmid serum was 
subjected to direct binding immunoassay on fli^ plates coated with peroxynitrit 
modified plasmid. Anti-peroxynitrite'-rrtodified plasmid IgG showed strong binding 
with the coated antigen whereas preimmune IgG, used as control, showed 
negligible binding (Fig.24). The specificity of anti-peroxynitrit^5^odified plasmid 
I2G was evaluated bv competition ELISA. wherg in 92% inhibition in the antibody 
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Fig. 19 Level of induced antibodies against peroxynitrite modified plasmid. 
Direct binding ELISA with preimmune (o) and immune serum (•). 
The microtitre plate was coated with peroxynitrite modified plasmid 
(2.5^g/ml). 
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Fig.20 Inhibition ELISA of serum antibodies against peroxynitrite 
modified plasmid (-•-) and preimmune serum (-o-). Peroxynitrite 
modified plasmid was used as a coating antigen (2.5 |ig/ml) as well 
as an inhibitor. 
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Fig.21 Level of induced antibodies against native plasmid. Direct binding 
ELISA with preimmune serum (o) and immune serum (•). The 
microtitre wells were coated with native plasmid (2.5|ig/ml). 
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Fig.22 Inhibition ELISA of anti-native plasmid antibodies (-•-) and 
preimmune (-o-) sera. Native plasmid was used as a coating antigen 
(2.5 ng/ml) as well as inhibitor. 
77 
2 3 4 5 
Fraction Number 
Fig.23 Elution profile of anti-peroxynitrite modified plasmid IgG on 
Protein-A agarose affinity column. Inset: SDS-PAGE of purified 
IgG on 7.5% polyacrylamide gel. 
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(•) and preimmune IgG (o) to peroxynitrite plasmid . Microtitre 
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binding wets -acliievecl with the peroxynitrit^^cmbdified plasmid, while native 
^tasffltd-Xould cau&c only 37% inhibition in antibody acttvity (Fig.25). Fifty 
percent inhibition,ibf peroxynitrite modified plasmid binding was observed at an 
inhibitor concentration of 3.4 ^g/ml. 
Gel Shift Assay 
Antigen-antibodies interaction was further evaluated by gel shift assay. 
Constant amount of plasmid DNA or its peroxynitrite-Wiodified form was incubated 
with varying amount of anti-peroxynitrite=modified DNA IgG for 2 hr at 37°C and 
overnight at 4°C. The resulting immune complexes were then electrophoresed on 
1% agarose for 2 hr at 30 mA. Figure 26 (a) shows the binding of IgG to 
peroxynitrite modified plasmid. As.clearly evident, with an increase in the amount 
of IgG, there was an increase in the formation of high molecular weight immune 
J 
complex, which resulted in retarded mobility and increased fluorescence intensity 
near the well. However, under identical experimental conditions the unmodified 
plasmid failed to show the shift in its mobility when incubated with anti-
peroxynitrit^^odified plasmid IgG (Fig.26 (b)). These results suggest that 
epitopes on plasmid and modified plasmid are quite distinct. 
Immuno-crossreactivity of Anti-Peroxynitrite Modified Plasmid 
Antibodies 
Antigenic specificity of the induced anti-peroxynitrite modified plasmid 
antibodies was investigated by competitive inhibition assay. The induced 
antibodies exhibit a wide range of heterogeneity in recognizing varied inhibitors 
that include nucleic acid polymers and bases (both unmodified and modified 
forms). A maximum of 92% inhibition of the anti-peroxynitrite plasmid IgG was 
observed with the immunogen as an inhibitor (Fig.25). The induced antibodies 
were highly specific for peroxynitritq^odified plasmid with only 2.5 i^g/ml 
inhibitor required to cause 50% inhibition. Native plasmid caused considerably 
rSmieed inhibition in antibody activity. Incubation of immune IgG with native 
plasmid inhibited its binding to the immunogen by 37% at 20 |ig/ml (Fig.25). 
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Fig. 25 Inhibition of anti-peroxynitrite modified plasmid IgG binding by 
piasmid (-0-), and peroxynitrite modified plasmid (-•-). The 
microtiter plate was coated with peroxynitrite modified plasmid (2.5 
|xg/ml). 
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(a) 
(b) 
Fig.26 Band shift assay of anti-peroxynitrite modified plasmid-IgG binding to (a) 
Peroxynitrite modified plasmid and (b) Native piasmid. Electrophoresis 
was carried out on I % agarose gel for 2 hr at 30mA. 
(a) Peroxynitrite modified plasmid (l|ig , Lane 1) was incubated with 10, 
20,40 and 60 \ig of anti-peroxynitrite modified plasmid-IgG (lanes 2-5) for 
2 hr at 37° C and overnight at 4° C. 
(b) Native plasmid (lug . Lane I) was incubated with 10, 20,40 and 60 ng of 
anti-peroxynitrite modified plasmid-IgG (lanes 2-5) under identical 
conditions. 
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Native, ROS^nd peroxynitrite--Tnodified calf thymus DNA showed 
inhibition of 38%, 43.5% and 60% respectively (Fig.27). To achieve 50% 
inhibition, 13 |Jg/ml peroxynitrite calf thymus DNA was required. Whereas ROS 
modified plasmid showed maximum inhibition of 56% at 20 \ig/m\. 
Human placental DNA, its ROS and peroxynitrite modified forms caused 
33%, 55% and 63% inhibition respectively in the binding of the immune IgG to the 
modified DNA (Fig.28). 
Lymphocj^e DNA of human origin modified by peroxynitrite and ROS 
showed the maximum inhibition of 65% and 56% respectively (Fig.29). While 
native lymphocyte DNA exhibited 35% of binding of immune IgG to immunogen. 
The 200 bp fragments of calf thymus DNA caused 23.2% inhibition, while 
its R0S(5Snd peroxynitritCinodified forms exhibited 38% and 67% inhibition 
respectively (Fig.30). Fifty percent of inhibition of antigen-antibody interaction 
was obtained with 9 jag/ml of peroxynitri1<e3J»odified 200 bp of calf thymus DNA. 
The DNA bases-guanine, cytosine, adenine, thymine, their ROS (hydroxyl 
radical)--;inodified and peroxynitrite;5itiodified forms were used as inhibitors of 
antibody binding activity. Guanine showed a moderate inhibition of 39%. In 
contrast, ROSr:and peroxynitritOriodified guanine were found to be potent 
inhibitors showing maximum inhibition of 59% and 76% .respectively (Fig.31). 
The amount of ROS-guanine and peroxynitrite-guanine required for 50% inhibition 
in antibody activity was 12 [ig/ml and 4 |ag/ml respectively. Cytosine caused less 
inhibition (28%), whereas its ROS modified form was a moderate inhibitor, 
showing a maximum of 53% inhibition in antibody activity. In contrast, 
peroxynitrite modified form was found to be a potent inhibitor, showing a 
maximum inhibition of 63% (Fig.32). The amount of peroxynitrite-cytosine 
required for 50% inhibition was 13 fig/ml. Thymine and its ROS-modified form 
produced of 25% and 31% inhibition respectively (Fig.33), whereas peroxynitrite-
thymine showed a moderate inhibition of 45%. In contrast, adenine and its ROSCJ' 
and peroxynitrit^^odified forms showed a maximum of 26%, 45% and 51% 
inhibition respectively (Fig.34) Table 4 summarizes the binding characteristics 
data of anti-peroxynitrite plasmid antibodies as evaluated by inhibition ELISA. 
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Fig. 27 Inhibition of anti-peroxynitrite modified plasmid IgG binding by 
calf thymus DNA (-0-), ROS modified calf thymus DNA (-•-) , 
ROS modified plasmid(B) and peroxynitrite modified calf thymus 
DNA (-A-) . The microtiter plate was coated with peroxynitrite 
modified plasmid (2.5 /ag/ml). 
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Fig. 28 Inhibition of anti-peroxynitrite modified plasmid IgG binding by 
human placental DNA (-0-), ROS modified human placental 
DNA (-•-) , and peroxynitrite modified human placental DNA 
(-A-) . The microliter plate was coated with peroxynitrite 
modified plasmid (2.5 )ig/ml). 
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Fig. 29 Inhibition of anti-peroxynitrite modified piasmid IgG binding by 
lymphocyte DNA (-o-) , ROS modified lymphocyte DNA ( - • - ) , 
and peroxynitrite modified lymphocyte DNA ( - A - ) . The 
microtiter plate was coated with peroxynitrite modified piasmid 
(2.5 ng/ml). 
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Fig. 30 Inhibition of anti-peroxynitrite modified plasmid IgG binding by 
200 bp DNA (-0-) , ROS modified 200 bp DNA ( - • - ) , and 
peroxynitrite modified 200 bp DNA ( - A - ) . The plate was coated 
with peroxynitrite modified plasmid (2.5 |ig/ml). 
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Fig. 31 Inhibition of anti-peroxynitrite modified plasmid IgG binding by 
guanine ( -0-) , ROS modified guanine ( - • - ) , and peroxynitrite 
modified guanine ( - A - ) . The microliter plate was coated with 
peroxynitrite modified plasmid (2.5 |ig/ml). 
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Fig. 32 Inhibition of anti-peroxynitrite modified plasmid IgG binding by 
cytosine ( -0-) , ROS modified cytosine ( - • - ) , and peroxynitrite 
modified cytosine (—A—). The microtiter plate was coated with 
peroxynitrite modified plasmid (2.5 |Jg/ml). 
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Fig. 33 Inhibition of anti-peroxynitrite modified plasmid IgG binding by 
thymine (-0-), ROS modified thymine ( -• - ) , and peroxynitrite 
modified ( -A- ) thymine. The microtiter plate was coated with 
peroxynitrite modified plasmid (2.5 \iglm\). 
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Fig. 34 Inhibition of anti-peroxynitrite modified plasmid IgG binding by 
adenine ( -0- ) , ROS modified adenine ( - • - ) , and peroxynitrite 
modified adenine ( - A - ) . The microtiter plate was coated with 
peroxynitrite modified plasmid (2.5 |j.g/ml). 
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TABLE 4 
Cross-reaction of Anti-Peroxynitrite Modified Plasmid IgG 
Inhibitors 
OONO"-plasmid 
Native plasmid 
ROS plasmid 
Human placental DNA 
OONO~-human placental DNA 
ROS human placental DNA 
Native calf thymus DNA 
0 0 N 0 ~ - calf thymus DNA 
ROS calf thymus DNA 
Native 200 bp DNA 
OONO"-200bp DNA 
ROS 200bp DNA 
Native guanine 
0 0 N 0 ~ - guanine 
ROS guanine 
Native adenine 
OONO~-adenine 
ROS adenine 
Native cytosine 
OONO - cytosine 
ROS cytosine 
Native thymine 
OONO"-thymine 
ROS thymine 
Native human lymphocyte DNA 
OONO -human lymphocyte 
DNA 
ROS human lymphocyte DNA 
MaximumVo 
inhibition 
at 20 rig/ml 
92% 
37% 
56% 
33% 
63% 
55% 
38% 
60% 
43.5% 
23.2% 
67% 
38% 
39% 
76% 
59% 
26% 
51% 
45% 
28% 
63% 
53% 
25% 
45% 
31% 
35% 
65% 
56% 
Concentration 
for 
50%inhibition 
(Hg/ml) 
2.5 
— 
13 
— 
7 
16 
— 
13 
— 
— 
9 
— 
4 
12 
— 
18 
— 
13 
18 
— 
— 
— 
— 
15 
18 
Percent 
relative 
affinity 
100 
— 
26.1 
— 
51.3 
21.2 
— 
26.1 
— 
— 
— 
— 
68 
28.3 
— 
20 
— 
24.2 
17 
— 
— 
— 
— 
22.6 
18.8 
Microtitre plates were coated with peroxynitrite modified plasmid (2.5iag/ml) 
OONO" — Peroxynitrite 
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Binding of Autoantibodies from Diabetics Type I Patients to Native 
and Peroxynitrite Modified Plasmid 
In this study, we have analyzed randomly selected 89 cases of diabetes type 
I divided into three age groups ranging from 4 to 60 year. Sera from age and sex-
matched normal healthy individuals served as control. All sera were diluted to 
1:100 in PBS and subjected to direct binding ELISA on solid phase separately 
coated with equal amounts of plasmid and peroxynitrite modified plasmid. Only 
54 out of 89 diabetic sera showed^^igher binding"•^STperoxynitrite-modified 
plasmid. The remaining samples showing low absorbance were discarded and have 
not been included for further studies. In the 4 to 15 year age group, 21 sera out of 
30 samples tested, showed enhanced binding with modified plasmid as compared 
to the native form (Fig.35). Direct binding ELISA data of 30 samples of diabetic 
patients in 16 to 30 year age group revealed that only 14 samples had better 
binding with modified plasmid (Fig.36). In the case of 31 to 60 year old diabetic 
patients, only 19 out of 29 sera showed higher binding to modified plasmid 
(Fig.37). 
Immuno-crossreactivity of Autoantiobodies from Diabetes Type I 
Patients 
Competition ELISA was carried out to analyze the specific binding of 
circulating autoantibodies in diabetic patients (type 1) for native and peroxynitrite 
modified plasmid. For this we selected serum samples in each group showing high 
binding in direct binding ELISA. 
In the case of eleven sera chosen from age group of 4 to 15 year, the 
observed maximum inhibition with peroxynitrite modified plasmid was in the 
range of 42 to 62 percent while with native plasmid it ranged from 20 to 39% 
(Figs.38-41). Mean inhibition for the entire sample tested with native plasmid was 
26.7±6.3%, while for peroxynitrite modified plasmid , it was 54±6%. Table 5 
summarizes the inhibition data of anti-DNA antibodies binding to native and 
peroxynitrite modified plasmid. 
In the case of diabetic sera from age group of 16 to 30 year, the observed 
mean inhibition with modified plasmid was found to be 54.5±5.9% while for 
native plasmid, it was 26 ±5.9% (Table 6). Inhibitions in the range of 42% to 62% 
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Fig.35 Direct binding ELISA of serum autoantibodies from diabetes patients 
(age group: 4-15 yr) to native (•) and peroxynitrite modified plasmid 
(•). Normal human sera (1) served as negative control. The plate was 
coated with peroxynitrite modified plasmid (2.5 ^g/ml). 
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Fig.36 Direct binding ELISA of serum autoantibodies from diabetes patients 
(age group: 16-30 yr) to native (•) and peroxynitrite modified plasmid 
(•). Normal human sera (1) served as negative control. The plate was 
coated with peroxynitrite modified plasmid (2.5 ^ g/ml). 
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Fig.37 Direct binding ELISA of serum autoantibodies from diabetes patients 
(age group: 31-60 yr) to native (•) and peroxynitrite modified plasmid 
(•). Normal human sera (1) served as negative control. The plate was 
coated with peroxynitrite modified plasmid (2.5 |ag/ml). 
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Fig. 38 Serum autoantibodies detection against native (o, A, D) and 
peroxynitrite modified plasmid (•, • , • ) in type I diabetic 
patients. Sera 3, 5 and 9 in 4-15 yr age group were analyzed on the 
microtitre plate coated with peroxynitrite modified plasmid 
(2.5Mg/ml) 
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Fig. 39 Serum autoantibodies detection against native (o, A, n) and 
peroxynitrite modified plasmid (•, • , • ) in type I diabetic 
patients. Sera 12, 13 and 16 in 4-15 yr age group were analyzed on 
the microtitre plate coated with peroxynitrite modified plasmid 
(2.5^g/ml). 
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Fig. 40 Serum autoantibodies detection against native (o, A, D) and 
peroxynitrite modified plasmid (•, A, • ) in type I diabetic 
patients. Sera 17, 18 and 19 in 4-15 yr age group were analyzed on 
the microtitre plate coated with peroxynitrite modified plasmid 
(2.5^g/ml). 
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Fig. 41 Serum autoantibodies detection against native (o, A) and 
peroxynitrite modified plasmid (•, • ) in type I diabetic patients. 
Sera 21 and 22 in 4-15 yr age group were analyzed on the 
microtitre plate coated with peroxynitrite modified plasmid 
(2.5^g/ml) 
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TABLE 5 
Competitive Inhibition Data of Serum Autoantibodies in Diabetes 
Type I Patients 
Sera no Maximum percent inhibition at 20^g/ml 
Native Plasmid Peroxynitrite Modified Plasmid 
56 
42 
56 
62 
52 
55 
52 
61 
58 
46 
52 
53.8±6 
The microtitre plates were coated with peroxynitrite modified plasmid (2.5 }ig/ml). 
Serum samples were from 4-15 yr age group. 
3 
5 
9 
12 
13 
16 
17 
18 
19 
21 
22 
n±SD 
34 
29 
29 
24 
39 
20 
23 
32 
22 
20 
22 
26.7±6.3 
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TABLE 6 
Competitive Inhibition Data of Serum Autoantibodies in Diabetes 
Type I Patients 
Sera no Maximum percent inhibition at 20^g/ml 
Native Plasmid Peroxynitrite Modified Plasmid 
53 
51 
62 
59 
57 
52 
56 
42 
59 
54.1±6 
The microtitre plates were coated with peroxynitrite modified plasmid (2.5 |ig/ml). 
Serum samples were from 16-30 yr age group. 
3 
4 
5 
6 
7 
8 
9 
10 
15 
Mean ±SD 
20 
25 
32 
37 
22 
19 
25 
28 
31 
26±5.9 
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were obtained with peroxynitrite modified plasmid. Whereas a low inhibition, 
ranging from 19% to 37% could be achieved with native plasmid (Figs. 42-44). 
Ten sera from type I diabetes patients were collected in the age group of 
31 to 60 year. Inhibitions ranging from 45% to 72% were obtained in Lab\n&^ LMT^ 
modified plasmid. *Miile with native plasmid, the observed inhibition ranged from 
22% to 34% (Figs.45-47). The mean inhibition with all the diabetic sera of this age 
group was 59±8.3% with modified plasmid and 25.6±4.7% with native plasmid 
respectively. The data has been summarized in the Table 7. 
Isolation of IgG from the Sera of Diabetes Type I Patients 
IgG was isolated from selected sera of diabetic patients within the 
different age groups (4-15, 16-30 and 31-60 years) on a Protein A-agarose column. 
A single symmetrical peak was obtained. The purity of the IgG isolated from all 
sera was confirmed by single band movement in polyacrylamide gel. A 
representation of IgG isolation and purity has been depicted in figure 48. 
Binding of Immunoglobulin G from Different Diabetes Type I 
Patients to Native and Peroxynitrite Modified Plasmid 
Purified IgG from type I diabetes patients, were first subjected to direct 
binding ELISA, on a microtitire plate coated with native plasmid and peroxynitrite 
modified plasmid to evaluate the amount required for antigen saturation. 
The binding specificity of the isolated IgG, towards plasmid and 
peroxynitrite modified plasmid, was evaluated by inhibition ELISA. Each IgG 
sample was mixed with varying amounts of plasmid or peroxynitrite modified 
plasmid (0.1-20 ^g/ml) and incubated for 2 hr at 37°C and overnight at 4°C. The 
inhibition results of diabetic sera IgG of 4 to 15 year age group have been are 
presented in figures 49-52. The observed antibody (IgG) activity inhibition ranged 
from 41-67% with the modified plasmid while with native plasmid it varied from 
28-39%. The mean of inhibitions for various sample tested with native plasmid 
was 34.7±3.7%, while with peroxynitrite modified plasmid, it was 57±7.3%. Table 
8 summarizes the inhibition data of isolated IgG of this age group. 
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Fig. 42 Serum autoantibodies detection against native (o. A, D) and 
peroxynitrite modified plasmid (•, • , • ) in type I diabetic 
patients. Sera 3, 4 and Sin 16-30 yr age group were analyzed on 
the microtitre plate coated with peroxynitrite modified plasmid 
(2.5ng/ml) 
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Fig. 43 Serum autoantibodies detection against native (o, A, D) and 
peroxynitrite modified plasmid (•, • , • ) in type I diabetic 
patients. Sera 6, 7 and 8 in 16-30 age group were analyzed on the 
microtitre plate coated with peroxynitrite modified plasmid 
(2.5^g/ml) 
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Fig. 44 Serum autoantibodies detection against native (o, A, a) and 
peroxynitrite modified plasmid (•, • , • ) in type I diabetic 
patients. Sera 9, 10 and 15 in 16-30 yr age group were analyzed on 
the microtitre plate coated with peroxynitrite modified plasmid 
(2.5^ig/ml) 
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Fig. 45 Serum autoantibodies detection against native (o, A, a) and 
peroxynitrite modified plasmid (•, • , • ) in type I diabetic 
patients. Sera 3, 4 and 5 in 31-60 yr age group were analyzed on 
the microtitre plate coated with peroxynitrite modified plasmid 
(2.5^g/ml) 
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Fig. 46 Serum autoantibodies detection against native (o, A, a) and 
peroxynitrite modified plasmid (•, • , • ) in type I diabetic 
patients. Sera 9, 10 and 11 in 31 -60 yr age group were analyzed on 
the microtitre plate coated with peroxynitrite modified plasmid 
(2.5^g/ml) 
108 
100 
Inhibitor Concentration, M9/rnl 
Fig. 47 Serum autoantibodies detection against native (o, A, D) and 
peroxynitrite modified plasmid DNA (•, • , • , T) in type I 
diabetic patients. Sera 14, 18, 19 and 20 in 31-60 yr age group 
were analyzed on the microtitre plate coated with peroxynitrite 
modified plasmid (2.5(ig/ml) 
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TABLE 7 
Competitive Inhibition Data of Serum Autoantibodies in Diabetes 
Type I Patients 
Sera no Maximum percent inhibition at 20^g/ml 
Native Plasmid Peroxynitrite Modified Plasmid 
45 
56 
50 
56 
57 
62 
62 
70 
61 
72 
59.1±8.2 
The microtitre plates were coated with peroxynitrite modified plasmid (2.5 |ig/ml). 
Serum sample were from 31-60 yr age group. 
3 
4 
5 
9 
10 
11 
14 
18 
19 
20 
Mean ±SD 
23 
22 
31 
23 
34 
24 
22 
23 
22 
32 
25.6±4.7 
no 
3 4 
Fraction Number 
Fig.48 Elution profile of IgG from the serum of diabetes type I patients on 
Protein A-agarose affinity column. Inset: SDS-PAGE of purified IgG 
on 7.5% polyacrylamide gel. 
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Fig.49 Inhibition of IgG, samples 3,5 and 9, isolated from type I diabetic 
patients by native (o,A, n) and peroxynitrite modified plasmid 
( • , A , H ) in 4-15 yr age group. The microtitre plates were coated 
with peroxynitrite modified plasmid (2.5|ig/ml). 
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Fig 50. Inhibition of IgG, samples 12,13 and 16, isolated from type I 
diabetic patients by native (o,A, n) and peroxynitrite modified 
plasmid (•, A , B ) in 4-15 yr age group. The microtitre plates were 
coated with peroxynitrite modified plasmid (2.5|ig/ml). 
113 
20-
: l 40 
c 60 
o if 
o 
Q. 80-
100 I I I I I I 111 I I i I • I 11 t I I I I • 11 1—I I I I 11 
0.01 0.1 1 10 100 
Inhibitor Concentration, pg/ml 
Fig 51. Inhibition of IgG, samples 17, 18 and 19 isolated from type I 
diabetic patients by native (o,A, n) and peroxynitrite modified 
plasmid ( • , A , H ) in 4-15 yr age group. The microtitre plates were 
coated with peroxynitrite modified plasmid (2.5ng/ml). 
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Fig. 52 Inhibition of IgG, samples 21 and 22 isolated from type I diabetic 
patients by native (o,A ) and peroxynitrite modified plasmid 
(•,A) in 4-15 yr age group.The microtitre plates were coated 
with peroxynitrite modified plasmid (2.5|ig/ml). 
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TABLE 8 
Competitive Inhibition Data of IgG isolated from Diabetes Type I 
patients in 4 to 15 year age group 
Sera no Maximum percent inhibition at 20^g/ml 
Native Plasmid Peroxynitrite Modified Plasmid 
62 
54 
61 
56 
61 
65 
51 
41 
67 
53 
55 
57±7 
The microtitre plates were coated with peroxynitrite modified plasmid (2.5 |ig/ml). 
3 
5 
9 
12 
13 
16 
17 
18 
19 
21 
22 
Mean ± SD 
35 
37 
33 
33 
38 
39 
28 
31 
39 
38 
31 
34.7±3.7 
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The binding specificity of isolated IgG from in 16-30 years age group has 
been shown in figures 53-55. The inhibition in diabetic patient IgG binding with 
peroxynitrite modified plasmid was in the range of 51%-73% whereas with native 
plasmid it ranged from 31-43%. Table 9 summarizes the inhibition data of isolated 
IgG of this age group. 
Inhibition ELISA was also performed with IgG isolated from sera of 
patients in the 31 to 60 year age group. The complex was formed as described 
earlier. With the modified plasmid , 61-73% inhibition was obtained where as with 
native plasmid the observed inhibition was 31-43%) (Figs 56-58). The results have 
been summarized in Table 10. 
Band Shift Assay 
Band shift assay was employed to visualize and thus confirm the interaction 
of native and peroxynitrite modified plasmid with autoantibodies from diabetes 
patients. Constant amount of antigens were incubated with varying amount of 
IgG for 2 hr at 37°C and overnight at 4°C. Immune complexes were 
electrophoresed on 1% agarose for 2 hr at 30 mA. Figure 59 a & b show the 
binding of diabetes IgG to native and peroxynitrite modified plasmid. With 
increasing concentration of IgG, there was a corresponding increase in the 
formation of higher molecular weight immune complexes which resulted in 
retarded mobility and corresponding decrease in the fluorescence intensity of 
unbound antigen. Normal human IgG incubated under identical conditions did not 
show immune complex formation. 
Probing Nitrosative DNA Damage in Diabetes Type I Patients 
Using Anti-Peroxynitrite Modified Plasmid Antibodies 
DNA was isolated from lymphocytes of various diabetic patient in 
different age groups. The purity and concentration of the DNA preparations was 
ascertained by A260 and A2go measurements. DNA isolated from lymphocytes of 
normal healthy individuals were used as controls for this study. Anti-peroxynitrite 
modified plasmid IgG was used as a probe to detect nitrosative lesions in the DNA 
from diabetic type I patients of different age group through solid 
phase immunoassay. Immune complexes, formed by incubating isolated DNA 
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Fig. 53 Inhibition of IgG, samples 3,4 and 5 isolated from type I diabetic 
patients by native (o,A, n) and peroxynitrite modified plasmid 
( • , A , H ) in 16-30 yr age group.The microtitre plates were coated 
with peroxynitrite modified plasmid (2.5|ig/ml). 
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Fig. 54 Inhibition of IgG, samples 6,7 and 8 isolated from type I diabetic 
patients by native (o,A, D) and peroxynitrite modified plasmid 
( • , A , B ) in 16-30 yr age group. The microtitre plates were coated 
with peroxynitrite modified plasmid (2.5^g/ml). 
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Fig. 55 Inhibition of IgG, samples 9,10 and 15 isolated from type I 
diabetic patients by native (o,A, D) and peroxynitrite modified 
plasmid ( • , A , B ) in 16-30 yr age group. The microtitre plates 
were coated with peroxynitrite modified plasmid (2.5fag/ml). 
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TABLE 9 
Competitive Inhibition Data of IgG isolated from Diabetes Type I 
patients in 16 to 30 year age group 
Sera no Maximum percent inhibition at 20^g/ml 
Native Plasmid Peroxynitrite Modified Plasmid 
66 
73 
51 
59 
68 
63 
59 
68 
67 
63.7±6.5 
3 
4 
5 
6 
7 
8 
9 
10 
15 
Mean ±SD 
43 
42 
32 
38 
43 
39 
31 
40 
42 
38.3±4.5 
The microtitre plates were coated with peroxynitrite modified plasmid (2.5 |ig/ml). 
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Fig. 56 Inhibition of IgG, samples 3,4 and 5 isolated from type I diabetic 
patients by native (o, A, o) and peroxynitrite modified plasmid 
( • , A , B ) in 31-60 yr age group. The microtitre plates were coated 
with peroxynitrite modified plasmid (2.5|ig/ml). 
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Fig. 57 Inhibition of IgG, samples 9,10 and 11 isolated from type I 
diabetic patients by native (o,A, n) and peroxynitrite modified 
plasmid (•, A , B ) in 31-60 yr age group. The microtitre plates were 
coated with peroxynitrite modified plasmid (2.5|ig/ml). 
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Fig. 58 Inhibition of IgG, samples 14,18,19 and 20 isolated from type I 
diabetic patients by native (o,A, D) and peroxynitrite modified 
plasmid (•, A , B ) in 31-60 yr age group. The microtitre plates were 
coated with peroxynitrite modified plasmid (2.5ng/ml). 
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Table 10 
Competitive Inhibition Data of IgG Isolated from Diabetes Type I 
Patients in 31 to 60 year age group 
Sera no Maximum percent inhibition at 20^g/ml 
Native Plasmid Peroxynitrite Modified Plasmid 
61 
63 
67 
70 
61 
72 
67 
62 
67 
73 
66.3±4.4 
The microtitre plates were coated with peroxynitrite modified plasmid (2.5 |ig/ml). 
3 
4 
5 
9 
10 
11 
14 
18 
19 
20 
Mean ±SD 
39 
35 
39 
39.5 
32 
39 
32 
42.2 
43 
31 
37.1±4.3 
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(a) 
(b) 
Fig. 59 Band shift of IgG from diabetic patient using (a) native and (b) 
peroxynitrite modified plasm id. Varying concentrations of IgG were 
incubated with a constant amount of piasmid (I |ig) for 2 hr at 37" C 
and overnight at 4°C. Electrophoresis was carried out on 1% Agarose 
for 2hr at 30 mA. Lane 1 contains native (or modified) piasmid while 
lanes 2-5 contain native or peroxynitrite modified piasmid with 
20,40,60 and 80 (ig of IgG from type I diabetes patient. 
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(0-20|ig/ml) and anti-peroxynitrite modified plasmid IgG were used in 
competitive-inhibition ELISA. The coating antigen on microtitre plate was 
peroxynitrite modified plasmid DNA (2.5 ng/ml). 
DNA was isolated from eleven type 1 diabetic patients in 4-15 year age 
group. The induced inhibition in the activity of anti-peroxynitrite plasmid 
antibodies ranged for 53 % to 71 % with the mean inhibition being 62.5 ± 5.5% 
(Figs. 60-62). 
Nine DNA samples were isolated from the age group of 16-30 year. The 
induced anti-peroxynitrite modified plasmid antibodies were inhibited in the range 
of 61% to 72% (Figs.63 and 64). 
On same pattern, DNA samples isolated from age group of 31 -60 year type 
I diabetic patients, recognized anti-peroxnitrite modified plasmid IgG appreciably 
and inhibited its activity in the range of 63% to 73% (Figs. 65 and 66). 
On the contrary, DNA isolated from normal healthy individuals of all the 
age groups showed maximum inhibition of 23% to 31%. The binding data of the 
anti-peroxynitrite modified plasmid IgG to DNA isolated from diabetic patients is 
summarized in Table 11. 
Serum Estimation Total Nitrite In Diabetes Type I Sera 
Serum nitrite levels of diabetic patients in 4-15 yearr age group were 
50.6±7.33 nmol/1 whereas in control sera it was found to be 25.13±6.7 |amol/l. In 
the 16-30 year age group the serum nitrite concentration was 55±6.53 nmol/1 but in 
age matched control it was 24.27±7.27^mol/l. Serum nitrite levels of the 31-60 
year age group patients was found to be slightly higher; it was calculated to be 
58±5.79 nmol/1. In age matched control it came to be 23.7±5.43 ^mol/1 (Fig.67). 
Detection of Antibodiesy^ie- Native and Peroxynitrite Modified 
Plasmid in Diabetes Type 11 Patients 
Twenty five samples from diabetes type II patients were analyzed. Sera 
from normal healthy individuals served as control. 
The binding of circulating antibodies in diabetic type II sera (1:100 
dilution) with native and peroxynitrite modified plasmid was assessed by direct 
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Fig. 60 Inhibition of anti-peroxynitrite modified plasmid antibody binding 
to peroxynitrite modified plasmid by DNA isolated from 
lymphocytes of diabetic type I patients in age group of 4-15 yr 
(3, 5, 9, 12) represented by ( • , B , A ) . (O) represents lymphocyte 
DNA from healthy control. The microtitre plates were coated with 
peroxynitrite modified plasmid (2.5|ig/ml). 
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Fig.61 Inhibition of anti-peroxynitrite modified plasmid antibody binding 
to peroxynitrite modified plasmid by DNA isolated from 
lymphocytes of diabetic type I patients in age group of 4-15 yr 
(13, 17, 18) represented by ( • , B , A ) . (O) represents lymphocyte 
DNA from healthy control. The microtitre plates were coated with 
peroxynitrite modified plasmid (2.5|ag/ml). 
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Fig. 62 Inhibition of anti-peroxynitrite modified plasmid antibody binding 
to peroxynitrite modified plasmid by DNA isolated from 
lymphocytes of diabetic type I patients in age group of 4-15 yr 
(19,21,22) represented by ( • , B , A ) . (O) represents lymphocyte 
DNA from healthy control. The microtitre plates were coated with 
peroxynitrite modified plasmid (2.5|ig/ml). 
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Fig. 63 Inhibition of anti-peroxynitrite modified plasmid antibody binding 
to peroxynitrite modified plasmid by DNA isolated fi-om 
lymphocytes of diabetic type I patients in age group of 16-30 yr. 
(• ,B,A,T) represent sera no. 3,4,5 and 6. (o) represents 
lymphocyte DNA from healthy control. The microtitre plates were 
coated with peroxynitrite modified plasmid (2.5|ag/ml). 
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Fig. 64 Inhibition of anti-peroxynitrite modified plasmid antibody binding 
to peroxynitrite modified plasmid by DNA isolated from 
lymphocytes of diabetic type I patients in age group of 16-30 yr. 
(•,",A,T,A) represent sera no 7,8,9,10 and 15. (o) represents 
lymphocyte DNA from healthy control. The microtitre plates were 
coated with peroxynitrite modified plasmid (2.5ng/ml). 
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Fig. 65 Inhibition of anti-peroxynitrite modified plasmid antibody binding 
to peroxynitrite modified plasmid by DNA isolated from 
lymphocytes of diabetic type I patients in age group of 31-60 yr. 
(•,B,A,A,T) represent sera no. 3,4,5,9 andlO. (o) represents 
lymphocyte DNA from healthy control.The microtitre plates were 
coated with peroxynitrite modified plasmid (2.5ng/ml). 
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Fig. 66 Inhibition of anti-peroxynitrite modified plasmid antibody binding 
to peroxynitrite modified plasmid by DNA isolated from 
lymphocytes of diabetic type I patients in age group of 31-60 yrs. 
(•,«,A,A,T) represent sera no. 11,14,18,19 and 20. (o) 
represents lymphocyte DNA from healthy control. The microtitre 
plates were coated with peroxynitrite modified plasmid 
(2.5Mg/ml). 
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TABLE 11 
Detection of Nitrosative Lesions in DNA of Diabetes Type I 
Patients. Binding of Anti-peroxynitrite modified plasmid IgG to 
DNAisolated from Lymphocytes of Diabetes type I Patients 
Patient sera Number of Max. percent inhibition Mean +SD 
(different age group) samples (at 20^g/ml) 
56,62,63,59,63,53,69,71,65, 
4-15 yrs 11 62.5±5.5 
68,59 
15-30 yrs 9 61,63,64,67,61,71,71,72,67 66.3±4.3 
64,63,73,72,68,63,64,69,71, 
30-60 yrs 10 67.6±3.6 
69 
Normal Human 
DNA 
23, 29,31,23,27,28,26 26.7±2.7 
The microtitre plates were coated with peroxynitrite modified plasmid (2.5 |ag/ml). 
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Fig.67 Comparison of serum nitrite content in normal human sera (•) and 
diabetic type I patients (•) of each age group. Each histogram 
represents mean ± S.D. 
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Fig.68 Direct binding ELISA of serum autoantibodies from diabetes type II 
patients to native (•) and peroxynitrite modified plasmid (•). Normal 
human sera (1) served as negative control. The plate was coated with 
peroxynitrite modified plasmid (2.5 fig/ml). 
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binding ELISA. Serum antibodies exhibited nearly similar binding with native 
plasmid and peroxynitrite modified plasmid (Fig.68). 
The specific binding of serum antibodies to native and peroxynitrite 
modified plasmid was studied by competitive inhibition solid phase assay. An 
inhibition in the range of 21 % to 37 % and 31% to 42 % was recorded with 
native and peroxynitrite modified plasmid respectively. The data, which has been 
presented in Table 12, shows negligible difference in the inhibition of serum 
antibodies, from diabetes type 11 patients, by native and peroxynitrite modified 
plasmid. 
Affinity isolated IgG from diabetes type 11 patients was also used for 
binding studies with native and peroxynitrite modified plasmid .Not much 
difference in the inhibition of IgG from diabetes type II patients was obtained with 
native and peroxynitrite modified plasmid . The inhibition ranged from 25 to 39 
percent with native plasmid and 29 to 42 percent with the peroxynitrite modified 
plasmid (Table 13). 
Genomic DNA was isolated from lymphocyte of diabetes type II patients. 
The purity and concentration of DNA preparations were ascertained by A260 nm 
and A280 nm measurement. Anti-peroxynitrite modified plasmid antibody was used 
as a probe to detect the nitrosative damage in the DNA isolated from type II 
diabetic patients. DNA sample from diabetes type II patients as well as healthy 
individuals caused an inhibition ranging from 11.2 to 34 % in the activity of the 
induced anti-peroxynitrite modified plasmid antibodies. Data show no appreciable 
difference in the inhibition caused by the DNA of healthy individuals and type II 
diabetes patients. 
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TABLE 12 
Competitive Inhibition Data of Serum Antibodies from Diabetes 
Type II Patients 
Sera no Maximum percent inhibition at 20 M.g/ml 
Native Plasmid Peroxynitrite modified plasmid 
1 31 39 
2 27 32 
3 32 36 
4 29 37 
5 21 28 
6 29 42 
7 30 39 , 
8 31.3 37 
9 27 34 
10 23 34 
11 34 39 
12 37 39 
13 31 41 
14 31 41 
15 33 37 
16 32 38 
17 25 31 
Microtitire plates were coated with peroxynitrite modified plasmid (2.5 pg/ml) 
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TABLE 13 
Competitive Inhibition Data of IgG Isolated From Diabetes 
Type II Patients 
Sera no. Maximum percent inhibition at 20 ^g/ml 
Native Plasmid Peroxynitrite modified plasmid 
1 35 34 
2 33 37 
3 39 38 
4 31 42 
5 39 29 
6 32 38 
7 31 37 
8 32 41 
9 35 40 
10 38 40 
11 39.4 33 
12 26 31 
13 38.2 29 
14 28.3 34 
15 25 41 
16 32.5 39 
17 25 37 
Microtitire plate were coated with peroxynitrite modified plasmid (2.5 |ig/ml). 
140 
TABLE 14 
Detection of Nitrosative Lesions in DNA of Diabetes Type II 
Patients. Binding of Anti-peroxynitrite plasmid-IgG to DNA 
isolated from Lymphocytes of Diabetes Type II Patients 
Sera no Max. percent inhibition (at 20^g/ml) 
i JTs 
2 33 
3 29 
4 23 
5 11.2 
6 29 
7 32 
8 25 
9 29 
10 30 
11 33 
12 16 
13 29 
14 32 
15 25 
16 32 
17 28.3 
N 26.7±2.7 
The microtitre plates were coated with peroxynitrite modified plasmid. 
N represents normal human DNA. Data given here is mean ± S.D of 10 samples. 
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Peroxynitrit^ (ONOCO, a product of the rtfhction ^f nitric oxide with 
superoxide, is a potent and versatile oxidant that can attack a wide range of 
biological molecules. The peroxynitrite anion is relatively stable under basic 
conditions but is protonated at physiological pH. The half-life of the protonated 
species, peroxynitrous acid, is about 1 second. Peroxynitrite anion can cross cell 
membrane freely and is an extremely strong and reactive oxidant (Chang et 
a/.,2005). It can react with DNA, proteins and lipids leading to cellular damage 
and cytotoxicity. Its relatively slow reactions with a wide variety of biological 
molecules render it highly toxic. Cellular injuries caused by peroxynitrite are 
considered to contribute to the D^hogjenesis of a series of diseases, including 
inflammatory processes, iscl^emiarrep^fusion, septic shock, neurodegenerative 
processes (Boulanger,1999; Szabo,1996), atherosclerosis, rheumatoiji^ arthritis, 
myocardial dysfunction and autoimmune diabetes (Grace et a/., 1998). Evaluation 
of the potentially injuring mechanisrfi'of peroxynitrite.has proved difficult, due to 
its short life span ( half-life ~ 10-15 min) and low concentration in vivo (Yang et 
al.,2000). In recent years, many literatures, have focused on protein and DNA 
damage caused by peroxynitrite (Millar, 2005). 
/ ^ Reaction of peroxynitrite with DNA can lead to oxidation and/or nitration 
to initiate a complex series of transformations involving base damage or strand 
breaks as well as reactions with the deoxyribose portion of the DNA. In addition to 
DNA strand breaks, peroxynitrite reacts primarily with guanine in DNA to form a 
variety of modifications including 8-nitroguanine and 8-oxo-guanine. The latter is 
at least 1000 times more susceptible to further oxidation by peroxynitrite than 
guanine itself Thus, both sugar and base damage result from exposure of DNA to 
peroxynitrite in vitro (Kennedy et al., 1997; Tretyakova et al.,2001). However, it 
has recently been recognized that the proportions of the various DNA products are 
strongly dependent on the presence of CO2 and thus the formation of 
nitrosoperoxycarbonate (ONOOCO2") (Yermilov et al., 1996; Tretyakova et 
a/.,2001). Peroxynitrite causes predominantly deoxyribose oxidation (i.e., strand 
breaks and oxidized abasic sites) (Tretyakova et ai,2001). However, in the 
presence of 25 mM bicarbonate (pH 7.4), base damage involving predominantly 
guanine becomes the major product with a large increase in the proportion of 8-
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nitro dG (Yermilov et al, 1996; Tretyakova et a/.,2001). Interestingly, while there 
is a major shift in chemistry from deoxyribose to nucleobases in the presence of 
CO2, the total quantum of DNA damage remains constant (Tretyakova et 
a/., 2001). 
Peroxynitrite can also induce oxidative and nitrative damage to biological 
components other than DNA, including lipids and proteins. Damage to lipids, as 
determined by several in vitro studies, includes peroxidation and nitration 
(O'Donnell et a/., 1999; Radi et al .,1991). In vitro, bolus addition of peroxynitrite 
has been shown to lead to efficient nitration of free and protein-bound tyrosine 
(Ischiropoulos et a/., 1992; Gow et a/., 1996; Lymar et a/., 1996 ; Ramezanian 
et al .,1996 ). Among the proteins modified and inactivated by nitration are Mn-
SOD (MacMillan-Crow, 1998 &1999), tyrosine phosphatases (Takakura et al, 
1999), cytochrome P450 2B1 (Roberts et o/.,1999) and ribonucleotide reductase 
(Guittet et al.,2000), to list a few. Several enzymes are also inactivated by 
oxidation of critical cysteine residues involved in the catalytic mechanism, such as 
in yeast alcohol dehydrogenase (Crow et a/., 1997) and glyceraldehyde-3-
phosphate dehydrogenase (Mohr et a/., 1994; Souza and Radi, 1998). Thiolates in 
[4Fe-4S] clusters are also susceptible to peroxynitrite attack ( Keyer and Imlay, 
1997). Several proteins including neurofilament-L ( Crow et a/., 1997; Strong et 
a/., 1998), Mn-SOD (MacMillan-Crow,1996 ) and the sarcoplasmic reticulum Ca-
ATPase (SERCa-2a;) (Viner et al, 1996) have been determined to contain 3-
nitrotyrosine, presumably as a result of their exposure to peroxynitrite. In spite of 
these in vitro and in vivo findings, it is still not clear whether the functional 
changes observed in vitro extend also to the in vivo situation, and whether the in 
vivo findings simply reflect chemical modifications with no functional 
significance. 
According to recent WHO reports, there are approximately 171 million cases 
of diabetes. The number is increasing rapidly and it is estimated that the number will 
double by the year 2030. Indians are genetically more susceptible to diabetes and the 
WHO has predicted that the number of diabetes in India would go up to 40 million 
by year 2010, and 74 million by year 2025. The WHO has also issued a warning 
that India is going to be the diabetic capital of the world. If the predictions are real 
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then the Asian continent appears to be the hub of the disease. Compared to urban 
population (13%), people living in rural areas are reporting low incidence of 
diabetes (3%). 
Diabetes mellitus is a chronic disease and one of the most import^t public 
health problems in the world, especially in developing countriesCT^ow a days^ 
when blood glucose and insulin levels of patients can be carefully controlled, life 
quality is mainly determined by the development of late complications. These 
complications include atherosclerosis, microvascular dysfunction of the eye 
causing retinopathy, cataract, nephropathy in the kidney and damage of the 
peripheral nerves (peripheral neuropathy), perforating ulcers in the gastrointestinal 
tract, etc (Halliwell and Gutteridge ,1999). Diabetic state is often associated with 
oxidative and nitrosative stress which is supposed to play an important role in the 
development of late diabetic complications. The production of nitric oxide and 
peroxynitrite are increased in diabetes . ( Pacher et al ., 2007; Vareniuk et ai, 
2007). Peroxynitrite has been found to be a source of platelet damage in diabetes 
(Tannouse/a/.,1999). 
Peroxynitrite induces DNA damage and thus triggers the activation of DNA 
repair systems. A DNA nick sensor enzyme, poly (ADP-ribose) polymerase-1 
(PRAP-1) becomes activated upon sensing DNA breakage (Zanchi e/ al, 2001). 
PRAP activation plays a central role in the pathophysiological change during the 
development of Type 1 diabetes and also during the development of various forms 
of diabetic complications including cardiovascular dysfunction, nephropathy, 
neuropathy and retinopathy (Pacher et ai, 2007). Inhibition of insulin secretion, 
induction of DNA damage radicals (Szabo., 2005) and islets cell lysis and 
apoptosis have all been observed in rat and human islets exposed to NO or 
peroxynitrite in vitro. Type-1 diabetes results from the destruction of insulin 
producing beta-cells. This destruction has been attributed to peroxynitrite 
formation in the islet beta-cells. Peroxynitrite reacts with the zinc-cluster of NOS 
leading to its uncoupling, suggesting that peroxynitrite not only depletes exisiting 
NO* but also reduces a tissue's ability to produce more NO'. Hyperglycemia is 
linked with the regulation of NOS expression and the production of peroxynitrite. 
Glucose induced aortic expression of eNOS (endothelial NOS) can be suppressed 
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by the addition of PKC inhibitor, suggesting that PKC activation is a key event in 
hyperglycemia-induced NOS upregulation (perhaps mediated by NF-kappa B) 
(Hinketal.,2001). 
In the present study, pUC 18 plasmid was isolated from E. coH. and 
modified respectively by different concentrations of peroxynitrite (125 |iM, 250 
\xM and 500 ^M) generated from nitrite and acidified hydrogen peroxide by rapid 
quenched flow method. Peroxynitrite caused extensive damage to the plasmid, 
leading to single strand breaks and base modification. The plasmid exhibited 
19.9%, 28%, and 69% hyperchromicity after peroxynitrite modification compared 
to the native double stranded analogue. This could be attributed to the single strand 
breaks, destabilization of hydrogen bonds and modification of nitrogenous bases 
which result in the destruction of the chromophoric groups through attack on the 
sugar-phosphate back bone. Furthermore, another peak was observed in the case of 
peroxynitrite modified plasmids at a wavelength of 400 nm, which is characteristic 
of 8-nitroguanine. Nitration of guanine residues in nucleic acid can be visually 
detected owing to the characteristic yellow color .8-nitroguanine, within modified 
plasmid, was separated and quantified by HPLC. The concentration of 8-
nitroguanine, in the modified plasmid, was found to be 3.8 |iM. However, the 
HPLC of native plasmid did not show any peak resembling 8-nitroguanine. It 
confirms that the presence of 8-nitroguanine in the modified plasmid is a result of 
nitration caused by peroxynitrite. 
Fluorescence spectra of both native and peroxynitrite modified plasmid was 
taken using ethidium bromide. A decrease in the fluorescence intensity of the 
EtBr-peroxynitrite modified plasmid compared to EtBr-plasmid in the fluorescence 
emission spectra confirms the destruction of structural integrity of plasmid and 
generation of single strand breaks which results in poor intercalation of ethidium 
bromide in the modified form of pUC 18. 
The native plasmid, upon peroxynitrite modification, showed susceptibility 
to rise in temperature when subjected to thermal denaturation studies. The melting 
temperature of the modified plasmid was found to be 12°C less as compared to the 
melting temperature of native calf thymus DNA, used as reference. This could be 
attributed to the presence of single strand regions in the modified DNA and also a 
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partial destruction in its secondary structure. Base stacking as well as hydrogen 
bonding is involved in stabilizing the native structure of DNA and their disruption 
by high temperature favours denaturation (Casperson and Voss, 1983; Thomas, 
1993). The decreased in Tm, therefore, points towards the destabilization of these 
interactions and consequent helix disruption. 
The CD spectrum of native plasmid consists of a positive and negative 
band of nearly equal magnitude with intersection point at the absorption maxima. 
The decrease in ellipticity and slight change in the peaks of plasmid after 
peroxynitrite modification may be due to unstacking of bases as a result of helix 
destabilization. 
Appreciable evidence for generation of strand breaks (single and double) 
in the plasmid as a consequence of peroxynitrite modification was gathered by 
agarose gel electrophoresis. The electrophoretic pattern of peroxynitrite modified 
plasmid revealed a decrease in the fluorescence intensity of supercoiled form (form 
I) with a concomitant increase in the linear form. The finding is a clear indicator of 
the generation of strand break in pUC 18 plasmid upon peroxynitrite exposure. The 
data is compatible with an earlier report in this regard (Dixit et al.,2005). 
Earlier studies demonstrate that the structural alteration in DNA, following 
damage by various agents, may at the times be large enough to act as substrate for 
single strand specific nuclease SI (Shishido and Ando, 1974: Yamasaki et al., 
1997). Native and peroxynitrite modified plasmid were subjected to nuclease SI 
digestion, in order to confirm the generation of single strands breaks. The results 
show almost total digestion of peroxynitrite modified plasmid upon treatment with 
nuclease SI, while native DNA remains undigested. These observations clearly 
demonstrate that sufficient distortions are caused in the helical structure of DNA 
by peroxynitrite, rendering it susceptible to digestions by single strand specific 
nuclease S1. 
Native DNA differs from other macromolecules in its lack of 
immunological activity (Madaio et al., 1984; Stollar, 1986). Immunization with 
single stranded DNA can elicit a limited antibody response, whereas double 
stranded RNA, RNA-DNA hybrids, DNA modified with drugs, hormones, 
chromatin or DNA complexes with DNA binding proteins are effective 
otent 
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immunogens (Stollar, 1975; Anderson et ai, 1988; Desai et al, 1993; Moinuddin 
and Ali, 1994; Hasan et al., 1995; Theofilopoulos, 1995; Arjumand et al., 1997). 
EvidenceX sugges^hat DNA from various species differ in their immunological 
activity and that bacterial DNA can induce the in vitro proliferation of normal 
murine B-cells (Messina et al., 1993). The mitogenic activity of DNA is 
dependent on sequence specific determinai€5'"that can be presentedjby synthetic 
duplexes (GC-rich region) as well as bacterial single stranded and double stranded 
DNA, suggesting that DNA regions enriched in GC content have enhanced 
immunological activity. The immune stimulation by bacterial DNA results from 
characteristic CpG sequence motifs. 
L ' 
Antibodies against peroxynitrite modified plasmid were induced in rabbits 
by immunizing with peroxynitrita^odified plasmid complexed with methylated 
bovine serum albumin. The peroxynitrite^^Hiodified plasmid proved a poti 
stimulant of immune system, inducing high titrej^^ntibodies. The antigei 
specificity of anti-peroxynitrite modified plasmid IgG was ascertained by 
competitive binding assay. A maximum of 92% inhibition in the antibody activity 
at inhibitor (immunogen) concentration of 20 |Jg/ml and just 2.5 |ig/ml of the 
inhibitor concentration caused 50% inhibition, clearly indicating at very high 
specificity and affinity of the induced antibodies towards the immunogen, i.e the 
peroxynitrite modified plasmid. Low inhibition will native plasmid (37%) and 
moderate inhibition (~ 65%) with the peroxynitrite modified human DNA; 
placental and lymphocyte, shows that majority of the antibodies are directed 
towards the peroxynitrite modified epitopes on the DNA. 
Visual detection of interaction between immune IgG and the immunogen 
was facilitated by the gel retardation assay. The results r«i!orated high affinity of 
the induced antibodies for the immunogen. However, anti-peroxynitrite plasmid 
IgG did not show any appreciable binding with the native plasmid. These results 
further confirm that the induced antibodies are predominantly directed against the 
antigenic determinants generated as a result of peroxynitrite modification of 
plasmid. 
Native calf thymus and native human DNA showed inhibitionJTof 38% and 
33% respectively, whereas their peroxynitrite modified forms showed hijher 
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inhibition of 63% and 59.5% respectively. These resuUs demonstrate the 
preferential recognition of peroxynitrite modified epitopes by the immune IgG. 
ROS-modified forms of calf thymus and human DNA inhibited antibody activity to 
a lesser extent possibly because the ROSQnodified epitopes are not so distinctly 
recognized by the induced antibodies. Amongst peroxynitrite modified bases, 
guanine showed substantial inhibition (76%). Earlier reports have demonstrated 
guanine to be particularly susceptible to modification by peroxynitrite, generating 
products such as 8-nitroguanine, 5-nitro-4-guanidinohydantoin, 4,5-dihydro-5-
hydroxy-4-(nitrosooxy) guanine (Douki et.al,\996). The result clearly indicates 
preferential specificity of the immune IgG towards peroxynitrite modified guanine. 
Type 1 diabetes results from the autoimmune destruction of the insulin<f-— ' 
producing pancreatic P-cells. For years, the notion that T-lymphocytes played a 
crucial role in disease induction was considered such a sound dogma that interest 
in B-lymphocytes and autoantibodies as pathogenic variables was largely relegated 
to second-class status. However, much of our knowledge regarding the 
pathogenesis and natural history of this disease has been obtained by analysis of 
subjects having type I diabetes associated autoantibodies. While autoantibodies to 
more than two dozen autoantigens have been associated with this disease, a 
majority of interest has been directed to only four— islet cell cytoplasmic (ICA), 
insulin (lAA), glutamic acid decarboxylase (GAD) and 1A2/ICA512 autoantigen 
(1A2A). These autoantibodies, combined with other metabolic and genetic 
markers, are extremely effective for predicting eventual development of type 1 
diabetes in otherwise healthy individuals. Such autoantibodies have also aided in 
our understanding of disease heterogeneity and suggest that the autoimmune 
processes underlying type 1 diabetes injikrte in the earliest stages of life (e.g., 
initial autoantibody formation at 9-18 months of age). Additional improvements 
are needed to more accurately define the time for disease onset, response to 
therapeutic intervention, the pathogenic features of the autoimmune response, and 
perhaps even the quantity of residual beta cell function. It is documented that anti-
DNA antibodies are observed in type 1 diabetes (Wasserfall and Atkinson, 2006). 
However, it is still not clear how the DNA becomes antigenic ? 
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In view of/'these,- type I diabetes sera were screened for the presence of 
autoantibodies reactive to native and peroxynitrite modified plasmid. The binding 
of circulating atrteantibodies from eighty nine type 1 diabetes patients and twelve 
healthy normal subjects in 4-60 year age group, to native and peroxynitrite 
modified plasmid was studied by direct binding ELISA. Of these, over sixty 
percent of diabetes sera showed preferentially high binding to peroxynitrite 
modified plasmid as compared to its native analogue. No appreciable binding, 
either with native or modified plasmid, was observed with the serum antibodies 
from healthy normal subjects. Competition ELISA results showed 20-39% 
inhibition in the type I diabetes atrteantibodies binding to native plasmid, where as 
42-72 % inhibition was observed with peroxynitrite modified plasmid. These 
results indicate substantial recognition of the peroxynitrite modified plasmid by the 
autoantibodies in diabetic patients. The binding specificity of the isolated IgG, 
towards plasmid and peroxynitrite modified plasmid was evaluated by competition 
ELISA. Immunoglobulin G (IgG) from diabetic patients (type I) recorded an 
inhibition of 51 % to 71 % with the peroxynitrite modified plasmid, while with 
native plasmid the range was 31-43%. The affinity purified IgG from diabetic 
patients showed appreciably high binding towards peroxynitrite modified plasmid, 
reiterating the results obtained with serum antibodies. There are various reports, 
which establish a link between peroxynitrite induced diabetes and nitrosative stress 
^^^The anti-peroxynitrite modified plasmid antibody was used as an 
immunochemical probe to detect the nitrosative damage in the lymphocyte DNA 
isolated from diabetic patients. 
The binding pattern of these DNA isolates was quite revealing. Our data 
has a direct correlationi as tjag j^yiapj^ gicyte DNA of the diabetic patients, whose 
antibodies were extensively^ inhibited by the modified DNA, produced 
appreciable inhibitiQ0uin4he- binding, of .tkejnduced anti-peroxynitrite modified 
plasmid anfibodies. The results of the binding of atrteantibodies for diabetic 
patients as well as significantly high level of recognition of the lymphocyte DNA 
from diabetic patients, give ample evidence of the presence of nitrosative lesions 
in the patients' DNA which may lead to the generation of neo-epitopes on the 
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DNA molecule that are recognized as ' alien' by the immune system resulting in 
autoantibody generation. ^_^ 
Our studies further indicate that recognition of^peroxynitrite modified 
plasmid by circulatory .aoteantibodies in diabetic patients is directly related to age 
s. Hiehe/bindi .•-H'>. of the patient i^g  i ng was observed in elderly group as compared to the h 
^ 
-- t 
relatively younger ones. This might be due to'Toading of the system by modified 
DNA under nitrosative stress which challenges the humoral immune system to 
respond. It is well established that nitrosative stress / oxidative stress increases 
with advancing age which thereby increase the chances of DNA damage . 
Recognition of the modified epitopes was further analyzed by band shift 
assay through visual detection of the immune complexes, formed between 
peroxynitrite modified plasmid and the IgG from diabetic patients, in agarose gels. 
An increase in the amount of the high molecular weight immune complexes having 
retarded mobility with progressive increase of IgG content clearly establish the 
modified plasmid as a preferred antigen for these autoantibodies as compared to 
the native analogue. 
Nitric oxide is a highly unstable molecule and cannot be directly measured 
but its abundance can be estimated from its stable breakdown products, nitrite and 
nitrate (total nitrite) (Doganay et ai,2002). The total nitrite concentration was 
^Iwt^ higher in all age groups of diabetic type I patients as compared to the 
healthy (normal) controls. This is a clear indication of elevated nitrosative stress in 
diabetes. Earlier also, shown increased serum nitrite has been reported in diabetes 
type 1 patients (Robert et ai,2003) 
The strong binding of_autfiantibodies from diabetes type I patients to 
peroxynitrite modified plasmid is i ^ evidence to^ fOT s^ the involvement of 
modified bases and single strand regions in the disease pathogenesis.^ Role of 
nitrosative stress inydiabetic complication has been reported ejtflf^r (Szabo, 2005). 
The spontaneous production of autoantibodies in type I diabetes might be a result 
of the generation of antigenic epitopes on the DNA molecules that are recognized 
as 'non self ' by the body's immune systeraf: Itcould , therefore, be one of the 
factors for the autoimmune response in diabetes. 
Sera from type II diabetes patients showed low binding botfi with native 
pk3mid as-w^f-ft9-4ts peroxynitrite modified femr The degree of binding was 
almost similar to that obtained with serum antibodies from normal healthy 
subjects. The poor recognition of peroxynitrite modified plasmid by the 
aateantibodies in type II diabetes patients was further confirmed by competitive 
inhibition analysis wherein again the inhibition in the antibody activity was quite 
low with peroxynitrite modified plasmid (28-42%). Native plasmid caused an 
inhibition in the range of 23-33%. These results are in sharp contrast to the 
findings obtained with autoantibodies from type I diabetes patients which showed 
appreciably high binding specificity with the peroxynitrite modified plasmid. 
Similarly IgG isolated from type II diabetes patients recorded an inhibition in the 
range of 24-42% and 25-39%, when peroxynitrite modified plasmid and its native 
form were respectively used as inhibitors. Also, nitrosative lesions could not be 
detected in the DNA isolated from these patients, as presented in table 14. The 
results show ample evidence 6f the involvement of peroxynitrite in type I diabetes 
while the same could not be established for the type II. 
Based on the above studies, the following conclusions can be drawn. 
1. Peroxynitrite modification of pUC 18 plasmid resulted in the formation of 
strand breaks and base modification. 
2. Thermal transition studies showed that modification has rendered the 
plasmid susceptible to rise in temperature. 
3. Peroxynitrite modified plasmid was highly immunogenic in experimental 
animals, inducing high titre antibodies. 
4. The induced antibodies, though highly specific for the immunogen, also 
exhibited polyspecific binding. The antibodies showed significant binding 
with various nucleic acid conformers and nitrogenous bases. 
5. Diabetes type I ast&antibodies showed preferential binding to peroxynitrite 
modified plasmid as compared to the native form. 
6. The degree of binding (or specificity) of -atrteantibodies from type I 
diabetes patients, for the peroxynitrite modified plasmid, exhibited a 
proportional increase with the age of the patients . 
151 
7. Serum nitrite levels are high in diabetes type I patients as compared to 
healthy human subjects. 
8. Peroxynitrite modified plasmid presents,, discriminating antige^n for the 
binding of diabetes type I autoantibodies. It is suggested that peroxynitrite 
modified plasmid presents unique epitopes that are recognized as 'alien' by 
the immune system , leading to autoantibody production in case of diabetes 
mellitus, type I. 
9. Antibodies from type II diabetes patients exhibited fairly low binding (as 
well as specificity) with the peroxynitrite modified plasmid. The degree of 
binding with the native and modified form of the plasmid was almost 
comparable in these patients. The observed serum nitrite levels were also 
.appreciable low in the case of diabetes type II patients. Our results could 
not establish a role for peroxynitrite injtype II diabetes mellitus. 
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